0001213900-19-002391.txt : 20190213 0001213900-19-002391.hdr.sgml : 20190213 20190213172159 ACCESSION NUMBER: 0001213900-19-002391 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190213 DATE AS OF CHANGE: 20190213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RELMADA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001553643 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455401931 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55347 FILM NUMBER: 19598762 BUSINESS ADDRESS: STREET 1: 750 THIRD AVENUE, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-547-9591 MAIL ADDRESS: STREET 1: 750 THIRD AVENUE, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: CAMP NINE, INC. DATE OF NAME CHANGE: 20120706 10-Q 1 f10q1218_relmadatherapeutics.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2018

 

or

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________________ to ___________________________

 

Commission File Number: 000-55347

 

Relmada Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   45-5401931

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

     

880 Third Avenue, 12th Floor

New York, NY

  10022
(Address of Principal Executive Offices)   (Zip Code)

 

(212) 547-9591

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes     No 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes   No 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

As of February 13, 2019 there were 30,266,373 shares of common stock outstanding $0.001 par value per share outstanding.

 

 

   

 

 

  

Relmada Therapeutics, Inc.

Index

 

  Page
Number
PART I - FINANCIAL INFORMATION  
   
Item 1. Unaudited Consolidated Financial Statements 1
  Unaudited Consolidated Balance Sheets as of December 31, 2018 and June 30, 2018 1
  Unaudited Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2018 and 2017 2
  Unaudited Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2018 and 2017 3-4
  Unaudited Consolidated Statement of Changes in Equity 5
  Notes to Unaudited Consolidated Financial Statements 6-15
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation 16-24
Item 3. Quantitative and Qualitative Disclosures About Market Risk 24
Item 4. Controls and Procedures 24
     
PART II - OTHER INFORMATION  
     
Item 1. Legal Proceedings 25
Item 1A. Risk Factors 25
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
Item 3. Defaults Upon Senior Securities 25
Item 4. Mine Safety Disclosures 25
Item 5. Other Information 25
Item 6. Exhibits 26
SIGNATURES 27

 

i

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1.FINANCIAL STATEMENTS

 

Relmada Therapeutics, Inc.

Consolidated Balance Sheets

(Unaudited)

 

   December 31,
2018
   June 30,
2018
 
Assets        
Current assets:        
Cash and cash equivalents  $2,426,751   $2,238,943 
Other receivable   -    7,617 
Lease payments receivable – short-term   67,235    64,486 
Prepaid expenses   537,665    426,921 
Total current assets   3,031,651    2,737,967 
Fixed assets, net of accumulated depreciation   9,374    12,080 
Other assets   18,908    24,788 
Lease payments receivable – long-term   238,925    273,244 
           
Total assets  $3,298,858   $3,048,079 
           
Liabilities and Stockholders’ Equity (Deficit)          
           
Current liabilities:          
Accounts payable  $358,892   $765,439 
Accrued expenses   1,390,547    659,455 
Notes payable   114,738    285,170 
Derivative liabilities   -    4,194,634 
           
Total current liabilities   1,864,177    5,904,698 
           
Promissory notes payable, net of discount of $0 and $4,548,543   -    2,656,457 
           
Total liabilities   1,864,177    8,561,155 
           
Commitments and contingencies          
           
Stockholders’ equity:          
Preferred stock, $0.001 par value, 200,000,000 shares authorized, no shares issued or outstanding   -    - 
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, no shares issued and outstanding   -    - 
Common stock, $0.001 par value,100,000,000 shares authorized, 29,764,210 and 12,549,870 shares issued and outstanding, respectively   29,764    12,550 
Additional paid-in capital   106,258,627    88,818,681 
Accumulated deficit   (104,853,710)   (94,344,307)
           
Total stockholders’ equity (deficit)  $1,434,681   $(5,513,076)
           
Total liabilities and stockholders’ equity (deficit)  $3,298,858   $3,048,079 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

1

 

 

Relmada Therapeutics, Inc.

Consolidated Statements of Operations

(Unaudited)

 

   Three Months Ended
December 31,
   Six Months Ended
December 31,
 
   2018   2017   2018   2017 
Operating expenses:                
Research and development  $1,257,418   $150,720   $2,678,900   $316,470 
General and administrative   2,221,566    1,305,865    3,211,314    2,120,971 
Total Operating Expenses   3,478,984    1,456,585    5,890,214    2,437,441 
Loss from Operations   (3,478,984)   (1,456,585)   (5,890,214)   (2,437,441)
                     
Other income (expenses):                    
Change in fair value of derivative liabilities   263,907    341,106    (54,634)   335,404 
Loss on extinguishment of debt   (3,774,468)   -    (3,774,468)   - 
Interest expense, net   (139,765)   (311,871)   (790,087)   (309,349)
Other income   -    -    -    2,350 
Total other income (expenses)   (3,650,326)   29,235    (4,619,189)   28,405 
Net loss  $(7,129,310)  $(1,427,350)   (10,509,403)   (2,409,036)
                     
Loss per common share – basic  $(0.28)  $(0.11)   (0.55)   (0.19)
                     
Loss per common share – diluted  $(0.28)  $(0.11)   (0.55)   (0.19)
Weighted average number of common shares outstanding – basic and diluted   25,583,922    12,547,176    19,066,896    12,540,208 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

2

 

 

Relmada Therapeutics, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

   Six Months Ended
December 31,
 
   2018   2017 
         
Cash flows from operating activities        
Net loss  $(10,509,403)  $(2,409,036)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation expense   2,707    1,130 
Stock-based compensation   415,844    202,908 
Amortization of deferred financing costs   661,167    207,781 
Change in fair value of derivative liabilities   54,636    (335,404)
Fair value of shares relinquished in litigation   (394,410)   -   
Loss on promissory note extinguishment   3,774,468    -   
Changes in operating assets and liabilities:          
Other receivable   7,617    232,597 
Other assets   5,880    -   
Lease payment receivable   31,570    29,040 
Prepaid expenses   (110,744)   232,043 
Accounts payable   (406,549)   (321,995)
Accrued expenses   1,648,372    50,274)
Net cash used in operating activities  $(4,818,845)   (2,110,662)
           
Cash flows from investing activities          
Purchase of fixed assets   -      (2,591)
Net cash used in investing activities   -      (2,591)
           
Cash flows from financing activities          
Proceeds from promissory notes and warrants, net of fees   -      6,507,700 
Principal payments of notes payable   (170,432)   (165,435)
Net proceeds from sale of units   5,177,085    -   
Net cash provided by financing activities  $5,006,653    6,342,265 
Net (decrease) increase in cash and cash equivalents   187,808    4,229,012 
Cash and cash equivalents at beginning of the period   2,238,943    1,710,512 
           
Cash and cash equivalents at end of the period  $2,426,751   $5,939,524 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

3

 

 

Relmada Therapeutics, Inc.

Consolidated Statements of Cash Flows (Continued)

(Unaudited)

 

   Six Months Ended
December 31,
 
   2018   2017 
         
Supplemental disclosure of cash flow information:        
         
Cash paid during the period for:        
Income taxes  $-     $-   
Interest  $1,509   $2,131 
           
Non-cash investing and financing transactions:          
Issuances of common stock resulting from cashless exercise of warrants  $-     $17 
Warrants issued to placement agent  $-     $200,658 
Warrants issued to promissory note holders  $-     $1,266,344 
Derivative associated with issuance of promissory notes  $-     $3,843,019 
Debt issuance cost from accrued financing fees  $-     $127,757 
Write-off of derivative liability due to adoption of ASU 2017-11  $59,397      
Conversion of promissory notes and accrued interest to common stock  $8,030,365      

  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

4

 

 

Relmada Therapeutics, Inc.

Statements of Stockholders’ Equity

(Unaudited)

 

           Additional       Total 
   Common Stock   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Capital   Deficit   Deficit 
Balances at June 30, 2018   12,549,870   $12,550   $88,818,681   $(94,344,307)  $(5,513,076)
Cumulative effect of write-off of derivative liability for adoption of ASU 2017-11   -      -      59,397    -      59,397 
Adjusted Balances as at June 30, 2018   12,549,870   $12,550   $88,878,078   $(94,344,307)  $(5,453,679)
Stock based compensation   -      -      152,801    -      152,801 
Net loss   -      -      -      (3,380,093)   (3,380,093)
                          
Balances at September 30, 2018   12,549,870    12,550    89,030,879    (97,724,400)   (8,680,971)
                          
Stock based compensation   -      -      263,044    -      263,044 
Conversion of Notes and accrued interest   10,731,669    10,731    11,794,102    -      11,804,833 
Equity units issued for cash   6,482,671    6,483    5,170,602    -      5,177,085 
Net loss   -      -           (7,129,310)   (7,129,310)
                          
Balances at December 31, 2018   29,764,210   $29,764   $106,258,627   $(104,853,710)  $1,434,681 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

5

 

 

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 1 – BUSINESS

 

Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (a Nevada corporation), is a clinical-stage, publicly traded biotechnology company focused on the development of d-methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. d-Methadone is a new chemical entity that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. REL-1017 is in Phase 2 for the treatment of major depressive disorder.

 

The Company has a portfolio of three 505b2 product candidates at various stages of development. These products are: LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab (oral buprenorphine, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and MepiGel (topical mepivacaine, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. These products are not currently in active development.

 

In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the FDA and other governmental regulations and approval requirements.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim unaudited consolidated financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. The unaudited consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended June 30, 2018 and notes thereto contained in the Company’s Annual Report on Form 10-K.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the issuance of these consolidated financial statements. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $4,818,845 for the six months ended December 31, 2018 and accumulated deficit of $104,853,710 from inception through December 31, 2018. These conditions raise doubt as to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company will need to raise additional funds in order to continue our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. Management plans to raise additional funds through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements, to fund operations until the Company is able to generate enough revenues to cover operating costs. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders. In addition, the Company may never be able to generate sufficient revenue if any from its potential products.

 

Principles of Consolidation

 

The unaudited consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and recorded amounts related to income taxes.

  

6

 

    

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Cash and Cash Equivalents

 

The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash deposits at these institutions exceed federally insured limits.  

 

Patents

 

Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.

 

Fixed Assets

 

Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software, leasehold improvements, and furniture and fixtures. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments primarily include cash, accounts payable and notes payable. Due to the short-term nature of cash, accounts payable and notes payable the carrying amounts of these assets and liabilities approximate their fair value.

 

Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:

 

Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

 

Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.

 

Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

  

Fair Value on a Recurring Basis

 

As required by Accounting Standard Codification (“ASC”) Topic No. 820 - 10 Fair Value Measurement, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments resulting from equity offerings in May 2014 and June 2014 have a down-round protection provision that, prior to the adoption of ASU 2017-11, was calculated with the Black Scholes option pricing model. Sensitivity analysis for the Black-Scholes has many inputs and is subject to judgement which includes volatility. Volatility is based upon the Company’s historical volatility and the expected term is based upon the expiration date of the warrants. The estimated fair value of the derivative instruments from the convertible promissory notes issued during the year ended June 30, 2018, which have a redemption feature was estimated using the Monte Carlo pricing model, prior to the debt conversion. On the date of debt conversion, when the conversion price of the notes was established and there was no uncertainty as to the conversion of the debt, the estimated fair value of the derivative instrument from the convertible promissory notes was valued using the Black-Scholes model which closely approximates the value under the Monte Carlo pricing model.

 

7

 

    

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. As of December 31, 2018 and June 30, 2018, the Company had recognized a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.

 

The Company files a U.S. Federal income tax return and, various state returns. Uncertain tax positions taken on the Company’s tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at December 31, 2018 and June 30, 2018. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2015 through June 30, 2018.

 

Research and Development

 

Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. 

 

Stock-Based Compensation

 

The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased. 

 

Loss per Common Share

 

Basic loss per common share attributable to common stockholders is calculated by dividing the loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

 

For the six months ended December 31, 2018 and 2017, the following potentially dilutive securities were excluded from the computation of diluted net loss per share, as the inclusion of such shares would be anti-dilutive: 

 

   Six months ended 
   December 31,
2018
   December 31,
2017
 
Stock options   5,743,240    2,619,240 
Restricted common stock   -    37,625 
Common stock warrants   14,975,591    9,627,426 
Total   20,718,831    12,284,291 

 

8

 

 

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Recent Accounting Pronouncements 

 

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), whereby lessees will be required to recognize for all leases at the commencement date a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new standard is effective for us on July 1, 2019. with early adoption permitted. We expect to adopt the new standard on its effective date. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. We expect to adopt the new standard on July 1, 2019 and use the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before July 1, 2019.

 

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2017-11 effective October 1, 2018.

 

In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, which simplifies the accounting for share-based payments made to non-employees so the accounting for such payments is substantially the same as those made to employees. Under this ASU, share based awards to non-employees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2018-07 effective October 1, 2018 and will apply the guidance to any future equity-classified share based awards to nonemployees.

 

NOTE 3 – PREPAID EXPENSES

 

Prepaid expenses consisted of the following (rounded to nearest $00):

 

   December 31,
2018
   June 30,
2018
 
Rent  $-   $9,200 
Research and development   230,700    20,800 
Insurance   216,000    345,700 
Taxes   6,000    - 
Legal   18,300    10,000 
Other   66,700    41,200 
Total  $537,700   $426,900 

 

NOTE 4 – FIXED ASSETS

 

Fixed assets, net of accumulated depreciation, consisted of the following (rounded to nearest $00):

 

    Useful lives   December 31,
2018
    June 30,
2018
 
Computer and software   3 years   $ 16,700     $ 16,700  
Less: accumulated depreciation         (7,300 )     (4,600 )
Fixed assets       $ 9,400     $ 12,100  

 

9

 

 

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 5 – ACCRUED EXPENSES

 

Accrued expenses consisted of the following (rounded to nearest $00):

 

   December 31,
2018
   June 30,
2018
 
Research and development  $25,400   $10,400 
Professional fees   122,800    173,600 
Interest on promissory notes   -    371,600 
Accrued vacation   68,300    48,000 
Litigation settlement, net   1,105,700    - 
Other   68,300    55,900 
Total  $1,390,500   $659,500 

 

NOTE 6 – NOTES PAYABLE

 

In June 2018, the Company entered into a note for approximately $285,200 in conjunction with a renewal of its director and officer insurance policy. The interest rate was 2.35% per annum. The note matures on April 9, 2019.

 

At December 31, 2018 and June 30, 2018, the note payable outstanding balances were approximately $114,700 and $285,200, respectively. 

 

NOTE 7 – DERIVATIVE LIABILITIES

 

ASC Topic No. 815 – Derivatives and Hedging provides guidance on determining what types of instruments or embedded features in an instrument issued by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. These requirements can affect the accounting for warrants and convertible preferred instruments issued by the Company.

 

At December 31, 2018 and June 30, 2018, the Company had warrants resulting from equity offerings in May 2014 and June 2014 that do not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future, the Company concluded that the instruments are not indexed to the Company’s stock.

 

Until September 30, 2018, the Company followed ASC Topic No 815 and treated the warrants as derivative liabilities. In determining the fair value of the derivative liabilities, the Company used the Black-Scholes option pricing model at September 30 and June 30, 2018.

 

As noted in Note 2, the Company elected to early adopt ASU 2017-11 and reversed the derivative liability into equity effective July 1, 2018. The warrants balance of $59,397 was reversed to equity effective July 1, 2018.

 

The following is a summary of the assumptions used in the valuation model at June 30, 2018:

 

   June 30, 
   2018 
Common stock issuable upon exercise of warrants   2,574,570 
Market value of common stock on measurement date  $1.01 
Exercise price   $7.50 and $11.25 
Risk free interest rate (1)   2.33%
Expected life in years  $0.95 
Expected volatility (2)   102%
Expected dividend yields (3)   None 

 

(1) The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date.
(2) The historical trading volatility was determined by calculating the volatility of the Company’s stock.
(3) The Company does not expect to pay a dividend in the foreseeable future.

 

10

 

  

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 7 – DERIVATIVE LIABILITIES (continued)

 

Until October 18, 2018, the Company had promissory notes with a redemption feature that was not clearly and closely related to the host instrument and therefore is considered an embedded derivative which was bifurcated and recorded as a derivative liability. In determining the fair value of the derivative liabilities, the Company used the Monte-Carlo pricing model. The assumptions used in the valuation model considers the probability of redemption, the length of time to maturity and value of the redemption feature.

 

On October 12 and 18, 2018, the Company conducted closings on its private placement of securities. As a result of these closings, the outstanding promissory notes converted into common stock. The redemption feature associated with the promissory notes was valued on October 18, 2018 using the Black Scholes model. The change in value of the derivative between October 1, 2018 and the October 18, 2018 was recorded as income. The notes were converted to common stock on October 18, 2018.

 

The Company had no financial liabilities accounted for at fair value on a recurring basis as of December 31, 2018.

 

The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018:

 

   Markets for
Identical
Assets
   Other
Observable
Inputs
   Significant
Unobservable
Inputs
   Carrying
Value as of
June 30,
 
Description  (Level 1)   (Level 2)   (Level 3)   2018 
Derivative liability – warrant instruments  $       -   $          -   $30,526   $30,526 
Derivative liabilities – embedded redemption feature of promissory notes   -    -    4,164,108    4,164,108 
   $-   $-   $4,194,634   $4,194,634 

 

The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy for the six months ended December 31, 2018 and 2017:

 

   Six Months Ended 
   December 31,   December 31, 
   2018   2017 
Beginning balance  $4,194,634   $175,853 
Adoption of ASU 2017-11 – warrants   (59,397)   - 
Fair value of derivative liabilities for redemption feature of promissory notes payable   -    3,843,019 
Change in fair value of derivative liabilities   54,634    (335,404)
Extinguishment of derivative liabilities on conversion of promissory notes.   (4,189,871)   - 
Ending balance  $-   $3,683,468 

 

11

 

 

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 8 – PROMISSORY NOTES PAYABLE

 

Between September 2017 and January 2018, the Company issued two-year Convertible Promissory Notes (the “Notes”) and warrants, for aggregate gross proceeds of $7,205,000, $6,534,400 net of direct debt issuance costs. The notes had an interest rate of 7% per annum.

 

As a result of financings in October 2018, the principal and accumulated interest on the Convertible Promissory Notes was automatically converted into 10,731,669 shares of its common stock in accordance with the terms of the Notes. “This resulted in a loss on extinguishment of debt, a non cash item, of approximately $3,774,500 in the quarter ended December 31, 2018.”

 

NOTE 9 – STOCKHOLDERS’ EQUITY

 

Common Stock

 

During the six months ended December 31, 2018, the Company closed on its private placements of securities on October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018 pursuant to Unit Purchase Agreements dated as of October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018, and Subscription Agreements, dated as of October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018. The Company issued an aggregate of 6,482,671 shares of common stock to investors in these closings, for net proceeds of $5,177,085.

 

The October 12, 2018 and October 18, 2018 financings represented an Equity Financing as defined in the Convertible Promissory Note agreement. As a result of the October 12, 2018 and October 18, 2018 financings, the Company’s outstanding 7% Convertible Promissory Notes and accumulated interest converted into 10,731,669 shares of common stock.

 

Options

 

In December 2014, the Board of Directors adopted and the shareholders approved Relmada’s 2014 Stock Option and Equity Incentive Plan, as amended (the “Plan”), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors. The Plan allowed for the granting of 1,611,769 options or stock awards. In August 2015, the board approved an amendment to the Plan. Among other things, the Plan Amendment updates the definition of “change of control” and provides for accelerated vesting of all awards granted under the plan in the event of a change of control of the Company. In January 2017, the stockholders approved an increase of 2,500,000 shares authorized to be issued under the Plan, raising the total shares allowed under the Plan to 4,111,768. In December 2017 the board approved, and in February 2018 the shareholders approved, an amendment to the Plan that increased the number of shares of common stock authorized for issuance under the Plan by an additional 2,500,000 shares from 4,111,768 to 6,611,768.

 

Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of December 31, 2018, 868,528 shares were available for future grants under the Plan.

 

In December 2018 the board of directors approved an amendment to the Plan to increase the number of shares of common stock authorized for issuance under the Plan by an additional 4,000,000 shares from 6,611,768 to 10,611,768.

 

As of December 31, 2018, no stock appreciation rights have been issued.

 

The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options and warrants. The price of common stock prior to the Company being public was determined from a third party valuation. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based on historical volatility. The Company routinely reviews its calculation of volatility changes in future volatility, the Company’s life cycle, its peer group, and other factors.

 

The Company uses the simplified method for share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. Prior to the adoption of ASU 2018-07 on October 1, 2018, the Company used the contractual term for non-employee options to estimate the expected term, for share-based compensation in its option-pricing model.

 

12

 

 

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 9 – STOCKHOLDERS’ EQUITY (continued)

  

On February 13, 2017, Mr. Michael Becker, the Company’s Chief Financial Officer, resigned and entered into a consulting agreement with the Company to provide financial, investor, digital media, and public relations services for the Company. As a result of Mr. Becker’s change from an employee to a consultant, his options and shares of restricted stock outstanding on such date continued to vest pursuant to the awards’ original terms and were reclassified as non-employee awards. On December 15, 2017 Mr. Becker’s consulting agreement expired and all unvested options were cancelled.

 

On December 20, 2018, the Company awarded a total of 2,700,000 options to its chief executive officer, chief medical officer and board members with exercise price of $1.15 and a 10-year term vesting over 4-year period. The options have an aggregate fair value of $2.5 million calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends.

 

At December 31, 2018, the Company has unrecognized stock-based compensation expense of approximately $3,754,000 related to unvested stock options over the weighted average remaining service period of 3.56 years.

 

Options

 

A summary of the changes in options during the six months ended December 31, 2018 is as follows:

 

   Number
of
Options
   Weighted Average Exercise Price For Share   Weighted Average Remaining Contractual Term (Years)   Aggregate Intrinsic
Value
 
Outstanding and expected to vest at June 30, 2018   3,068,865   $1.45    8.8   $511,000 
Forfeited   (25,625)  $7.59    -   $- 
Issued   2,700,000    1.15    10.0    - 
Outstanding and expected to vest at December 31, 2018   5,743,240   $1.28    9.1   $882,000 
Options exercisable at December 31, 2018   949,118   $2.58    7.25   $192,900 

 

Warrants

 

A summary of the changes in outstanding warrants during the six months ended December 31, 2018 is as follows:

 

   Number of Shares   Weighted Average Exercise Price Per Share 
Outstanding and vested at June 30, 2018   9,815,025   $3.96 
Forfeited   (7,500)   - 
Issued   5,168,066    1.00 
Outstanding and vested at December 31, 2018   14,975,591   $2.22 

 

During the six months ended December 31, 2018, in connection with the closings on October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018, the Company issued an aggregate of 4,213,732 warrants to the investors. The investor warrants have an exercise price of $1.50, are non-cancellable, vest upon issuance and expire on the fifth anniversary of the warrant date of issuance. The Company additionally issued an aggregate of 854,334 warrants to the placement agent in connection with the closings. The agent warrants have an exercise price of $0.99, are non-cancellable, vest upon issuance and expire on the fifth anniversary of the warrant date of issuance.

 

13

 

  

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 9 – STOCKHOLDERS’ EQUITY (continued)

 

On December 20, 2018, the Company granted 100,000 warrants to a contractor with exercise price of $1.15, a 10-year term and immediate vesting. The warrants have an aggregated fair value of $93,762 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends.

 

At December 31, 2018 and June 30, 2018, the aggregate intrinsic value of warrants vested and outstanding was approximately $415,000 and $215,000, respectively.

 

The following summarizes the components of stock-based compensation expense which includes stock options in the consolidated statements of operations for the six months ended December 31, 2018 and 2017 (rounded to nearest $00):

 

   Six Months Ended December 31,
2018
   Six Months Ended December 31,
2017
 
Research and development  $29,500   $14,100 
General and administrative   386,300    188,800 
Total  $415,800   $202,900 

   

NOTE 10 – RELATED PARTY TRANSACTIONS

 

Consulting Agreements

 

On August 4, 2015, the Company entered into an Advisory and Consulting Agreement with Sandesh Seth, the Company’s Chairman of the Board. The effective date of the consulting agreement is June 30, 2015. Mr. Seth has substantial experience in, among other matters, business development, corporate planning, corporate finance, strategic planning, investor relations and public relations, and an expansive network of connections spanning the biopharmaceutical industry, accounting, legal and corporate communications professions. Mr. Seth will provide advisory and consulting services to assist the Company with strategic advisory services, assist in prioritizing product development programs per strategic objectives, assist in recruiting of key personnel and directors, corporate planning, business development activities, corporate finance advice, and assist in investor and public relations services. In consideration for the services to be provided, the Company agreed to pay Mr. Seth $12,500 per month on an ongoing basis. On June 6, 2017, Mr. Seth resigned from the Company to focus his attention on matters external to Relmada. The Company agreed to continue its advisory and consulting arrangement with Mr. Seth until December 31, 2017. 

 

On June 12, 2017, the Company and Maged Shenouda, a director of the Company, entered into a Consulting Agreement. Pursuant to the terms of the agreement, Mr. Shenouda will assist the Company with matters that may be requested by the Company. Mr. Shenouda will be paid a consulting fee of $10,000 per month. The term of the agreement is for one year. On November 13, 2017, Mr. Shenouda and the Company agreed to terminate the Consulting Agreement effective December 31, 2017.

 

NOTE 11 – COMMITMENTS AND CONTINGENCIES

 

Legal

 

From time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence. Except as disclosed below, the Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company’s business, financial condition, operating results, or cash flows.

 

In 2014, Relmada dismissed with prejudice its lawsuit against Najib Babul, which had sought to compel Najib Babul, Relmada’s former President, to account for questionable expenditures of Relmada funds made while Babul controlled the Company. Relmada’s decision to end its claims was informed by the fact that Babul came forward with plausible explanations for some of the expenditures, and the fact that, because Babul was a former officer and director of Relmada being sued for his conduct in office, the Company was required to advance his expenses of the litigation; hence, Relmada was paying all the lawyers and consultants on both sides of the dispute. Relmada also agreed to reinstate certain stock purchase warrants in Babul’s name, which had been cancelled during the pendency of the litigation, and offered Babul the right to exchange his shares in Relmada Therapeutics, Inc. (a Delaware corporation and subsidiary of the Company) for shares in the Company.

 

Najib Babul has brought a second lawsuit against Relmada. Ruling on Relmada’s Motion to Dismiss, the United States District Court for the Eastern District of Pennsylvania dismissed Babul’s claims for breach of contract and intentional infliction of emotional distress, and left intact his claims for defamation, and wrongful use of civil process. The parties settled the lawsuit on February 6, 2019 see Note 12. Subsequent Events.

 

14

 

    

Relmada Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

 

NOTE 11 – COMMITMENTS AND CONTINGENCIES (continued)

   

Leases and Sublease

 

The Company leased its corporate headquarters at 750 Third Avenue, 9th Floor, New York, New York 10017. The monthly rental fee was $9,454 per month. The lease was terminated effective January 1, 2019. Effective January 1, 2019, the Company leased its headquarters at 880 Third Avenue, 12th floor, New York, NY 10022. The annualized monthly rent for 2019 is approximately $7,500.

  

On June 8, 2017, the Company entered into an Amended and Restated License Agreement with Actinium Pharmaceuticals, Inc. (“Actinium”). Pursuant to the terms of the agreement, Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office (“FFE”) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403. As of December 31, 2018, the balance of unearned interest income was approximately $55,232.

 

Contractual Obligations

 

The following tables sets forth our contractual obligations for the next five years and thereafter:

 

   Total   Less than
1 year
   1 - 2 years   3 - 5 years   More than
5 years
 
Office lease  $90,200    90,200   $-   $-   $- 
Note payable   114,700    114,700    -    -    - 
Total obligations  $204,900   $204,900   $-   $-   $- 

  

NOTE 12 – SUBSEQUENT EVENTS

 

On February 6, 2019 the Company entered into a settlement agreement in which Najib Babul relinquished his 303,392 shares in Relmada, signed a consulting contract and Relmada committed to a $500,000 initial payment and four subsequent payments of $250,000 on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019. For accounting purposes no fair value was attributed to the consulting agreement. The Company recorded a liability at December 31, 2018 of $1,105,590 representing the total cash payments of $1,500,000 less the fair value of shares relinquished.

 

On February 12, 2019 the Company closed a private placement of securities to accredited investors. The Company received $725,000 and sold an aggregate of 805,554 units representing 805,554 shares of common stock and 523,610 warrants. The price per unit was $0.90 and the exercise price of each warrant is $1.50 with a 5-year term.

 

15

 

     

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 

FORWARD-LOOKING STATEMENT NOTICE

 

This Quarterly Report on Form 10-Q (this “Report”) contains forward looking statements that involve risks and uncertainties, principally in the sections entitled “Description of Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All statements other than statements of historical fact contained in this Quarterly Report, including statements regarding future events, our future financial performance, business strategy and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under “Risk Factors” or elsewhere in this Quarterly Report, which may cause our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements.

 

You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Quarterly Report on Form-10-Q. Before you invest in our securities, you should be aware that the occurrence of the events described in the section entitled “Risk Factors” and elsewhere in this Quarterly Report could negatively affect our business, operating results, financial condition and stock price. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Quarterly Report on Form-10-Q to conform our statements to actual results or changed expectations.

 

BUSINESS OVERVIEW

 

Relmada is a clinical-stage, publicly traded biotechnology company focused on the development of d-methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. d-Methadone is a new chemical entity that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders.

 

Our lead product candidate, d-methadone, is a New Chemical Entity (NCE) being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. We have completed Phase 1 single and multiple ascending dose studies. A Phase 2 study in major depressive disorder is ongoing, with the first patient dosed in June 2018, and we expect to have top line results in the first half of 2019.

 

NMDA receptors are present in many parts of the central nervous system and play important roles in regulating neuronal activity. We believe that dextromethadone acting as a NMDA receptor antagonist can have potential applications in a number of disease indications which mitigates risk and offers significant upside.

 

The Company has a legacy portfolio of three 505b2 product candidates at various stages of development. These products are: LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab (oral buprenorphine, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and MepiGel (topical mepivacaine, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. These products are not currently in active development.

  

16

 

   

Our four development projects are briefly described below:

 

d-Methadone (dextromethadone, REL-1017) and Treatment-Resistant Depression (TRD)

 

Background

 

In 2014, the National Institute of Mental Health (NIMH) estimated that 15.7 million adults aged 18 or older in the United States had at least one major depressive episode in the past year. According to data from nationally representative surveys supported by NIMH, only about half of Americans diagnosed with major depression in a given year receive treatment. Of those receiving treatment with as many as four different standard antidepressants, 33% of drug-treated depression patients do not achieve adequate therapeutic benefits according to the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial published in the American Journal of Psychiatry. Accordingly, we believe that approximately 3 million patients with such treatment-resistant depression are in need of new treatment options.

 

In addition to the high failure rate, none of the marketed products for depression can demonstrate rapid antidepressant effects and most of the products take up to a month to show effectiveness. The urgent need for improved, faster acting antidepressant treatments is underscored by the fact that severe depression can be life-threatening, due to heightened risk of suicide.

 

Recent studies have shown that ketamine, a drug known previously as an anesthetic, can lift depression in many patients within hours. However, it is unlikely that ketamine itself will become a practical treatment for most cases of depression. It must be administered through intravenous infusion, requiring a hospital setting, and more importantly can potentially trigger adverse side effects including psychedelic symptoms (hallucinations, memory defects, panic attacks), nausea/vomiting, somnolence, cardiovascular stimulation and, in a minority of patients, hepatoxicity. Ketamine also hasn’t been thoroughly studied for long-term safety and effectiveness, and the FDA hasn’t approved it to treat depression.

 

d-Methadone Overview and Mechanism of Action

 

d-Methadone’s mechanism of action, as a non-competitive NMDA channel blocker or antagonist, is fundamentally differentiated from all currently FDA-approved antidepressants, as well as all atypical antipsychotics used adjunctively with standard, FDA-approved antidepressants. Working through the same brain mechanisms as ketamine but potentially lacking its adverse side effects, Relmada’s d-Methadone is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions.

 

In chemistry an enantiomer, also known as an optical isomer, is one of two stereoisomers that are mirror images of each other that are non-superposable (not identical), much as one’s left and right hands are the same except for being reversed along one axis. A racemic compound, or racemate, is one that has equal amounts of left- and right-handed enantiomers of a chiral molecule. For racemic drugs, often only one of a drug’s enantiomers is responsible for the desired physiologic effects, while the other enantiomer is less active or inactive.

 

Racemic methadone has been used since the 1950s as a treatment for opioid addiction and has remained the primary therapy for this condition for more than 40 years. Methadone is a highly lipophilic molecule that is suitable for a variety of administration routes, with oral bioavailability close to 80%.

 

As a single isomer of racemic methadone, d-Methadone has been shown to possess NMDA antagonist properties with virtually no traditional opioid or ketamine-like adverse events at the expected therapeutic doses. In contrast, racemic methadone is associated with common opioid side effects that include anxiety, nervousness, restlessness, sleep problems (insomnia), nausea, vomiting, constipation, diarrhea, drowsiness, and others. It has been shown that the left (levo) isomer, l-Methadone, is largely responsible for methadone’s opioid activity, while the right (dextro) isomer, d-Methadone, is much less active as an opioid while maintaining affinity for the NMDA receptor.

 

NMDA receptors are present in many parts of the central nervous system and play important roles in regulating neuronal activity and promoting synaptic plasticity in brain areas important for cognitive functions such as executive function, learning and memory. Based on these premises, d-methadone could show benefits in several different CNS indications.

 

17

 

 

d-Methadone Phase 1 Clinical Safety Studies

 

The safety data from two Company-funded d-Methadone Phase 1 clinical safety studies and a third study conducted by researchers at Memorial Sloan-Kettering Cancer Center indicate that d-Methadone was safe and well tolerated in both healthy subjects and cancer patients at all projected therapeutic doses tested.

 

In November 2014, Health Canada approved a Clinical Trial Application (“CTA”) to conduct the first Phase 1 study with d-methadone. This was a Single Ascending Dose (“SAD”) study and was followed by a Multiple Ascending Dose (“MAD”) study, both in healthy volunteers. The two studies were designed to assess the safety, tolerability and pharmacokinetics of d-methadone in healthy, opioid-naïve subjects. The SAD study included single escalating oral doses of d-methadone to determine the maximum tolerated dose, defined as the highest dose devoid of unacceptable adverse events. In the MAD study, healthy subjects received daily oral doses of d-methadone for several days to assess its safety, pharmacokinetics and tolerability. In March 2015, we reported that d-methadone demonstrated an acceptable safety profile with no dose limiting side effects after four cohorts were exposed to increasing higher doses. In April 2015, the Company received clearance from Health Canada to continue with dose escalation and explore even higher single doses of d-methadone. In June 2015, the Company successfully completed the SAD study identifying the maximum tolerated dose and subsequently received a No Objection Letter (NOL) from Health Canada to conduct the MAD clinical study in August 2015. The MAD study was completed in January 2016 and the results successfully demonstrated a potential therapeutic dosing regimen for d-methadone with a favorable side effect and tolerability profile. The data from these studies was used to design a Phase 2a study in patients with depression.

  

d-Methadone In Vivo Study for Depression

 

In May 2016, we announced the results of an in vivo study showing that administration of d-methadone results in antidepressant-like effects in a well-validated animal model of depression, known as the forced swim test (FST), providing preclinical support for its potential as a novel treatment of depression.

 

According to the Journal of Visualized Experiments, the FST is based on the assumption that when placing an animal in a container filled with water, it will first make efforts to escape by swimming or climbing, but eventually will exhibit “immobility” that may be considered to reflect a measure of behavioral despair. This test has been extensively used because it involves the exposure of the animals to stress, which was shown to have a role in the tendency for major depression. Additionally, the FST has been shown to be influenced by some of the factors that are altered by or worsen depression in humans, including changes in food consumption and sleep abnormalities. The main advantages of this procedure are that it is relatively easy to perform and that its results are easily and quickly analyzed. Importantly, the FST’s sensitivity to a broad range of antidepressant drugs makes it a suitable screening test and is one of the most important features leading to its high predictive validity.

 

In the Company’s FST study, male Sprague Dawley rats were administered single doses of placebo, ketamine, or d-methadone on day one (after habituation; 24 hours prior to forced swim testing). At all doses tested, d-methadone significantly decreased immobility of the rats compared to the placebo, suggesting antidepressant-like activity. In addition, the effect of d-methadone on immobility at the two highest doses tested was larger than the effect seen with ketamine. Moreover, the effects of d-methadone in the forced swim test were not caused by a stimulant effect on spontaneous locomotor activity of the rats. Locomotor activity of lab animals is often monitored to assess the behavioral effects of drugs.

 

In September 2017 we completed two additional in vivo studies to confirm and support the antidepressant-like effect of dextromethadone in validated animal models, the Novelty Suppressed Feeding Test (NSFT) and the Female Urine-Sniffing test (FUST) test. The studies were performed by Professor Ronald S. Duman, Ph.D. at Yale University School of Medicine.

 

For FUST, rats are first exposed to a cotton tip dipped in tap water and later exposed to another cotton tip infused with fresh female urine. Male behavior was video recorded and total time spent sniffing the cotton-tipped applicator is determined. For NSFT, rats were food deprived for 24 hr and then placed in an open field with food pellets in the center; latency to eat is recorded in seconds. As a control, food consumption in the home cage is quantified. Rats were administered vehicle, ketamine or d-methadone.

 

The results of the FUST demonstrate that administration of ketamine significantly increases the time male rats spent engaged in sniffing female urine compared to vehicle group. Similarly, a single dose of d-methadone significantly increased the time spent sniffing female urine compared to vehicle. In contrast, ketamine or d-methadone had no effect on time sniffing water, demonstrating that the effect of drug treatment was specific to the rewarding effects of female urine. The results of the NSFT demonstrate that a single dose of ketamine significantly decreases the latency to eat in a novel open field. Similarly, a single dose of d-methadone also significantly decreased the latency to enter and eat in the novel feed. In contrast, neither ketamine nor methadone influenced latency to feed in the home cage.

 

These findings demonstrate that ketamine and d-methadone produce rapid antidepressant actions in the FUST and NSFT, effects that are only observed after chronic administration of an SSRI antidepressant.

 

A separate in vitro electrophysiology study of d-methadone was conducted using 2 subtypes of cloned human NMDA receptors.

 

The results of this study demonstrated functional antagonist activity with d-methadone comparable to that of both racemic ketamine and the isomer [S]-ketamine.

  

18

 

 

Phase 2 Program for d-Methadone

  

Combined with the results of our Phase 1 studies, the encouraging results of in vivo and in vitro studies strongly support further evaluation of d-methadone in a Phase 2 study as a rapidly acting, oral agent for the treatment of major depressive disorder. Relmada filed an Investigational New Drug (“IND”) application for the Phase 2 study with the FDA, which was accepted on January 25, 2017.

 

On April 13, 2017, we announced that the FDA granted Fast Track designation for d-methadone (REL-1017 dextromethadone) for the adjunctive treatment of major depressive disorder. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose, according to the FDA, is to get important new drugs to the patient earlier. Drugs that receive Fast Track designation may be eligible for more frequent meetings and written communications with the FDA, accelerated review and priority approval, and rolling New Drug Application review.

 

On January 17, 2018, we announced that Relmada had acquired the global rights to develop and market dextromethadone for the treatment of neurological conditions including certain rare diseases with symptoms affecting the CNS.

 

In February 2018, Relmada initiated its Phase 2 study of d-methadone in patients with major depressive disorder.

  

d-methadone (dextromethadone, REL-1017) in other indications

 

In addition to developing dextromethadone in major depression, Relmada is initiating work in additional indications. In particular, we have initiated a preclinical program to test the potential efficacy of dextromethadone in Rett syndrome. Rett syndrome is an X-linked neurodevelopmental disorder with high unmet need caused by Mecp2 gene mutation. Loss of Mecp2 disrupts synaptic function and structure and neuronal networks. Rett syndrome is an Orphan Disease affecting ~15,000 in U.S., primarily girls, with no approved therapy. The disease begins with a short period of developmental stagnation, then rapid regression in language and motor skills, followed by long-term stability.

 

Studies of ketamine, a NMDAR antagonist with mechanistic similarities with dextromethadone, in Rett Syndrome mouse models show that low-dose ketamine acutely reverses multiple disease manifestations and chronic administration of ketamine improves Rett Syndrome progression, providing a solid rationale to pursue this indication with dextromethadone.

 

Other indications that Relmada may explore in the future, potentially includes restless leg syndrome, and other neurological diseases.

  

In January 2018, we entered into an Intellectual Property Assignment Agreement (the “Assignment Agreement”) and License Agreement (the “License Agreement” and together with the Assignment Agreement, the “Agreements”) with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (collectively, the “Licensor”). Pursuant to the Agreements, Relmada assigned its existing rights, including patents and patent applications, to d-methadone in the context of psychiatric use (the “Existing Invention”) to Licensor. Licensor then granted Relmada under the License Agreement a perpetual, worldwide, and exclusive license to commercialize the Existing Invention and certain further inventions regarding d-methadone in the context of other indications such as those contemplated above.

  

LevoCap ER (REL-1015)

 

LevoCap ER (REL-1015) is a novel version of a proven drug product. LevoCap ER -is an extended release, abuse deterrent, and proprietary formulation of levorphanol (levo-3-hydroxy-N-methyl-morphinan), a unique, broad spectrum opioid with additional “non-opioid” mechanisms of action. In particular, levorphanol binds to all three opioid receptor subtypes involved in analgesia (mu, kappa, and delta), the NMDA receptor, and the norepinephrine and serotonin reuptake pumps, whereas morphine, oxycodone, hydrocodone, and other opioids are highly selective for the mu receptor subtype. Due to its multi-modal mechanism of action, levorphanol could achieve analgesia in patients resistant to other strong opioids. In clinical studies, levorphanol has demonstrated a remarkably broad spectrum of analgesic activity against many different types of pain including neuropathic pain, post-surgical pain, and chronic pain in patients refractory to other opioids.

 

Levorphanol is a potent opioid analgesic first introduced in the U.S. around 1953 for the treatment of moderate to severe pain where an opioid analgesic is appropriate. Extended-release (long-acting opioid) agents may be preferable to immediate release formulations due to better patient adherence, less dose-watching, and result in improved sleep. Both immediate- and extended-release opioids can potentially be crushed to produce concentrated drug with greater appeal to abusers. Intentional crushing or extracting the active ingredient from the extended-release dosage form by addicts and recreational drug users can destroy the timed-release mechanism and result in a rapid surge of drug into the bloodstream for the purpose of achieving a high or euphoric feeling. Serious side effects and death have been reported from such misuse.

  

19

 

    

LevoCap ER is the first product candidate utilizing SECUREL™, Relmada’s proprietary abuse deterrent extended release technology for opioid drugs. SECUREL dosage forms cannot be easily crushed for inhalation or to obtain rapid euphoria from high blood levels when swallowed. It is also exceedingly difficult for intravenous abusers to extract the active drug from the dosage form using common solvents, including alcohol.

 

LevoCap ER can be developed under the 505(b)(2) regulatory pathway. Following an exchange of correspondence and meeting with the FDA in January 2017, we have defined a path forward for the Phase 3 clinical study for LevoCap ER and a new drug application (“NDA”) filing. In light of the promising data generated by Relmada’s d-methadone research program, and Relmada’s focus on the d-methadone program, Relmada is currently limiting the investments in LevoCap ER.

  

BuTab (REL-1028)

 

BuTab (REL-1028) represents a novel formulation of oral, modified release buprenorphine as a potential therapeutic for both chronic pain and opioid dependence. Buprenorphine has been widely used by the sublingual and transdermal routes of administration, but was believed to be ineffective by the oral route because of poor oral bioavailability. We have completed a preclinical program to better define the pharmacokinetic profile of BuTab and to assess the time course of systemic absorption of buprenorphine using several different oral modified release formulations of buprenorphine in dogs, compared to an intravenous administration. Based on the results of this work, we obtained approval from Health Canada and initiated a Phase 1 pharmacokinetic study in healthy volunteers in the second quarter of 2015. This trial was completed in the fourth quarter of 2015. The absolute bioavailability of BuTab relative to intravenous (IV) administration exceeded published data with non-modified buprenorphine when administered orally and compares favorably with a currently marketed transdermal patch. There were no safety or tolerability issues. The data generated by this study will guide formulation optimization and inform the design of subsequent clinical pharmacology studies. BuTab can be developed under the 505(b)(2) regulatory pathway. In light of the promising data generated by Relmada’s d-methadone research program, and Relmada’s focus on the d-methadone program, Relmada is currently limiting the investments in BuTab.

 

MepiGel (REL-1021)

 

MepiGel (REL-1021), is a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia and painful HIV-associated neuropathy. Mepivacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to the brain. It is chemically related to bupivacaine but pharmacologically related to lidocaine. Mepivacaine is currently indicated for infiltration, nerve block and epidural anesthesia. Relmada has received two FDA Orphan Drug Designations for mepivacaine, one each for “the treatment of painful HIV-associated neuropathy” and for “the management of postherpetic neuralgia,” or PHN. We have selected the formulations to be advanced into clinical studies for MepiGel after the evaluation of results from in vitro and ex vivo studies comparing various topical prototypes of mepivacaine that were conducted by MedPharm Ltd, a specialist formulation development company recognized internationally for its expertise in topical and transdermal products. Multiple toxicology studies were successfully conducted and completed in 2015. MepiGel can be developed under the 505(b)(2) regulatory pathway. In light of the promising data generated by Relmada’s d-methadone research program, and Relmada’s focus on the d-methadone program, Relmada is currently limiting the investments in MepiGel.

  

Overview of the 505(b)(2) Pathway

 

Part of our strategy is the utilization of FDA’s 505(b)(2) new drug application process, (“NDA”) for approval. The 505(b)(2) NDA is one of three FDA drug approval pathways and represents an appealing regulatory strategy for many companies. The pathway was created by the Hatch-Waxman Amendments of 1984, with 505(b)(2) referring to a section of the Federal Food, Drug, and Cosmetic Act. The provisions of 505(b)(2) were created, in part, to help avoid unnecessary duplication of studies already performed on a previously approved (“reference” or “listed”) drug; the section gives the FDA express permission to rely on data not developed by the NDA applicant.

 

A 505(b)(2) NDA contains full safety and effectiveness reports but allows at least some of the information required for NDA approval, such as safety and efficacy information on the active ingredient, to come from studies not conducted by or for the applicant. This can result in a less expensive and faster route to approval, compared with a traditional development path [such as 505(b)(1)], while creating new, differentiated products with tremendous commercial value.

 

20

 

 

Overview of Orphan Drug Status

 

In accordance with laws and regulations pertaining to the Regulatory Agencies, a sponsor may request that the Regulatory Agencies designate a drug intended to treat a “Rare Disease or Condition” as an “Orphan Drug.” For example, in the United States, a “Rare Disease or Condition” is defined as one which affects less than 200,000 people in the United States, or which affects more than 200,000 people but for which the cost of developing and making available the product is not expected to be recovered from sales of the product in the United States. Upon the approval of the first NDA or BLA for a drug designated as an orphan drug for a specified indication, the sponsor of that NDA or BLA is entitled to 7 years of exclusive marketing rights in the United States unless the sponsor cannot assure the availability of sufficient quantities to meet the needs of persons with the disease. In Europe, this exclusivity is 10 years, and in Australia it is 5 years. However, orphan drug status is particular to the approved indication and does not prevent another company from seeking approval of an off-patent drug that has other labeled indications that are not under orphan or other exclusivities. Orphan drugs may also be eligible for federal income tax credits for costs associated with such as the disease state, the strength and complexity of the data presented, the novelty of the target or compound, risk-management approval and whether multiple rounds of review are required for the agency to evaluate the submission. There is no guarantee that a potential treatment will receive marketing approval or that decisions on marketing approvals or treatment indications will be consistent across geographic areas.

   

Results of Operations

 

For the Three Months Ended December 31, 2018 versus December 31, 2017

 

   Three Months Ended   Three Months Ended     
   December 31
2018
   December 31,
2017
   Increase
(Decrease)
 
Operating Expenses            
General and administrative  $2,221,566   $1,305,865   $915,701 
Research and Development   1,257,418    150,720    1,106,698 
Total  $3,478,984    1,456,585    2,022,399 

 

General and Administrative Expense 

 

General and administrative expense for the three months ended December 31, 2018 was approximately $2,221,600 compared to $1,305,800 for the three months ended December 31, 2017, an increase of approximately $915,700. The increased expense resulted from an increase in legal fees of $1,069,700, driven by the legal and settlement expenses from the resolution of the Babul litigation; an increase in stock-based compensation costs of $119,900; and an increase in other G&A expenses of $91,000; these increases were partially offset by a decrease patent related costs of $293,400 and a decrease of professional fees of $66,800.

 

Research and Development Expense

 

Research and development expense for the three months ended December 31, 2018 was approximately $1,257,400 compared to $150,700 for the three months ended December 31, 2017, an increase of $1,106,700. The increase was driven by an increase in study costs of $1,063,100, of which the majority, $996,200, pertained to our ongoing Phase 2a study and an increase in compensation costs of $43,500.

 

Other Income (Expense)

 

The change in the fair value of derivative liabilities was a non-cash unrealized gain of approximately $263,900 for the three months ended December 31, 2018 versus a non-cash unrealized gain of approximately $341,100 for the three months ended December 31, 2017.

 

The loss on extinguishment of debt, a non cash item, of approximately $3,774,500 for the three months ended December 31, 2018, versus zero for the three months ended December 31, 2017, was due to the conversion of outstanding principal and accrued interest on Convertible Promissory Notes into 10,731,669 shares of common stock.

 

Interest expense for the three months ended December 31, 2018 and 2017, was $139,700 and $311,900, respectively. The decrease was due to the extinguishment of the Convertible Promissory Notes on October 18, 2018.

 

Net Loss

 

The net loss for the Company for the three months ended December 31, 2018 and 2017 was approximately $(7,129,300) and $(1,427,400) respectively. The Company had net loss per basic and diluted weighted average common share of $(0.28) and $(0.11) for the three months ended December 31, 2018 and 2017, respectively.

 

21

 

   

Results of Operations

 

For the Six Months Ended December 31, 2018 versus December 31, 2017

 

   Six Months Ended   Six Months Ended     
   December 31
2018
   December 31,
2017
   Increase
(Decrease)
 
Operating Expenses            
General and administrative  $3,211,314   $2,120,971   $1,090,343 
Research and Development   2,678,900    316,470    2,362,430 
Total  $5,890,214    2,437,441    3,452,773 

 

General and Administrative Expense

 

General and administrative expense for the six months ended December 31, 2018 was approximately $3,211,300 compared to $2,121,000 for the six months ended December 31, 2017, an increase of approximately $1,090,300. The increase resulted from an increase in legal fees of $1,072,300, driven by the legal and settlement expenses from the resolution of the Babul litigation; an increase in stock based compensation of $197,500; and an increase in other G&A of $152,800. These increases were partially offset by a decrease patent related costs of $274,200 and a decrease of professional fees of $42,500.

 

Research and Development Expense

 

Research and development expense for the six months ended December 31, 2018 was approximately $2,678,900 compared to $316,500 for the six months ended December 31, 2017, an increase of $2,362,400. The increase was driven by an increase in study costs of $2,279,800, of which the majority, $2,162,200, pertained to our ongoing Phase 2a study, as well as an increase in compensation costs of $82,700.

 

Other Income (Expense)

 

The change in the fair value of derivative liabilities was a non-cash unrealized loss for the six months ended December 31, 2018 of $54,600 and a non-cash unrealized gain of $335,400 for the six months ended December 31, 2017.

 

The loss on extinguishment of debt, a non-cash item, of approximately $3,774,500 for the six months ended December 31, 2018, versus zero for the six months ended December 31, 2017, was due to the conversion of outstanding principal and accrued interest on Convertible Promissory Notes into 10,731,669 shares of common stock.

 

Interest expense the six months ended December 31, 2018 and 2017 was $790,100 and $309,300, respectively.

  

Net Loss

 

The net loss for the Company for the six months ended December 31, 2018 and 2017 was approximately ($10,509,403) and ($2,409,036) respectively. The Company had net loss per basic and diluted weighted average common share of $(0.55) and $(0.19) for the six months ended December 31, 2018 and 2017, respectively.

  

Liquidity

 

To date, we have financed our operations primarily through issuance of common stock and warrants and subordinated debt (convertible to common stock). Since our inception, we have not generated any product revenue and do not anticipate generating any revenues for the foreseeable future. We have incurred losses from inception to December 31, 2018 of approximately $104,853,710. We have generated negative cash flows from operations since inception. We expect to incur additional losses over the next several years developing our products. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern.

 

At December 31, 2018, the Company had cash and cash equivalents of approximately $2,426,800. The Company will need to raise additional funds in order to continue its development plans. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. If additional funds are required, we may raise such funds from time to time through public or private sales of equity or debt securities or from bank or other loans or through strategic research and development, or licensing. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders.

 

22

 

 

The following table sets forth selected cash flow information for the periods indicated below:

 

   Six Months Ended
December 31,
2018
   Six Months Ended
December 31,
2017
 
Cash used in operating activities  $(4,818,845)  $(2,110,662)
Cash used in investing activities   -    (2,591)
Cash provided by financing activities   5,006,653    6,342,265 
Net (decrease) increase in cash and cash equivalents  $187,808   $4,229,012 

 

For the six months ended December 31, 2018, cash used in operating activities was $4,818,845 primarily due to the loss from operations for the six months ended December 31, 2018 of $10,509,403, offset by loss on promissory note extinguishment of $3,774,468, and an increase in accrued expenses of $1,241,823.

 

For the six months ended December 31, 2017, cash used in operating activities was $2,110,662 primarily due to the loss from operations for the six months ended December 31, 2017 of $2,409,036.

 

For the six months ended December 31, 2018 and 2017, cash used in investing activities was $0 and $2,591, respectively, due to purchases of fixed assets.

 

Net cash provided by financing activities for the six months ended December 31, 2018 was $5,006,653 due to the sale of units. Net cash provided by financing activities for the six months ended December 31, 2017 was $6,342,265 due to proceeds raised through the promissory note financing.

 

Effects of Inflation

 

Our assets are primarily monetary, consisting of cash and cash equivalents. Because of their liquidity, these assets are not directly affected by inflation. Because we intend to retain and continue to use our equipment, we believe that the incremental inflation related to replacement costs of such items will not materially affect our operations. However, the rate of inflation affects our expenses, such as those for employee compensation and contract services, which could increase our level of expenses and the rate at which we use our resources.

 

Off-Balance Sheet Arrangements

 

As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPEs), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually limited purposes. As of December 31, 2018 and June 30, 2018, we were not involved in any SPE transactions.

 

Contractual Obligations

 

Please refer to Note 12 in our Annual Report on Form 10-K for the year ended June 30, 2018 under the heading Commitments and Contingencies. To our knowledge there have been no material changes to the risk factors that were previously disclosed in the Company’s Annual Report on Form 10-K for the year ended June 30, 2018. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

 

23

 

 

Critical Accounting Policies and Estimates

 

A critical accounting policy is one that is both important to the portrayal of a company’s financial condition and results of operations and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

 

Our unaudited consolidated financial statements are presented in accordance with U.S. GAAP, and all applicable U.S. GAAP accounting standards effective as of December 31, 2018 have been taken into consideration in preparing the unaudited consolidated financial statements. The preparation of unaudited consolidated financial statements requires estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures. Some of those estimates are subjective and complex, and, consequently, actual results could differ from those estimates. The following accounting policies and estimates have been highlighted as significant because changes to certain judgments and assumptions inherent in these policies could affect our consolidated financial statements:

 

  Research and development expenses,
     
  Stock-based compensation expenses; and
     
  Fair value of derivative liabilities

 

We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an on-going basis and make changes when necessary. Actual results could differ from our estimates.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

There have been no material changes to our exposures to market risks as disclosed under the heading “Quantitative and Qualitative Disclosures about Market Risks” in the annual MD&A contained in our Form 10-K for the year ended June 30, 2018.  

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based upon our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of December 31, 2018, in ensuring that material information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the six months ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

24

 

    

PART II OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence. The Company is not currently aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company’s business, financial condition, operating results, or cash flows.

 

On February 6, 2019 the Company entered into a settlement agreement in which Najib Babul relinquished his 303,392 shares in Relmada and signed a three year consulting contract and Relmada committed to a $500,000 initial payment and four subsequent payments related to his consulting agreement of $250,000 on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019. As a result of the settlement agreement, all outstanding litigation between the parties was dismissed with prejudice, including all claims and counterclaims in all legal proceedings related to Najib Babul v. Relmada Therapeutics, Inc., et al., Case No. 2:15-cv-02937-GAM, pending in the United States District Court for the Eastern District of Pennsylvania.    

 

ITEM 1A. RISK FACTORS

 

There have been no material changes to the risk factors under Part I, Item 1A of our Form 10-K for the year ended June 30, 2018.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

On February 12, 2019 the Company sold to accredited investors an aggregate of 805,554 shares of common stock and 523,619 warrants pursuant to a private placement transaction. The price per unit was $0.90 and the exercise price of each warrant is $1.50 with a 5 year term. There were no commissions paid. We believe the issuance of the shares and warrants was exempt from registration and prospectus delivery requirements of the Securities Act of 1933 by virtue of Section 4(2) and/or Regulation D, Rule 506. The shares were issued directly by us and did not involve a public offering or general solicitation. The recipients of the shares were afforded an opportunity for effective access to our files and records that contained the relevant information needed to make their investment decision, including our financial statements and 34 Act reports. We reasonably believed that the recipients, immediately prior to granting the shares and warrants, had such knowledge and experience in our financial and business matters that they were capable of evaluating the merits and risks of their investment. The recipients had the opportunity to speak with our management on several occasions prior to their investment decision. 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

Not applicable.

 

25

 

    

ITEM 6. EXHIBITS

 

Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K

  

Exhibit No.   Title of Document   Location
         
10.1   Lease Agreement, effective January 1, 2019, between Relmada Therapeutics, Inc. and 880 Third Avenue Tenant LLC.   Attached
         
10.2   Settlement Agreement, dated February 6, 2019, among Najib Babul, Laidlaw & Company (UK) Ltd., Sandesh Seth, and Sergio Traversa.   Attached
         
10.3   Consulting Agreement, effective March 25, 2019, between Relmada Therapeutics, Inc. and Najib Babul.   Attached
         
31.1   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   Attached
         
31.2   Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   Attached
         
32.1   Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*   Attached
         
32.2   Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*   Attached
         
101.SCH   XBRL Taxonomy Extension Schema Document   Attached
         
101.CAL   XBRL Taxonomy Calculation Linkbase Document   Attached
         
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document   Attached
         
101.LAB   XBRL Taxonomy Label Linkbase Document   Attached
         
101.PRE   XBRL Taxonomy Presentation Linkbase Document   Attached

   

* The Exhibit attached to this Form 10-Q shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

26

 

    

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: February 13, 2019 By: /s/ Sergio Traversa
    Sergio Traversa
    Chief Executive Officer and
Interim Chief Financial Officer
   

(Duly Authorized Executive Officer,

Principal Executive Officer and
Principal financial and Accounting Officer)

  

27

EX-10.1 2 f10q1218ex10-1_relmadatherap.htm LEASE AGREEMENT, EFFECTIVE JANUARY 1, 2019, BETWEEN RELMADA THERAPEUTICS, INC. AND 880 THIRD AVENUE TENANT LLC.

Exhibit 10.1

 

 

MEMBERSHIP AGREEMENT

 

HI SERGIO TRAVERSA

 

 

Please review your Membership Details below.

 

If you have any questions or concerns, please don’t hesitate to reach out to us at WE-US-29617@wework.com

 

PRIMARY MEMBER INFORMATION

 

 

Relmada Therapeutics, Inc.

Primary member: Sergio Traversa

st@relmada.com

+19174051305

   

WeWork Membership Agreement1

 

 

JOINING

 

 

WeWork 880 3rd Avenue

05-112 ● 4 person office
$3,550.00/mo

Start Date: January 1, 2019
Commitment term: 12 months
Notice period: 2 months

   

05-102 ● 8 person office
$7,650.00/mo

Start Date: January 1, 2019
Commitment term: 12 months
Notice period: 2 months

 

Discounts

-$7,280.00/mo from January 1, 2019 to January 31, 2019

-$3,360.00/mo from February 1, 2019 to December 31, 2019

 

Additional Fees

Setup Fee $0.00

 

SERVICE RETAINER SUMMARY

 

 

Service retainer fees for WeWork
880 3rd Avenue

$28,000.00

2.5x monthly membership fee

Your service retainer balance will be charged with any other additional fees.

INCLUDED CREDIT ALLOTMENTS

 

 

Conference room credits

34 total credits per month starting on January 1, 2019.

 

Print credits

1440 total black & white prints and 240 total color prints per month starting on January 1, 2019.

 

WeWork Membership Agreement2

 

  

TERMS & CONDITIONS

 

 

By electronically signing the(se) membership agreement(s) below, your company is entering into legally binding agreement(s). Please download and read carefully prior to signing. Any Agreement(s), including the(se) Terms and Conditions and Membership Details form(s), and any applicable Service Package Addendum(s), will be effective when signed by both parties. In the event of any conflict between the(se) Terms and Conditions and the Membership Details form(s), the Membership Details form(s) shall prevail.

 

When signing this (these) Agreement(s) you must have the proper authority to execute this (these) Agreement(s) on behalf of the company listed above and incur the obligations described in this (these) Agreement(s) on behalf of such company.

 

þI agree to the(se) Terms & Conditions, Payment Authorization Terms, Membership Details Terms, and any applicable Service Package Addendum in this (these) Membership Agreement(s). I additionally agree that in the event I have any pre-existing Membership Agreement(s) the terms of such Agreement(s) which are not revised, amended or terminated herein remain unchanged.

 

Community Manager’s signature

Nicole Maxman
 

Electronic Signature

Sergio Traversa

880 3rd Ave Tenant LLC   Relmada Therapeutics, Inc.
Signed on December 21, 2018

 

WeWork

880 3rd Ave Tenant LLC

880 3rd Avenue
New York, NY, 10022, USA

WE-US-29617@wework.com

 

WeWork Membership Agreement3

 

 

TERMS & CONDITIONS

 

1.THE LINGO

 

“Agreement” means, collectively, these Terms & Conditions (the “Terms and Conditions”), the attached Membership Details Form cover page(s) (the “Membership Details Form”), and any other attachments, exhibits, and/or supplements.

 

“Authorized Signatory” means an individual authorized to legally bind your company.

 

“Capacity” means the maximum number of Memberships allotted to your Office Space as set forth in the Membership Details Form.

 

“Commitment Term” means the period of time from the Start Date to the last day of the period set forth on the Membership Details Form under “Commitment Term” with respect to each Individual Office Number, and which may be extended upon mutual agreement of the parties.

 

“Individual Office Number” means each individual office number and/or workspace location as may be specified in the Membership Details Form. If the symbol “Ø” is included on the Membership Details Form, we will provide the Individual Office Number(s) for the agreed upon Capacity prior to the Start Date.

 

“Main Premises” means the Premises in which the Office Space is located, as set forth in the Membership Details Form.

  

“Member” means each person you authorize to receive the Services (defined below) (each Member granted a “Membership”).

 

“Member Company” or “you” means the company, entity, or individual entering into this Agreement as listed in the Membership Details Form.

 

“Office Space” means the actual office or workspace corresponding to the Individual Office Number(s), taken together.

 

“Premises” means a building or portion of a building in which WeWork offers offices, workstations, other workspaces, and/or other services to Members.

 

“Primary Member” means the primary in-Premises Member contact for WeWork.

 

“Regular Business Days” are all weekdays, except local bank/government holidays.

“Regular Business Hours” are generally from 9:00 a.m. to 6:00 p.m. on Regular Business Days.

 

“Set-Up Fee” means the fee you will be charged for each individual Membership included in the Capacity of your Office Space; you are obligated to pay the Set-Up Fee for each Individual Office that you occupy, including such Setup Fees as may be due upon transfer, including upgrade or downgrade (i.e. transferring to an Office Space with a higher or lower Capacity), of Office Space.

 

“Start Date” means the date set forth in the Membership Details Form upon which the Services will begin being provided with respect to each Individual Office Number.

 

“WeWork,” “we” or “us” means the WeWork entity you are contracting with.

 

“WeWork Member Network” means the WeWork members-only online community accessed through the internet or our mobile app.

 

2.THE BENEFITS OF MEMBERSHIP

 

a.Services. Subject to the terms and conditions of this Agreement, and any other policies we make available to you with prior notice from time to time, during the Term (defined below), WeWork will use commercially reasonable efforts to provide you (and your Members, as applicable) the services described below. These services are referred to in this Agreement as the “Services.”

 

i.Non-exclusive access to the Office Space.

 

ii.Regular maintenance of the Office Space.

 

iii.Furnishings for the Office Space of the quality and in the quantity typically provided to other member companies with similar office space, workstations, and/or other workspace, as applicable, in the Premises.

 

iv.Access to and use of the WeWork Member Network in accordance with the terms of services available on our website.

 

v.Access to and use of the shared Internet connection in accordance with the terms of services available on our website.

 

vi.Use of the printers, copiers and/or scanners available to our members and member companies, in accordance with the terms described herein.

 

vii.Use of the conference rooms in your Main Premises and use of conference rooms in any other WeWork Premises during Regular Business Hours, in each case subject to availability and your prior reservation of such conference rooms, in accordance with the terms described herein.

 

1

 

 

viii.Heat and air-conditioning in the Office Space during Regular Business Hours.

 

ix.Electricity for reasonably acceptable office use.

 

x.Use of kitchens and beverages made available to our members and member companies.

 

xi.Acceptance of mail and deliveries on behalf of your business during Regular Business Hours.

 

xii.Opportunity to participate in members-only events, benefits and promotions.

 

Other services may be provided for an additional fee, such as car parking space, phone service, and IT services, subject to availability at the Main Premises and any additional terms and expenses applicable to those services.

 

b.Our Reserved Rights. We are entitled to access your Office Space, with or without notice, in connection with our provision of the Services, for safety or emergency purposes or for any other purposes. We may temporarily move furnishings contained in your Office Space. We reserve the right to alter or relocate your Office Space, provided that we will not do so in a manner that substantially decreases the square footage of your assigned Office Space or related amenities. We may also modify or reduce the list of Services or furnishings provided for your Office Space at any time. The Services may be provided by us, an affiliate or a third party.

 

c.Office Space Not Timely Available. If we are unable to make the Office Space available by the Start Date we will not be subject to any liability related to such inability, nor will such inability affect the enforceability of this Agreement. This Agreement shall remain in full force and effect, provided that: (i) the failure to provide access to the Office Space does not last longer than two (2) months and (ii) at our sole discretion we will either (x) provide you with alternate office space (which may or may not be within a WeWork building) with reasonably comparable Capacity during such period and charge your Membership Fee or (y) not charge you the Membership Fee during the period the Office Space is not available to you. Following the two (2) month period set forth in (i) above, you shall have the ability to terminate this Agreement upon seven (7) days’ prior notice to us. If we do provide you alternate office space as described in clause (x) above, during the period we provide you with such alternate office space, the individuals named as Members shall be deemed to be Members and otherwise shall be fully subject to the terms of this Agreement. Notwithstanding anything in this paragraph to the contrary, if the delay in providing the Office Space is due to your actions or inactions or due to changes in or work to the Office Space requested by you, we will not be subject to any liability related to such delay nor will such delay affect the validity of this Agreement and we shall have no obligations to provide you with the benefits described in subsections (x) and (y) of this paragraph and you shall not be entitled to terminate this Agreement and shall be liable for the payment of the Membership Fees from the Start Date.
d.Access Prior to Start Date. If we, in our sole discretion, provide you with access to your Office Space for any period of time prior to your Start Date (a “Soft Open Period”), during any such Soft Open Period you and your Members shall be fully subject to the terms of this Agreement, regardless of whether we choose to charge you the Membership Fee during any such Soft Open Period.

 

3.YOUR MEMBERS

 

a.Member List. You are responsible for maintaining the accuracy of your list of Members on the WeWork Member Network (your “Member List”). Only those individuals included on the Member List will be deemed to be “Members” and entitled to receive the Services described in this Agreement. To the extent permitted by law, all of your Members shall be required to provide valid government issued identification in order to be issued an activated key card to access the Premises. If the number of Members or other individuals regularly using your Office Space exceeds the Capacity, you will be required to pay the then current additional fee as set forth on our website. In no event will the number of Members exceed 1.5 times the Capacity, regardless of additional fees paid; however affiliated members with other active memberships offered by WeWork such as We Membership, Hot Desk, and/or separate Dedicated Desk Memberships using desks outside of the Office Space will not count towards this limit. We reserve the right to further limit the number of Members allowed at any point.

 

Upon the addition of a Member to the Member List, WeWork will create a profile for such Member on the WeWork Member Network. Such profile will be viewable by us, our employees and agents, and other members. The created profile will include only the Member’s name and the Member Company; any additional information, including a photograph, shall be added solely as determined by you or your Members.

 

2

 

 

b.Changes to or Removal of Primary Member or Authorized Signatory. An Authorized Signatory generally has the sole authority to make changes to or terminate this Agreement. A Primary Member will generally serve as WeWork’s primary contact regarding matters that involve your Members, the physical Office Space or the Premises. If no Authorized Signatory other than the Primary Member is designated by you on the Membership Details Form, the Primary Member will serve as the Authorized Signatory. We will be entitled to rely on communications to or from the Authorized Signatory or Primary Member as notice to or from the applicable Member Company. However, an Executive Officer of the applicable Member Company (“Executive Officer”) will have the authority to override the request of an Authorized Signatory or Primary Member, as applicable, provided that we receive such a request within 24 hours following such Authorized Signatory’s or Primary Member’s request. We will be entitled to request reasonable documentation to confirm that an individual claiming to be an Executive Officer truly is one and to exercise our discretion in determining whether a particular position constitutes an “Executive Officer.” An Executive Officer will also have the authority to remove or replace the individual serving as the Authorized Signatory and/or Primary Member. Unless we receive instructions from the Authorized Signatory or Executive Officer, if the individual designated as the Primary Member ceases to provide services to the Member Company or ceases using the Office Space regularly, we will use our reasonable judgment in designating a replacement Primary Member.

 

4.MEMBERSHIP FEES; PAYMENTS

 

a.Payments Due Upon Signing. Upon submitting a signed and completed Agreement, you will be obligated to deliver to us, in the amount(s) set forth on your Membership Details Form, (i) the Service Retainer and (ii) the Set-Up Fee.

 

b.Membership Fee. During the Term (defined below) of this Agreement, your Membership Fee will be due monthly and in advance as of the first (1st) day of each month. You are obligated to make payment of all Membership Fees owed throughout the Commitment Term and this obligation is absolute notwithstanding any early termination of the Agreement by you (“Membership Fee Obligations”). You agree to pay promptly: (i) all sales, use, excise, value added, and any other taxes which you are required to pay to any other governmental authority (and, at our request, will provide to us evidence of such payment) and (ii) all sales, use, excise, value added and any other taxes attributable to your Membership as shown on your invoice. The Membership Fee set forth on the Membership Details Form covers the Services for only the number of Members indicated in the Membership Details Form. Additional Members will result in additional fees as set forth on our website.

On each anniversary of the Start Date (including during any Commitment Term) the Membership Fee will be subject to an automatic three percent (3%) increase over the then current Membership Fee. Following any Commitment Term, we reserve the right to further increase or decrease the Membership Fee at our sole discretion upon thirty (30) days’ prior notice to you in advance of and in accordance with the Termination Notice Period described below in Section 5(d).

 

c.Invoices; Financial Information. WeWork will send or otherwise provide invoices and other billing-related documents, information and notices to the Primary Member or, if a Billing Contact is indicated on the Membership Details Form, the Billing Contact. Change of the Billing Contact will require notice from the Authorized Signatory in accordance with this Agreement.

 

d.Credits; Overage Fees. Each month, you will receive a certain number of credits for conference room use and a certain number of credits for color and black and white copies and printouts, as specified on the Membership Details Form. These allowances may not be rolled over from month to month. If these allocated amounts are exceeded, you will be responsible for paying fees for such overages. The current overage fee schedule is listed on our website. All overage fees are subject to increase from time to time at our sole discretion.

 

e.Late Fees. If payment for the Membership Fee or any other accrued and outstanding fee is not made by the tenth (10th) of the month in which such payment is due, you will be responsible for paying the then-current late charge. The current late fee schedule is listed on our website. All late fees are subject to increase from time to time at our sole discretion.

 

f.Form of Payment. We accept payment of all amounts specified in this Agreement solely by the methods we communicate to you during the membership sign up process or from time to time during the Term. You are required to inform us promptly of any changes to your payment information. Changing your payment method may result in a change in the amount required under this Agreement to be held as the Service Retainer.

  

3

 

 

g.Outstanding Fees. Any outstanding fees will be charged in arrears on a monthly basis. When we receive funds from you, we will first apply funds to any balances which are in arrears (including any outstanding late fees) and to the earliest month due first. Once past balances are satisfied, any remaining portion of the funds will be applied to current fees due. If any payments remain outstanding after we provide notice to you, we may, in our sole discretion, withhold Services or terminate this Agreement in accordance with Section 5.

 

h.No Refunds. Except as otherwise provided for herein, there are no refunds of any fees or other amounts paid by you or your Members in connection with the Services.

 

5.TERM AND TERMINATION

 

a.Term. This Agreement will be effective when signed by both parties (“Effective Date”); provided that we have no obligations to provide you with the Services until the later of (i) the date on which payment of your Service Retainer, Set-Up Fee and first month’s Membership Fee has been received by us or (ii) the Start Date. Unless otherwise set forth on the Membership Details Form, following the Commitment Term, this Agreement shall continue on a month-to-month basis (any term after the Commitment Term, a “Renewal Term”), subject to the Termination Notice Periods (defined below). The Commitment Term and all subsequent Renewal Terms shall constitute the “Term.” If no Commitment Term is indicated on your Membership Details Form, the default Commitment Term shall commence on the Start Date and end one (1) month after the Start Date. This Agreement will continue until terminated in accordance with this Agreement.

 

b.Move In / Move Out. If the Start Date is a Regular Business Day, you will be entitled to move into the Office Space no earlier than 11:00 a.m. on the Start Date, provided you have complied with the payment obligations described in Section 5(a). If the Start Date is not a Regular Business Day, you will be entitled to move into the Office Space no earlier than 11:00 a.m. on the first Regular Business Day after the Start Date. On the last Regular Business Day of the Termination Effective Month (defined below), you must vacate the Office Space by no later than 4:00 p.m.

 

c.Cancellation Prior to Start Date by You. You may cancel this Agreement prior to the Start Date upon delivery of notice to us. If you terminate more than one (1) full calendar month prior to your Start Date, you may be entitled to a refund of your Set-Up Fee, less any applicable charges, expenses or deductions; however, you will not be entitled to a refund of your Service Retainer. If you terminate within one (1) full calendar month prior to your Start Date, you will not be entitled to a refund of your Set-Up Fee or Service Retainer.
d.Termination by You. You may terminate this Agreement by providing written notice to us prior to the month in which you intend to terminate this Agreement (“Termination Effective Month”) in accordance with the notice periods set forth in the chart below (the “Termination Notice Period(s)”). The applicable Termination Notice Period shall be determined by the Commitment Term and Capacity for the relevant Individual Office Number, as depicted in the chart below, and as displayed on the Membership Details Form. The Termination Notice Periods shall apply to any termination by you during the Term. After receiving such notice we will deliver to you the WeWork Exit Form (“Exit Form”), which you must complete and submit to us. The termination will be effective on the later of the last Regular Business Day of the Termination Effective Month and the expiration of the Commitment Term. No termination by you shall be effective during the Commitment Term (except pursuant to Section 2(c)), and termination by you during the Commitment Term is a breach of this Agreement. Downgrade of the Office Space (i.e. transferring to an office space with a lower Capacity) is also not permitted during the Commitment Term. If you terminate this Agreement prior to the end of the Commitment Term (or during any relevant Termination Notice Period), your Membership Fee Obligations shall become immediately due. In addition to any rights, claims and remedies we choose to pursue in our discretion, your Service Retainer shall be forfeited immediately as a result of your breach. Notice must be provided during Regular Business Hours. The Exit Form needs to be completely filled out and signed by the Authorized Signatory; however, please note that the termination of your Agreement on the last Regular Business Day of the Termination Effective Month will be triggered upon your provision of written notice of termination to us, regardless of when you complete and submit the Exit Form. You will not be entitled to pro ration with respect to the last month’s Membership Fee. For instance, if you vacate your Office Space before the last Regular Business Day of April, you will still owe us the full Membership Fee for the full month of April.

 

4

 

 

Member Company Termination Notice Periods Required:

 

Commitment Term  Capacity
   0 - 24  25 - 74  75+
1 - 5 months  1 month  2 months  3 months
6 - 11 months  1 month  2 months  3 months
12 - 23 months  2 months  3 months  6 months
24 + months  3 months  6 months  6 months

 

Example: If the Capacity for the Office Space is between twenty-five (25) and seventy-four (74) Members, and the Commitment Term is between six (6) and eleven (11) months, the applicable Termination Notice Period would be two (2) months, and to terminate this Agreement effective the last Regular Business Day of April (provided that the Commitment Term shall have expired by such date) the last opportunity to provide notice to us would be during Regular Business Hours on the last Regular Business Day of February.

 

e.Termination or Suspension by Us. We may withhold Services or immediately terminate this Agreement: (i) upon breach of this Agreement by you or any Member; (ii) upon termination, expiration or material loss of our rights in the Premises; (iii) if any outstanding fees are still due after we provide notice to you; (iv) if you or any of your Members fail to comply with the terms and conditions of the WeWork Member Network Terms of Service, our Wireless Network Terms of Service, or any other policies or instructions provided by us or applicable to you; or (v) at any other time, when we, in our sole discretion, see fit to do so. You will remain liable for past due amounts, and we may exercise our rights to collect due payment, despite termination or expiration of this Agreement.

An individual Member will no longer receive the Services and is no longer authorized to access the Main Premises or other Premises upon the earlier of (x) the termination or expiration of this Agreement; (y) your removal of such Member from the Member List or (z) our notice to you that such Member violated this Agreement. We may withhold or terminate Services of individual Members for any of the foregoing reasons; in such circumstances this Agreement will continue in full force and effect to the exclusion of the relevant Member.

 

f.Service Retainer. The Service Retainer will be held as a retainer for performance of all your obligations under this Agreement, including the Membership Fee Obligations, and is not intended to be a reserve from which fees may be paid. In the event you owe us other fees, you may not rely on deducting them from the Service Retainer, but must pay them separately. We will return the Service Retainer, or any balance after deducting outstanding fees and other costs due to us, including any unsatisfied Membership Fee Obligations, to you by bank transfer or other method that we communicate to you within thirty (30) days (or earlier if required by applicable law) after the later of (i) the termination or expiration of this Agreement and (ii) the date on which you provide to us all account information necessary for us to make such payment. Return of the Service Retainer is also subject to your complete performance of all your obligations under this Agreement, including full satisfaction of your Membership Fee Obligations and any additional obligations applicable following termination or expiration of this Agreement.

 

g.Removal of Property Upon Termination. Prior to the termination or expiration of this Agreement, you will remove all of your, your Members’, and your or their guests’ property from the Office Space and Premises. After providing you with reasonable notice, we will be entitled to dispose of any property remaining in or on the Office Space or Premises after the termination or expiration of this Agreement and will not have any obligation to store such property, and you waive any claims or demands regarding such property or our handling or disposal of such property. You will be responsible for paying any fees reasonably incurred by us regarding such removal. We shall have no implied obligations as a bailee or custodian, and you hereby indemnify us and agree to keep us indemnified in respect of any claims of any third parties in respect of such property. Following the termination or expiration of this Agreement, we will not forward or hold mail or other packages delivered to us.

 

5

 

 

6.HOUSE RULES

 

In addition to any rules, policies and/or procedures that are specific to a Premises used by you:

 

a.You acknowledge and agree that:

   

i.keys, key cards and other such items used to gain physical access to the Premises, or the Office Space remain our property. You will cause your Members to safeguard our property and you shall promptly notify us and be liable for replacement fees should any such property be lost, stolen or destroyed;

 

ii.you shall promptly notify us of any change to your contact and/or payment information;

 

iii.we will provide notice to you of any changes to Services, fees, or other updates via email. It is your responsibility to read such emails and to ensure your Members are aware of any changes, regardless of whether we notify such Members directly;

 

iv.carts, dollies and other freight items which may be made available may not be used in the passenger elevator except at our discretion;

 

v.for security reasons, we may, but have no obligation to, regularly record certain areas in the Premises via video;

 

vi.all of your Members are at least 18 years of age;

 

vii.you shall be solely and fully responsible for ensuring that alcohol is consumed responsibly by your individual Members and that no alcohol is consumed by any of your Members or guests who is younger than the legal age for consuming alcohol in the applicable jurisdiction;

 

viii.common spaces are to be enjoyed by all our member companies, members and guests unless otherwise instructed by us, and are for temporary use and not as a place for continuous, everyday work;

 

ix.you will provide us with reasonable notice of and complete all required paperwork prior to hosting any event at the Premises;

 

x.you will be responsible for any damage to your Office Space other than normal wear and tear;

 

xi.you will be responsible for replacement fees for any item(s) provided to you by the WeWork community team for temporary use should any such property be lost, stolen or destroyed;

 

xii.we are not liable for any mail or packages received without a WeWork employee’s signature indicating acceptance;
xiii.you may not make any structural or nonstructural alterations or installations (including, but not limited to, wall attachments, furniture, IT equipment, and/or glass paneling) in the Office Space or elsewhere in the Premises without prior approval by us. In the event that any alterations or installations are made, you shall be responsible for the full cost and expense of the alteration or installation and, prior to the termination of this Agreement, the removal of such items and the restoration necessitated by any such alterations, and we shall deduct any such costs not otherwise paid by you from the Service Retainer. In no event are you permitted to perform any of these actions. Only a member of our facilities staff is entitled to perform an alteration, installation, removal or restoration. Reach out to a member of your community team for more information;

 

xiv.you and your Members’ computers, tablets, mobile devices and other electronic equipment must be (a) kept up-to-date with the latest software updates provided by the software vendor and (b) kept clean of any malware, viruses, spyware, worms, Trojans, or anything that is designed to perform malicious, hostile and/or intrusive operations. We reserve the right to remove any device from our networks that poses a threat to our networks or users until the threat is remediated; and

 

xv.you consent to our non-exclusive, nontransferable use of your Member Company name and/or logo in connection with identifying you as a Member Company of WeWork, alongside those of other member companies, on a public-facing “Membership” display on our website, as well as in video and other marketing materials. You warrant that your logo does not infringe upon the rights of any third party and that you have full authority to provide this consent. You may terminate this consent at any time upon thirty (30) days’ prior notice.

 

b.No Member will:

 

i.perform any activity or cause or permit anything that is reasonably likely to be disruptive or dangerous to us or any other member companies, or our or their employees, guests or property, including without limitation the Office Space or the Premises;

 

ii.use the Services, the Premises or the Office Space to conduct or pursue any illegal or offensive activities or comport themselves to the community in a similar manner; all Members shall act in a respectful manner towards other member companies and our and their employees and guests;

 

6

 

 

iii.misrepresent himself or herself to the WeWork community, either in person or on the WeWork Member Network;

 

iv.take, copy or use any information or intellectual property belonging to other member companies or their members or guests, including without limitation any confidential or proprietary information, personal names, likenesses, voices, business names, trademarks, service marks, logos, trade dress, other identifiers or other intellectual property, or modified or altered versions of the same, and this provision will survive termination of this Agreement;

 

v.take, copy or use for any purpose the name “WeWork” or any of our other business names, trademarks, service marks, logos, trade dress, marketing material, other identifiers or other intellectual property or modified or altered versions of the same, or take, copy or use for any purpose any pictures or illustrations of any portion of the Premises, or engage in any conduct that is likely to cause confusion between WeWork and yourself, without our prior consent, and this provision will survive termination of this Agreement, provided that during the term of this Agreement you will be able to use “WeWork” in plain text to accurately identify an address or office location;

 

vi.film within any Premises, including within the Office Space, without completing all required paperwork and receiving express written consent from WeWork;

 

vii.use the Office Space in a retail, medical, or other capacity involving frequent visits by members of the public, as a residential or living space, or for any exclusively non-business purpose;

 

viii.sell, manufacture or distribute any controlled substance, including alcoholic beverages, from the Office Space, or obtain a license for such sale, manufacture, importation, or distribution using the Office Space or the address of the Main Premises;

 

ix.use our mail and deliveries services for fraudulent or unlawful purposes, and we shall not be liable for any such use;

 

x.store significant amounts of currency or other valuable goods or commodities in the Office Space that are not commonly kept in commercial offices; in the event that you do so, we will not be liable for any such loss;
  xi. make any copies of any keys, keycards or other means of entry to the Office Space or the Premises or lend, share or transfer any keys or keycards to any third party, unless authorized by us in advance;

 

xii.install any locks to access the Office Space or anywhere within the Premises, unless authorized by us in advance;

 

xiii.allow any guest(s) to enter the building without registering such guest(s) and performing any additional required steps according to our policies;

 

xiv.operate any equipment within the Premises that has a higher heat output or electrical consumption than in a typical personal office environment, or places excessive strain on our electrical, IT, HVAC or structural systems, with such determination to be made in our sole discretion, without our prior approval; or

 

xv.bring any weapons of any kind, or any other offensive, dangerous, hazardous, inflammable or explosive materials into the Office Space or the Premises.

 

You are responsible for ensuring your Members comply with all House Rules and with all rules, policies and/or procedures that are specific to a Premises used by you, and agree that in the event of any penalty or fine resulting from the breach of any such rules, policies and/or procedures, you will be responsible for paying such penalty or fine.

 

7.ADDITIONAL AGREEMENTS

 

a.Information Technology. In order to utilize all the functionalities offered by us, it may be necessary to install software onto a Member’s computer, tablet, mobile device or other electronic equipment. In addition, a Member may request that we troubleshoot problems a Member may have with respect to printing, accessing the network connection or other issues. If we provide such services, we will not be responsible for any damage to your equipment.

 

7

 

 

b.Network Connection. WeWork provides shared Internet access to Members via a wireless network connection. Wired network connections are available for an additional monthly fee. For those Members wishing to implement a private wired network, WeWork may allow you to install a firewall device for your exclusive access and use, subject to WeWork IT approval, and you will be responsible for removal of the same. Prior to any such installation or removal, you shall coordinate with the WeWork IT team to discuss the actual setup, appropriate time, manner and means for such installation or removal and any additional fees that may result from the request. To the extent that we incur any costs in connection with such installation or removal, which are not otherwise paid by you, we shall deduct such costs from the Service Retainer. You shall also be responsible for any monthly fees incurred relating to your private, secured wired network.

 

c.Waiver of Claims. To the extent permitted by law, you, on your own behalf and on behalf of your Members, employees, agents, guests and invitees, waive any and all claims and rights against us and our landlords at the Premises and our affiliates, parents, and successors and each of our and their employees, assignees, officers, agents and directors (collectively, the “WeWork Parties”) resulting from injury or damage to, or destruction, theft, or loss of, any property, person or pet, except to the extent caused by the gross negligence, willful misconduct or fraud of the WeWork Parties.

 

d.Limitation of Liability. To the extent permitted by law, the aggregate monetary liability of any of the WeWork Parties to you or your Members, employees, agents, guests or invitees for any reason and for all causes of action, will not exceed the total Membership Fees paid by you to us under this Agreement in the twelve (12) months prior to the claim arising. None of the WeWork Parties will be liable under any cause of action, for any indirect, special, incidental, consequential, reliance or punitive damages, including loss of profits or business interruption. You acknowledge and agree that you may not commence any action or proceeding against any of the WeWork Parties, whether in contract, tort, or otherwise, unless the action, suit, or proceeding is commenced within one (1) year of the cause of action’s accrual. Notwithstanding anything contained in this Agreement to the contrary, you acknowledge and agree that you shall not commence any action or proceeding against any of the WeWork Parties other than the WeWork Party you are directly contracting with hereunder and the assets of such entity for any amounts due or for the performance of any obligations in connection with this Agreement.

 

e.Indemnification. You will indemnify the WeWork Parties from and against any and all claims, including third party claims, liabilities, and expenses including reasonable attorneys’ fees, resulting from any breach or alleged breach of this Agreement by you or your Members or your or their guests, invitees or pets or any of your or their actions or omissions, except to the extent a claim results from the gross negligence, willful misconduct or fraud of the WeWork Parties.

You are responsible for the actions of and all damages caused by all persons and pets that you, your Members or your or their guests invite to enter any of the Premises, including but not limited to any vendors hired by you that enter the Premises. You shall not make any settlement that requires a materially adverse act or admission by us or imposes any obligation upon any of the WeWork Parties unless you have first obtained our or the relevant WeWork Party’s written consent. None of the WeWork Parties shall be liable for any obligations arising out of a settlement made without its prior written consent.

 

f.Insurance. You are responsible for maintaining, at your own expense and at all times during the Term, personal property insurance and commercial general liability insurance covering you and your Members for property loss and damage, injury to your Members and your Members’ guests or pets and prevention of or denial of use of or access to, all or part of the Premises, in form and amount appropriate to your business. In addition you are responsible for maintaining, at your own expense and at all times during the Term, workers’ compensation insurance providing statutory benefits in accordance with the law and employer’s liability in an amount appropriate to your business. You will ensure that WeWork and the landlord of the applicable Premises shall each be named as additional insureds on your commercial general liability policy and that all insurance policies shall include a clause stating that the insurer waives all rights of recovery, under subrogation or otherwise, you may have against WeWork and the landlord of the applicable premises. You shall provide proof of insurance upon our request.

 

g.Pets. If the Office Space is in Premises designated by us to be one in which pets are permitted, and if any Member plans on regularly bringing a pet into the Office Space or otherwise into the Premises, we may require this Member to produce proof of vaccination for such pet and evidence of compliance with applicable local regulations. If any of your Members brings a pet into the Premises, you will be responsible for any injury or damage caused by this pet to other members or guests or other occupants of the Premises or to the property of (i) WeWork or any employees, members or guests or (ii) the owner(s) or other occupants of the Premises. None of the WeWork Parties will be responsible for any injury to such pets. We reserve the right to restrict any Member’s right to bring a pet into the Premises in our sole discretion.

 

h.Other Members. We do not control and are not responsible for the actions of other Member Companies, Members, or any other third parties. If a dispute arises between Member Companies, members or their invitees or guests, we shall have no responsibility or obligation to participate, mediate or indemnify any party.

 

8

 

 

i.Third Party Services. Services do not include, and we are not involved in or liable for, the provision of products or services by third parties (“Third Party Services”) that you may elect to purchase in connection with your Membership, including via the WeWork Services Store, even if they appear on your WeWork invoice. Third Party Services are provided solely by the applicable third party (“Third Party Service Providers”) and pursuant to separate arrangements between you and the applicable Third Party Service Providers. These Third Party Service Providers’ terms and conditions will control with respect to the relevant Third Party Services. By adding a Member to the Member List, you are thereby authorizing that Member to access and use the WeWork Services Store in accordance with the terms of service available on our website.

 

j.Privacy. We collect, process, transfer and secure personal data about you and your Members pursuant to the terms of our Privacy Policy, which can be found on our website (www.wework.com/legal/privacy), and in accordance with all applicable data protection laws. Note that you are not obligated to provide us with personal information and any information collected by us will be provided by you at your own will and with your explicit consent granted herein by execution of this Agreement. You hereby (i) undertake, where necessary, to obtain consent from such Member to the collection, processing, transferring and securing of data described herein and (ii) confirm that you in fact collect and process such Member’s personal data in accordance with applicable law.

 

8.ARBITRATION AND CLASS ACTION WAIVER

 

a.Governing Law. This Agreement and the transactions contemplated hereby shall be governed by and construed under the law of the State of New York, U.S.A. and the United States without regard to conflicts of laws provisions thereof and without regard to the United Nations Convention on Contracts for the International Sale of Goods.

 

b.Venue. Except that either party may seek equitable or similar relief from any court of competent jurisdiction, any dispute, controversy or claim arising out of or in relation to this Agreement, or at law, or the breach, termination or invalidity of this Agreement, that cannot be settled amicably by agreement of the parties to this Agreement shall be finally settled in accordance with the arbitration rules of JAMS then in force, by one or more arbitrators appointed in accordance with said rules. The place of arbitration shall be New York, New York, U.S.A.
c.Proceedings; Judgment. The proceedings shall be confidential and in English. The award rendered shall be final and binding on both parties. Judgment on the award may be entered in any court of competent jurisdiction. In any action, suit or proceeding to enforce rights under this Agreement, the prevailing party shall be entitled to recover, in addition to any other relief awarded, the prevailing party’s reasonable attorneys’ fees and other fees, costs and expenses of every kind in connection with the action, suit or proceeding, any appeal or petition for review, the collection of any award or the enforcement of any order, as determined by the arbitrator(s) or court, as applicable. This Agreement shall be interpreted and construed in the English language, which is the language of the official text of this Agreement.

 

d.Class Action Waiver. Any proceeding to resolve or litigate any dispute in any forum will be conducted solely on an individual basis. Neither you nor we will seek to have any dispute heard as a class action or in any other proceeding in which either party acts or proposes to act in a representative capacity. No proceeding will be combined with another without the prior written consent of all parties to all affected proceedings. You also agree not to participate in claims brought in a private attorney general or representative capacity, or any consolidated claims involving another person’s account, if we are a party to the proceeding. YOU ARE GIVING UP YOUR RIGHT TO PARTICIPATE AS A CLASS REPRESENTATIVE OR CLASS MEMBER ON ANY CLASS CLAIM YOU MAY HAVE AGAINST US INCLUDING ANY RIGHT TO CLASS ARBITRATION OR ANY CONSOLIDATION OF INDIVIDUAL ARBITRATIONS.

 

9.MISCELLANEOUS

 

a.Nature of the Agreement; Relationship of the Parties. Your agreement with us is the commercial equivalent of an agreement for accommodation in a hotel. The whole of the Office Space remains our property and in our possession and control. We are giving you the right to share with us the use of the Office Space so that we can provide the Services to you. Notwithstanding anything in this Agreement to the contrary, you and we agree that our relationship is not that of landlord-tenant or lessor-lessee and this Agreement in no way shall be construed as to grant you or any Member any title, easement, lien, possession or related rights in our business, the Premises, the Office Space or anything contained in or on the Premises or Office Space. This Agreement creates no tenancy interest, leasehold estate, or other real property interest. The parties hereto shall each be independent contractors in the performance of their obligations under this Agreement, and this Agreement shall not be deemed to create a fiduciary or agency relationship, or partnership or joint venture, for any purpose. You acknowledge and agree that you are entering into this Agreement for the purposes of and in the course of your trade, business and/or profession, and not as a consumer. Neither party will in any way misrepresent our relationship.

 

9

 

 

b.Updates to the Agreement. Changes to membership and overage fees, will be governed by Section 4(b) and 4(d) of this Agreement, respectively. We may from time to time update this Agreement and will provide notice to you of these updates. You will be deemed to have accepted the new terms of the Agreement following the completion of two (2) full calendar months after the date of notice of the update(s). Continued use of the Office Space or Services beyond this time will constitute acceptance of the new terms.

 

c.Waiver. Neither party shall be deemed by any act or omission to have waived any of its rights or remedies hereunder unless such waiver is in writing and signed by the waiving party.

 

d.Subordination. This Agreement is subject and subordinate to our lease with our landlord of the Premises and to any supplemental documentation and to any other agreements to which our lease with such landlord is subject to or subordinate. However, the foregoing does not imply any sublease or other similar relationship involving an interest in real property.

 

e.Extraordinary Events. WeWork will not be liable for, and will not be considered in default or breach of this Agreement on account of, any delay or failure to perform as required by this Agreement as a result of any causes or conditions that are beyond WeWork’s reasonable control, including without limitation (i) any delays or changes in construction of, or WeWork’s ability to procure any space in, any Premises, and (ii) any delays or failure to perform caused by conditions under the control of our landlord at the applicable Premises.

 

f.Severable Provisions. Each provision of this Agreement shall be considered severable. To the extent that any provision of this Agreement is prohibited or otherwise limited, this Agreement shall be considered amended to the smallest degree possible in order to make the Agreement effective under applicable law.
g.Survival. Sections 1, 2(b), 4 (to the extent any payments remain outstanding), 5(d), 5(f), 5(g), 6(b), 7(a) through 7(f), 7(h), 8, and 9 and all other provisions of this Agreement reasonably expected to survive the termination or expiration of this Agreement will do so.

 

h.Notices. Any and all notices under this Agreement will be given via email, and will be effective on the first business day after being sent. All notices will be sent via email to the email addresses specified on the Membership Details Form, except as otherwise provided in this Agreement. WeWork may send notices to either (or both) the Primary Member or the Authorized Signatory, as WeWork determines in its reasonable discretion. Notices related to the physical Office Space, Premises, Members, other Member Companies or other issues in the Premises should be sent by the Primary Member. Notices related to this Agreement or the business relationship between you and WeWork should be sent by your Authorized Signatory. In the event that we receive multiple notices from different individuals within your company containing inconsistent instructions, the Authorized Signatory’s notice will control unless we decide otherwise in our reasonable discretion.

 

i.Headings; Interpretation. The headings in this Agreement are for convenience only and are not to be used to interpret or construe any provision of this Agreement. Any use of “including,” “for example” or “such as” in this Agreement shall be read as being followed by “without limitation” where appropriate. References to any times of day in this Agreement refer to the time of day in the Office Space’s time zone.

 

j.No Assignment. Except in connection with a merger, acquisition, corporate reorganization, or sale of all or substantially all of the shares or assets of you or your parent corporation, you may not transfer or otherwise assign any of your rights or obligations under this Agreement (including by operation of law) without our prior consent. We may assign this Agreement without your consent.

 

10

 

 

k.Sanctions. You hereby represent and warrant that (i) during the term of this Agreement you and your Members will comply with all applicable U.S. and non-U.S. economic sanctions and export control laws and regulations, including but not limited to the economic sanctions regulations implemented under statutory authority and/or Executive Orders and administered by the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”) (31 C.F.R. Part 500 et seq.), the U.S. Commerce Department’s Export Administration Regulations (15 C.F.R. Part 730 et seq.), the economic sanctions rules and regulations of the European Council, United Kingdom, and EU Member States, and EU’s Dual-use Regulation 428/2009 (collectively, “Trade Control Laws”); (ii) neither you nor any of your Members, subsidiaries or affiliates, nor directors or officers is (a) a citizen or resident of, an entity organized under the laws of, or otherwise located in, a country subject to comprehensive territorial sanctions maintained by OFAC (hereinafter referred to as “Sanctioned Countries”), (b) identified on U.S. Government restricted party lists including the Specially Designated Nationals List and Foreign Sanctions Evaders List administered by OFAC; the Denied Parties List, Unverified List or Entity List maintained by the U.S. Commerce Department Bureau of Industry and Security; or the List of Statutorily Debarred Parties maintained by the U.S. State Department Directorate of Defense Trade Controls, (c) a listed person or entity on the Consolidated List of persons and entities subject to asset-freezing measures or other sanctions maintained by the European Union, and by the Member States of the European Union, or (d) a person or entity subject to asset-freezing measures or other sanctions maintained by the United Kingdom’s HM Treasury (collectively referred to herein as “Restricted Parties”); (iii) neither you nor any of your Members, subsidiaries and/or affiliates are 50% or more owned, individually or in the aggregate, directly or indirectly by one or more Restricted Parties or otherwise controlled by Restricted Parties; (iv) less than 10% of your total annual revenues are, and will continue to be for the duration of the Agreement, generated from activities involving, directly or indirectly, one or more of the Sanctioned Countries; and (v) neither you nor any of your Members will, at any time during the Term, engage in any activity under this Agreement, including the use of Services provided by WeWork in connection with this Agreement, that violates applicable Trade Control Laws or causes WeWork to be in violation of Trade Control Laws.

 

l.Anti-Money Laundering. You hereby represent and warrant that at all times you and your Members have conducted and will conduct your operations in accordance with all laws that prohibit commercial or public bribery and money laundering (the “Anti-Money Laundering Laws”), and that all funds which you will use to comply with your payments obligations under this Agreement will be derived from legal sources, pursuant to the provisions of Anti-Money Laundering Laws. You will provide us with all information and documents that we from time to time may request in order to comply with all Anti-Money Laundering Laws.
m.Anti-Corruption Laws. Neither you nor any of your Members, your directors, officers, employees, agents, subcontractors, representatives or anyone acting on your behalf, (i) has, directly or indirectly, offered, paid, given, promised, or authorized the payment of any money, gift or anything of value to: (A) any Government Official or any commercial party, (B) any person while knowing or having reason to know that all or a portion of such money, gift or thing of value will be offered, paid or given, directly or indirectly, to any Government Official or any commercial party, or (C) any employee or representative of WeWork for the purpose of (1) influencing an act or decision of the Government Official or commercial party in his or her official capacity, (2) inducing the Government Official or commercial party to do or omit to do any act in violation of the lawful duty of such official, (3) securing an improper advantage or (4) securing the execution of this Agreement, (ii) will authorize or make any payments or gifts or any offers or promises of payments or gifts of any kind, directly or indirectly, in connection with this Agreement, the Services or the Office Space. For purposes this section, “Government Official” means any officer, employee or person acting in an official capacity for any government agency or instrumentality, including state-owned or controlled companies, and public international organizations, as well as a political party or official thereof or candidate for political office.

 

n.Compliance with Laws. You hereby represent and warrant that at all times you and your Members have conducted and will conduct your operations ethically and in accordance with all applicable laws.

 

o.Brokers. You hereby represent and warrant that you have not used a broker or realtor in connection with the membership transaction covered by this Agreement, except as may be provided for in the WeWork broker referral program. You hereby indemnify and hold us harmless against any claims arising from the breach of any warranty or representation of this paragraph.

 

p.Counterparts and Electronic Signature. This Agreement may be executed in any number of counterparts by either handwritten or electronic signature, each of which when executed shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement, and each of which counterparts may be delivered by emailing the other party to this Agreement signed scanned document or electronically signed portable document format (pdf) version of the contract (as applicable). Each party agrees to the execution of this Agreement in this manner, and the parties acknowledge that execution in this manner creates a binding contract between the parties on the Effective Date.

 

q.Entire Agreement. This Agreement constitutes the entire agreement between the parties relating to the subject matter hereof and shall not be changed in any manner except by a writing executed by both parties or as otherwise permitted herein. All prior agreements and understandings between the parties regarding the matters described herein have merged into this Agreement.

 

11

 

EX-10.2 3 f10q1218ex10-2_relmadatherap.htm SETTLEMENT AGREEMENT, DATED FEBRUARY 6, 2019, AMONG NAJIB BABUL, LAIDLAW & COMPANY (UK) LTD., SANDESH SETH, AND SERGIO TRAVERSA

Exhibit 10.2

 

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT

 

This Settlement Agreement, Mutual Release of all Claims, and Confidentiality Agreement (hereinafter referred to as the “Agreement”) is made and entered into effect as of the latest date on which this Agreement is fully executed and receipt by the Designated Payee (term defined below) of the First Payment (term defined below) by and between Najib Babul and Cinergen, LLC, on the one hand (Najib Babul and Cinergen, LLC are collectively referred to as “Babul”) and Relmada Therapeutics, Inc., a Delaware Corporation (“Relmada I”), Relmada Therapeutics, Inc. a Nevada Corporation (“Relmada II”), on the other hand, (Relmada I and Relmada are collectively referred to as “Relmada”), Laidlaw & Company (UK) Ltd. (“Laidlaw”), Sandesh Seth (“Seth”), and Sergio Traversa (“Traversa”) (Relmada I, Relmada II, Laidlaw, Seth and Traversa are collectively referred to as “Defendants”). Each of Babul, Relmada I, Relmada II, Laidlaw, Seth, and Traversa is referred to individually as “Party” and collectively they are the “Parties.”

 

WHEREAS, on or about January 9, 2014, Relmada I filed a complaint styled Relmada Therapeutics, Inc. v. Najib Babul in the United States District Court for the Eastern District of Pennsylvania, Case No. 2:14-cv-00104-GAM (“Relmada v. Babul”), in which Relmada I asserted a claim for breach of fiduciary duty. Relmada v. Babul concluded on December 3, 2014;

 

WHEREAS, on or about May 26, 2015, Najib Babul filed a complaint styled Babul v. Relmada Therapeutics, Inc., a Delaware Corporation, Relmada Therapeutics, Inc., a Nevada Corporation, Laidlaw & Company (UK) Ltd., Jamess Capital Group, LLC, Sandesh Seth, Sergio Traversa, Robinson Brog Leinwand Greene Genovese & Gluck P.C., David C. Burger, and David E. Danovitch in the United States District Court for the Eastern District of Pennsylvania, Case No. 2:15-cv-02937-GAM (the “Lawsuit”), in which Najib Babul asserted claims for violation of Pennsylvania’s Dragonetti Act (wrongful use of civil proceedings), defamation, intentional infliction of emotional distress, civil conspiracy / aiding and abetting / substantial participation, and breach of contract;

 

WHEREAS, on or about January 20, 2016 the Honorable Gerald A. McHugh (the “Court”) dismissed from the Lawsuit Najib Babul’s claim for intentional infliction of emotional distress (Count III) and breach of contract (Count V);

 

WHEREAS, on or about February 21, 2018 Defendants Jamess Capital Group LLC, Robinson Brog Leinward Green Genovese & Gluck, P.C., David C. Berger, and David E. Danovitch, were dismissed from the Lawsuit;

 

WHEREAS, on January 26, 2019, the Parties attended a Pretrial Conference with the Court where an agreement in principle was reached among the Parties who thereafter agreed to execute a full and complete settlement agreement, the terms of which are contained in this present Agreement;

 

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 1

 

 

WHEREAS, each Party acknowledges and agrees that neither this Agreement, nor anything provided in this Agreement, shall be taken or construed as an admission or concession of any kind with respect to any fact, liability, or fault;

 

AND WHEREAS, the Parties desire to enter into this Agreement in order to effect a full, complete, and final settlement of all claims or disputes between them, which existed or could have existed as of the Effective Date hereof, including all claims which were asserted, or which could have been asserted between them.

 

NOW, therefore, in consideration of the mutual promises, agreements, and representations contained herein, and together with good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intended to be legally bound, the Parties hereby agree as follows:

 

1. Monetary Payment. Upon receipt of a completed W-9 form from each Designated Payee, Relmada II shall pay a sum total of One Million Five Hundred Thousand Dollars ($1,500,000.00) (the “Payment”) to the identified Designated Payee by wire transfer according to the banking and wire transfer instructions attached hereto as Exhibit “A” and as provided below. The Defendants shall not be responsible for the payment of any federal, state, or local taxes under this Agreement. Any and all taxes, federal, state and/or local, if any, shall be the responsibility of Babul and/or the Designated Payee. Relmada will issue two 1099s, one in the amount of $676,126.00 to Steve Harvey Law, and another in the amount of $823,874.00 to Cinergen, LLC. No monies whatsoever are due and owing from any of the Defendants, except for such amounts from Relmada II as stated in this paragraph.

 

a. Relmada II shall pay Two Hundred and Fifty Thousand Dollars ($250,000.00) (the “First Payment”) by wire transfer immediately after both Babul and Relmada II have executed this Agreement.

 

b. Relmada II shall pay Two Hundred and Fifty Thousand Dollars ($250,000.00) (the “Second Payment”) no later than February 6, 2019.

 

c. Relmada II shall pay Two Hundred and Fifty Thousand Dollars ($250,000.00) (the “Third Payment”) no later than March 31, 2019.

 

d. Relmada II shall pay Two Hundred and Fifty Thousand Dollars ($250,000.00) (the “Fourth Payment”) no later than June 30, 2019.

 

e. Relmada II shall pay Two Hundred and Fifty Thousand Dollars ($250,000.00) (the “Fifth Payment”) no later than September 30, 2019.

 

f. Relmada II shall pay Two Hundred and Fifty Thousand Dollars ($250,000.00) (the “Sixth Payment”) no later than December 31, 2019.

 

2. Late Payment Penalty. If any payment due hereunder is not received on the date such payment is due, Relmada II shall pay interest on the late payment at the Wall Street Journal Prime Rate as of the date payment was due.

 

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 2

 

 

3. Event of Default. Following written Notice (as described in paragraph 23 below) and a thirty (30) day cure period, Relmada II shall be in default under this Agreement if it fails to timely make the Second Payment, Third Payment, Fourth Payment, Fifth Payment, or Sixth Payment as provided in Paragraph 1 above (“Event of Relmada Default”). Following written Notice and a thirty (30) day cure period, Babul shall be in default under this Agreement, if he breaches any obligations contained in this Agreement, including but not limited to those contained in Paragraphs 5, 6, 7, and 8 below (“Event of Babul Default”). In the Event of Relmada Default or in the Event of Babul Default, Relmada II and Babul have entered into a separate Event of Default Agreement, which shall be held in escrow and under seal by Judge McHugh.

 

4. Share Exchange. Babul specifically acknowledges that he waives any and all claims to any shares of Relmada stock that he was entitled to under the April 2012 Private Placement Memorandum and/or pursuant to the May 20, 2014 Share Exchange Agreement; and further warrants and represents that as of the Effective Date, Babul does not own, nor has any rights or claims to rights to any shares of stock in either Relmada I or Relmada II. Nothing contained in this Agreement prevents Babul from legally acquiring Relmada stock following the Effective Date.

 

5. Confidentiality. For the consideration listed above, the Parties and their counsel, together with their respective past, present, and future agents, affiliates, predecessors, successors, or other related persons or entities, hereby agree and promise that they shall keep the terms of this Agreement, any information obtained or work product generated in connection with the negotiations or execution of this Agreement, and all settlement negotiations confidential and shall not disclose or publish same to any person or entity at any time, for any reason whatsoever, unless ordered to do so by a court of law or other judicial authority, or except as reasonably necessary in order to prepare financial statements, tax returns, or other regulatory filings, including SEC disclosures or as otherwise required by law. No Party will publicize the existence or terms of this settlement on social media, through traditional media, or elsewhere, although nothing in that prohibition prevents Babul from making reference to resolution of Relmada v. Babul and the Lawsuit for purposes of seeking employment, consulting opportunities, or when specifically asked about Relmada v. Babul.

 

6. Relmada Letter. Relmada II will provide a letter to Babul on Relmada II letterhead, signed by its Chief Executive Officer, in the form attached hereto as Exhibit “B”. Relmada II will provide this letter to Babul no later than February 6, 2019. Babul shall not publicize this letter or its contents on social media, through traditional media, or elsewhere, but Babul may use this letter when he is seeking employment, consulting opportunities, or when specifically asked about Relmada v. Babul. Babul acknowledges that such letter may not be used as an admission of wrongdoing in any manner by the Defendants or their attorneys and may not be used with regard to any claim that Babul has or may assert against Robinson Brog Leinwand Greene Genovese & Gluck, P.C., or its attorneys.

 

7. Consulting Agreement. Relmada II and Babul agree as part of this Agreement and as part of the payments identified in paragraph 1 to enter into a separate consulting agreement (“Consulting Agreement”), which is attached hereto as Exhibit “C”, which shall be referenced in Relmada’s next SEC filing. Babul shall not publicize such Consulting Agreement, its existence or its contents on social media, through traditional media, or elsewhere, but Babul may use such Consulting Agreement when he is seeking employment, consulting opportunities, or when specifically asked about Relmada v. Babul.

 

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 3

 

 

8. Reference Letter and Response to Requests for Information. Relmada II will provide a letter to Babul on Relmada II letterhead, signed by its Chief Executive Officer, in the form attached hereto as Exhibit D. The language of this letter may be used as a script if Relmada II is contacted about Babul. Babul shall not publicize such Reference Letter, its existence or its contents on social media, through traditional media, or elsewhere, but Babul may use such Reference Letter when he is seeking employment, consulting opportunities, or when specifically asked about Relmada v. Babul. Babul specifically waives any and all claims it could assert against Relmada II or its officers or employees with regard to such Reference Letter and/or any contact request made to Relmada related to Babul.

 

9. Release of Defendants by Babul. In consideration of the agreements by Defendants as set forth in this Agreement, and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, Babul, on behalf of himself and his respective agents, representatives, heirs, affiliates, employees, consultants, independent contractors, alter egos and assigns (all of whom are hereinafter collectively referred to as the “Babul Releasors”) hereby remise, release, acquit, and forever discharge Defendants and Jamess Capital Group LLC, and all of their respective members, representatives, agents, servants, employees, attorneys, officers, directors, board members, shareholders, investors, trustees, partners, parent and subsidiary organizations, administrators, predecessors, successors, insurers, sureties, assigns, and other related entities (all of whom are hereinafter collectively referred to as the “Defendant Releasees”) of and from any and all actions and causes of action, damages, suits, debts, dues, accounts, bonds, agreements, contracts, covenants, promises, judgments, costs, attorneys’ fees, expenses, compensation, and claims and demands of any kind whatsoever, which the Babul Releasors or anyone claiming by, through or under them now has or ever had or could claim against the Defendant Releasees from the beginning of the world to the Effective Date of this Agreement arising out of, in connection with or in any way related or incidental to, either directly or indirectly, the Lawsuit, the claims that were or could have been asserted in Relmada v. Babul, the Lawsuit, the events that gave rise to the Lawsuit, and any claims related to Relmada’s failure to exchange Babul’s shares of common stock in Relmada I for securities in Relmada II in connection with the May 2014 Share Exchange (see Camp Nine, Inc.’s Form 8-K dated May 20, 2014) or thereafter.

 

Notwithstanding the foregoing, the Babul Releasors expressly exclude from the effect of this Release and do not release the Defendant Releasees from the terms and conditions of this Agreement. The Babul Releasors also expressly exclude from the effect of this Release and do not release the Defendant Releasors from any and all rights Babul has under the Indemnification Agreement between Relmada I and Babul, dated July 10, 2012, and the Amended and Restated By-laws of Relmada I, dated July 2012. The Babul Releasers also expressly exclude from the effect of this Release and do not release the claims Babul asserted in the Lawsuit against Robinson Brog Leinwand Greene Genovese & Gluck P.C., David C. Burger, and David E. Danovitch, or any and all claims Babul may have against Robinson Brog Leinwand Greene Genovese & Gluck P.C., David C. Burger, and David E. Danovitch.

 

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 4

 

 

10. Release of Babul by Defendants. In consideration of the agreements by Babul as set forth in this Agreement, and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, Defendants on behalf of themselves and all of their respective principals, directors, officers, shareholders, employees, agents, representatives, parent and subsidiary organizations and corporations, successors, insurers, assigns, and affiliates (all of whom are hereinafter collectively referred to as the “Defendant Releasors”) hereby remise, release, acquit, and forever discharge Babul and all of his respective agents, representatives, attorneys, and assigns (all of whom are hereinafter collectively referred to as the “Babul Releasees”) of and from any and all actions and causes of action, damages, suits, debts, dues, accounts, bonds, agreements, contracts, covenants, promises, judgments, costs, attorneys’ fees, expenses, compensation, claims and demands whatsoever, of every nature, kind, and description, which the Defendant Releasors or anyone claiming by, through or under them now has or ever had or could claim against the Babul Releasees from the beginning of the world to the Effective Date of this Agreement arising out of, in connection with or in any way related or incidental to, either directly or indirectly, the Lawsuit, the claims that were or could have been asserted in the Lawsuit, and the events that gave rise to the Lawsuit. Notwithstanding the foregoing, the Defendant Releasors expressly exclude from the effect of this Release and do not release the Babul Releasees from the terms and conditions of this Agreement.

 

11. Dismissal of Lawsuit with Prejudice. Within five (5) business days following receipt of the Second Payment described in Paragraph 1 above, Babul shall file a stipulation of dismissal with prejudice of the Lawsuit as against the Defendants, with each Party to bear its own fees and costs, and with the Court to retain jurisdiction of the Lawsuit with respect to Event of Default as discussed in Paragraph 3 above.

 

12. No Admission of Liability. It is expressly understood and agreed that this Agreement is not, and shall not be construed as, an admission of guilt, fault, or liability on behalf of any Party. Rather, the Parties have entered into this Agreement solely for the purpose of reaching a compromise and avoiding the expense and uncertainty of litigation and have relied on their own judgment in entering into this settlement and not on any representations of the other Party.

 

13. Authority; No Prior Assignment. Babul warrants and represents that he is fully entitled and duly authorizes the releases contained herein, and that he has not assigned any of the rights or causes of action released herein, and that he has not relied upon any representation, promise, or statement made by anyone which is not recited, contained or embodied in this Agreement. Similarly, Defendants warrant and represent that they are fully entitled and duly authorized to give the release contained herein, and that they have not assigned any of the rights or causes of action released herein, and that they have not relied upon any representation, promise, or statement made by anyone which is not recited, contained or embodied in this Agreement. Each of the signatories hereto represents and warrants that he or she is duly authorized to execute this Agreement on behalf of such Party.

 

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 5

 

 

14. Representation of Comprehension of Document and Rule of Construction. In entering into this Agreement, the Parties represent that they have had an opportunity to seek the advice of attorneys, and that the terms of this Agreement have been completely read and that these terms are fully understood and voluntarily accepted by such Party. Notwithstanding the identity of the drafters of this Agreement, the Parties agree that there will be no presumption against any Party arising out of or relating to the identity of such drafters. Babul specifically acknowledges that with regard to this Agreement, he is represented by Steve Harvey, Esquire and Steve Harvey Law LLC; and Defendants specifically acknowledge that they are being represented by Barry L. Cohen, Esquire and Royer Cooper Cohen Braunfeld, LLC.

 

15. Applicable Law and Venue for Enforcement. This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Pennsylvania. The Parties agree that any litigation concerning this Agreement or the performance by the Parties hereunder shall be brought exclusively in the United States District Court for the Eastern District of Pennsylvania, and the Parties agree to submit to the jurisdiction of such court.

 

16. No Third-Party Beneficiaries. This Agreement is made for the sole benefit of the Parties to it. No other person or entity not described herein shall have any rights or remedies under or by reason of this Agreement.

 

17. No Oral Modifications. This Agreement may not be amended, altered, modified or changed in any way except by a writing signed by the Parties.

 

18. Severability. If any term or provision of this Agreement shall be deemed or declared by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, it shall be severed herefrom, and the remaining provisions of this Agreement shall remain in effect and enforceable.

 

19. Headings. The headings of the various paragraphs of this Agreement have been included only in order to make it easier to locate the subject covered by each provision and are not to be used in construing this Agreement or in ascertaining its meaning.

 

20. Execution in Counterparts. This Agreement may be executed in multiple, separate counterpart originals, or with detachable signature pages, which together shall constitute the original thereof. Facsimile, photocopy, PDF, or other copied signatures shall be considered as original signatures for all purposes. This Agreement will become effective only upon the execution of the Agreement by all of the Parties and receipt of the First Payment and Second Payment.

 

21. Completeness of Agreement. This Agreement constitutes the complete and entire Agreement between the Parties regarding the claims Babul and Defendants asserted or could have asserted in the Lawsuit. All prior agreements, negotiations, correspondence, proposals, prior documents, and any verbal understandings regarding the claims Babul and Defendants asserted or could have asserted in the Lawsuit are merged into this Agreement, which shall supersede any provision of any agreement inconsistent with the terms of this Agreement.

 

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 6

 

 

22. Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective representatives, agents, officers, predecessors, successors, and assigns.

 

23. Notices. All notices and other communications required or permitted hereunder or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when hand delivered or mailed by registered or certified United States mail, or by reputable courier service with delivery confirmation, as follows (provided that notice of change of address shall be deemed given only when received):

 

If to Babul:

Najib Babul

P.O. Box 2790

16767 Bernardo Ctr Dr L-1

San Diego, CA 92128-9996

 

With a copy to:

Najib Babul, Fax # 858-431-4708;

 

and

 

With a copy to:

Stephen G. Harvey, Esquire

Steve Harvey Law LLC

1880 John F. Kennedy Blvd., Suite 1715

Philadelphia, PA 19103

Fax # 215- 438-6666

 

If to Relmada or Relmada II:

Relmada Therapeutics, Inc.

Attn: Sergio Traversa, CEO

880 Third Avenue, 12th Floor

New York, NY 10022

 

With a copy to:

Royer Cooper Cohen Braunfeld LLC

Attn: Barry L. Cohen, Esquire

101 West Elm Street, Suite 400

Conshohocken, PA 19428

Email: bcohen@rccblaw.com

Fax: 484-362-2630

 

If to Sergio Traversa

Sergio Traversa

Relmada Therapeutics, Inc.

880 Third Avenue, 12th Floor

New York, NY 1002

 

With a copy to:

Royer Cooper Cohen Braunfeld LLC

Attn: Barry L. Cohen, Esquire

101 West Elm Street, Suite 400

Conshohocken, PA 19428

Email: bcohen@rccblaw.com

Fax: 484-362-2630

 

If to Sandesh Seth:

Sandesh Seth

244 Fifth Avenue, 2nd Floor, Suite S217

New York, NY 10001

 

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 7

 

 

With a copy to:

Royer Cooper Cohen Braunfeld LLC

Attn: Barry L. Cohen, Esquire

101 West Elm Street, Suite 400

Conshohocken, PA 19428

Email: bcohen@rccblaw.com

Fax: 484-362-2630

 

If to Laidlaw & Company (UK) Ltd.:

Laidlaw & Company (UK) Ltd.

546 5th Avenue, 5th Floor

New York, NY 10036

 

With a copy to:

Royer Cooper Cohen Braunfeld LLC

Attn: Barry L. Cohen, Esquire

101 West Elm Street, Suite 400

Conshohocken, PA 19428

Email: bcohen@rccblaw.com

Fax: 484-362-2630

 

24. Incorporation of Recitals. The recitals set forth above are hereby incorporated by reference as if fully set forth herein.

 

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 8

 

 

IN WITNESS WHEREOF, the Parties have duly authorized and caused this Agreement to be executed effective as of the Effective Date.

 

/s/ Najib Babul  
NAJIB BABUL  
   
Date: February 6m 2019  

  

CINERGEN, LLC, A DELAWARE LIMITED LIABILITY COMPANY

 

By: /s/ Najib Babul  
Name: Najib Babul  
Title: CEO  
     
Date: February 6, 2019  

 

RELMADA THERAPEUTICS, INC., A DELAWARE CORPORATION
 

By: /s/ Sergio Traversa  
Name: Sergio Traversa  
Title: CEO  
     
Date: February 6, 2019  

  

RELMADA THERAPEUTICS, INC., A NEVADA CORPORATION
 

By: /s/ Sergio Traversa  
Name: Sergio Traversa  
Title: CEO  
     
Date: February 6, 2019  

 

LAIDLAW & COMPANY (UK) LTD.

 

By: /s/ Matthew D. Eitner  
Name: Matthew D. Eitner  
Title: CEO  
     
Date: February 6, 2019  

 

/s/ Sandesh Seth  
SANDESH SETH  
   
Date: February 6, 2019  

  

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 9

 

 

Exhibit A

 

Wire Transfer Instructions for Designated Payee & Schedule of Payments

 

Payment No  

Amount
(U.S. Dollars)

  Not Later Than   Wire Transfer Information
1   $250,000.00   February 6, 2019   Steve Harvey Law LLC Account: TD Bank, 1900 Market Street, Philadelphia, Pennsylvania 19103 (Tel.: 215-568-0900), Routing No. 036001808, Account No. 4288385375
2   $250,000.00   February 6, 2019   Steve Harvey Law LLC Account: TD Bank, 1900 Market Street, Philadelphia, Pennsylvania 19103 (Tel.: 215-568-0900), Routing No. 036001808, Account No. 4288385375
3   $250,000.00   March 31, 2019   Cinergen, LLC Account: Bank of America,10511 Craftsman Way, San Diego CA 92127  (Tel: 858-673-0770), Routing No. 121000358, Account No. 325087223530
4   $250,000.00   June 30, 2019   Cinergen, LLC Account: Bank of America,10511 Craftsman Way, San Diego CA 92127  (Tel: 858-673-0770), Routing No. 121000358, Account No. 325087223530
5a*   $176,126.00   September 30, 2019   Steve Harvey Law LLC Account: TD Bank, 1900 Market Street, Philadelphia, Pennsylvania 19103 (Tel.: 215-568-0900), Routing No. 036001808, Account No. 4288385375
5b*   $73,874.00   September 30, 2019   Cinergen, LLC Account: Bank of America,10511 Craftsman Way, San Diego CA 92127  (Tel: 858-673-0770), Routing No. 121000358, Account No. 325087223530
6   $250,000.00   December 31, 2019   Cinergen, LLC Account: Bank of America,10511 Craftsman Way, San Diego CA 92127  (Tel: 858-673-0770), Routing No. 121000358, Account No. 325087223530

Payment No. 5 (5a and 5 b) will be made to two payees.

  

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 10

 

 

EXHIBIT B

 

ON RELMADA II LETTERHEAD

 

Dated: February 5, 2019

 

Re: Najib Babul, PharmD, MBA (“Dr. Babul”) and Relmada v. Babul (E.D. Pa.)

 

To whom it may concern:

 

On January 9, 2014, Relmada Therapeutics, Inc. (“Relmada”) filed a lawsuit, Relmada v. Babul, in federal court in Philadelphia against Dr. Babul, who formerly served as President and Chief Scientific Officer of Relmada. Dr. Babul resigned these positions voluntarily in September 2012.

 

The lawsuit alleged that Dr. Babul breached his fiduciaries duties to the company. It ended in December 2014 with the entry of a Stipulated Judgment Order.

 

Relmada has now concluded that Dr. Babul did not engage in any wronging or do anything improper.

  

Sincerely,

 

NAME

Chief Executive Officer

  

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 11

 

 

EXHIBIT C

 

CONSULTING AGREEMENT

  

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 12

 

 

EXHIBIT D

 

ON RELMADA II LETTERHEAD

 

 

Dated: February 5, 2019

  

Re: Najib Babul, PharmD, MBA

 

To whom it may concern:

 

From January 1, 2004, to September 12, 2012, Dr. Najib Babul was the President and Chief Scientific Officer of Relmada Therapeutics, Inc. (“Relmada”), formerly known as TheraQuest Biosciences, Inc.

 

In September 2012, Dr. Babul resigned voluntarily from his positions at Relmada.

 

On February 5, 2019 Dr. Babul entered into a three year agreement with Relmada in which Dr. Babul acts as a Drug Development and Scientific Consultant to Relmada.

  

Sincerely,

  

NAME

Chief Executive Officer

  

SETTLEMENT AGREEMENT, MUTUAL RELEASE OF ALL CLAIMS, AND CONFIDENTIALITY AGREEMENT Page 13

EX-10.3 4 f10q1218ex10-3_relmadatherap.htm CONSULTING AGREEMENT, EFFECTIVE MARCH 25, 2019, BETWEEN RELMADA THERAPEUTICS, INC. AND NAJIB BABUL

Exhibit 10.3

  

CONSULTING AGREEMENT

 

This CONSULTING Agreement (this “Agreement”) is made by and between RELMADA THERAPEUTICS INC., a Nevada corporation (the “Company”) and Najib Babul (“Consultant”). This Agreement is effective as of March 25, 2019.

 

WITNESSETH:

 

WHEREAS, Consultant has substantial experience in, among other matters, pharmaceutical and biopharmaceutical businesses; and

 

WHEREAS, the Company desires to engage the Consultant as a “Drug Development and Scientific Consultant” to perform consulting services as an independent contractor and has requested that Consultant provide consulting services to the Company, and Consultant is willing to provide such services to the Company on the terms and conditions set forth below.

 

NOW THEREFORE, for valuable consideration, and intending to be legally bound hereby, the parties agree as follows:

 

1. Term. The term of this Agreement (the “Term”) shall be for a three year term commencing on March 25, 2019 and ending on March 24, 2022. The Term shall not be extended or renewed except by the mutual agreement of the parties in writing.

 

2. Consulting Services. Consultant shall be available to consult with the Company, on a part-time basis on such matters as may be reasonably requested by the Company from time to time and only to the extent such request is accepted by the Consultant (the "Consulting Services") during the Term of this Agreement. Such Consulting Services shall be rendered by Consultant at such time or times and at such place as the Company and the Consultant may mutually agree.

 

3. Compensation; Reimbursement of Expenses.

 

3.1 Compensation. In consideration of Consultant’s agreement to provide the Consulting Services to the Company as herein provided, the Company hereby agrees to pay Consultant a consulting fee of $333,333.33 per year for the three year period for a total consulting fee of $1 million, all of which shall be paid during 2019 as identified in Paragraph 1 of the separate Settlement Agreement entered into by and between the Company and Consultant. No fees are due and owing from the Company to Consultant during years two and three of this Agreement.

 

3.2 No Other Compensation. The fees paid for the Consulting Services shall be full compensation for the Consulting Services to be performed by Consultant hereunder, and Consultant shall receive no other compensation for the Consulting Services except as set forth in Paragraph 3.1.

  

 

 

 

4. Representations and Warranties. The Company and Consultant hereby represent and warrant that he or it has the full right and authority to enter into this Agreement and perform his or its obligations hereunder. Consultant makes no warranties, guarantees, or representations that any Consulting Services provided by Consultant will result in any increase or improvement in the development, marketing, promotion, or sale of the Company’s business, products, or services.

 

5. Independent Contractor Relationship. Consultant shall at all times be an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship. Consultant will not be entitled to any of the benefits which Company may make available to its employees, including, but not limited to, group health or life insurance, profit-sharing or retirement benefits. The manner and means by which Consultant chooses to complete his services are in Consultant's sole discretion and control. Consultant is solely responsible for, and will timely file all tax returns and payments required to be filed with, or made to, any federal, state or local tax authority with respect to the performance of services and receipt of any fees under this Agreement.

 

6. Termination. The Company may terminate this Agreement, with or without cause, upon thirty (30) days prior written notice to Consultant; provided, however, that no such termination of this Agreement by the Company, nor the death or disability of Consultant during the Term of this Agreement, shall require Consultant or his legal representatives to return or to repay or refund to the Company any amount in respect thereof; it being agreed that the compensation was fully earned upon the execution of this Agreement and payable per Paragraph 3.1 above.

 

7. Notices. All notices or other communications hereunder shall be in writing and may be delivered personally, by registered or certified mail, return receipt requested, by nationally recognized air courier service, by telegram or by facsimile transmission, to the addresses indicated below:

 

If to the Company:

Relmada Therapeutics

Attn: Mr. Sergio Traversa, CEO

880 Third Avenue, 12th Floor

New York, NY 10022

 

With a Copy to:

Royer Cooper Cohen Braunfeld LLC

Attn: Barry L. Cohen, Esquire

101 West Elm Street, Suite 400

Conshohocken, PA 19428

Email: bcohen@rccblaw.com

 

If to Consultant:

Najib Babul

P.O. Box 2790

16767 Bernardo Ctr Dr L-1

San Diego, CA 92128-9996

  

2

 

 

With a copy to:

Stephen G. Harvey, Esquire

Steve Harvey Law LLC

1880 John F. Kennedy Blvd., Suite 1715

Philadelphia, PA 19103

Fax # 215-438-6666

  

8. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to the conflicts of laws principles thereof.

 

9. Agreement Non-Exclusive for Consultant. This Agreement shall in no way limit or restrict Consultant from entering into any other or similar agreements with any other businesses or individuals.

 

10. Severability. If any provision of this Agreement or any part of any provision of this Agreement is determined to be unenforceable for any reason whatsoever, it shall be severable from the rest of this Agreement and shall not invalidate or affect the other portions or parts of this Agreement, which shall remain in full force and effect and be enforceable according to their terms.

 

11. Succession; Assignment. This Agreement shall be binding upon the parties hereto and shall inure to the benefit of their respective successors, heirs and assigns. This Agreement shall not be assigned by either party without the written consent of the other.

 

12. Entire Agreement. This Agreement, along with the Settlement Agreement, constitutes the entire agreement between the parties relating to this subject matter and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter. The recitals shall be a part of this Agreement. The terms of this Agreement will govern all services undertaken by Consultant for the Company. This Agreement may only be changed by mutual agreement of the parties in writing.

  

[signatures appear on next page]

  

3

 

 

In Witness Whereof, the parties have executed this Agreement as of the day and year first above written.

   

COMPANY:   CONSULTANT:  
       
RELMADA THERAPEUTICS INC.      
       
By: /s/ Sergio Traversa   /s./ Najib Babul  
Name: Sergio Traversa   Najib Babul  
Title: CEO      

  

4

EX-31.1 5 f10q1218ex31-1_relmadatherap.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Sergio Traversa, certify that:

 

1. I have reviewed this Form 10-Q of Relmada Therapeutics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not  misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial  reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred  during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Relmada Therapeutics, Inc.  
     
By: /s/ Sergio Traversa  
  Sergio Traversa  
 

Chief Executive Officer

(Principal Executive Officer)

 

 

February 13, 2019

EX-31.2 6 f10q1218ex31-2_relmadatherap.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Sergio Traversa certify that:

 

1. I have reviewed this Form 10-Q of Relmada Therapeutics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact  necessary to make the statements made, in light of the circumstances under which such statements were made, not  misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be  designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries is made known to us by others within those entities, particularly during the period in  which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting  and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual  report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Relmada Therapeutics, Inc.  
   
By: /s/ Sergio Traversa  
  Sergio Traversa  
 

Chief Executive Officer and

Interim Chief Financial Officer

 

 

February 13, 2019

EX-32.1 7 f10q1218ex32-1_relmadatherap.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Relmada Therapeutics, Inc. (the “Company”) on Form 10-Q for the three months ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sergio Traversa, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
2. The information contained in the Quarterly Report fairly presents, in all material respects, the consolidated financial condition and results of consolidated operations of the Company.

 

Relmada Therapeutics, Inc.  
   
By: /s/ Sergio Traversa  
  Sergio Traversa  
 

Chief Executive Officer

(Principal Executive Officer) 

 

 

February 13, 2019

 

 

EX-32.2 8 f10q1218ex32-2_relmadatherap.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Relmada Therapeutics, Inc. (the “Company”) on Form 10-Q for the three months ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sergio Traversa, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
2. The information contained in the Quarterly Report fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company.

 

Relmada Therapeutics, Inc.  
   
By: /s/ Sergio Traversa  
  Sergio Traversa  
 

Chief Executive Officer and

Interim Chief Financial Officer

 

 

February 13, 2019

EX-101.INS 9 rlmd-20181231.xml XBRL INSTANCE FILE 0001553643 2017-07-01 2018-06-30 0001553643 2017-06-30 0001553643 2018-06-30 0001553643 us-gaap:FairValueInputsLevel3Member 2018-06-30 0001553643 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember 2018-06-30 0001553643 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2018-06-30 0001553643 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember 2018-06-30 0001553643 us-gaap:FairValueInputsLevel3Member us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-06-30 0001553643 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-06-30 0001553643 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel1Member 2018-06-30 0001553643 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel2Member 2018-06-30 0001553643 us-gaap:FairValueInputsLevel1Member 2018-06-30 0001553643 us-gaap:FairValueInputsLevel2Member 2018-06-30 0001553643 us-gaap:PreferredClassAMember 2018-06-30 0001553643 us-gaap:CommonStockMember 2018-06-30 0001553643 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001553643 us-gaap:RetainedEarningsMember 2018-06-30 0001553643 srt:MinimumMember 2018-06-30 0001553643 srt:MaximumMember 2018-06-30 0001553643 us-gaap:EmployeeStockOptionMember 2017-07-01 2018-06-30 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember 2014-12-10 2014-12-31 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember 2017-01-01 2017-01-31 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember srt:MinimumMember 2018-02-01 2018-02-28 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember srt:MaximumMember 2018-02-01 2018-02-28 0001553643 us-gaap:EmployeeStockOptionMember 2018-06-30 0001553643 us-gaap:WarrantMember 2018-06-30 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember 2018-02-01 2018-02-28 0001553643 us-gaap:FairValueInputsLevel3Member 2017-06-30 0001553643 2017-12-31 0001553643 rlmd:AdvisoryFirmMember 2014-07-01 2015-06-30 0001553643 2017-06-01 2017-06-12 0001553643 2018-07-01 2018-12-31 0001553643 us-gaap:RestrictedStockMember 2017-07-01 2017-12-31 0001553643 us-gaap:StockOptionMember 2017-07-01 2017-12-31 0001553643 us-gaap:StockOptionMember 2018-07-01 2018-12-31 0001553643 us-gaap:RestrictedStockMember 2018-07-01 2018-12-31 0001553643 rlmd:CommonStockWarrantsMember 2017-07-01 2017-12-31 0001553643 rlmd:CommonStockWarrantsMember 2018-07-01 2018-12-31 0001553643 2017-07-01 2017-12-31 0001553643 us-gaap:FurnitureAndFixturesMember 2018-07-01 2018-12-31 0001553643 us-gaap:ComputerEquipmentMember 2018-07-01 2018-12-31 0001553643 2018-12-31 0001553643 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001553643 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001553643 us-gaap:WarrantMember 2018-07-01 2018-12-31 0001553643 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-12-31 0001553643 us-gaap:EmployeeStockOptionMember 2018-12-31 0001553643 us-gaap:WarrantMember 2018-12-31 0001553643 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-12-31 0001553643 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-12-31 0001553643 us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-01 2017-12-31 0001553643 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-12-31 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember 2018-07-01 2018-12-31 0001553643 us-gaap:LicensingAgreementsMember 2018-07-01 2018-12-31 0001553643 us-gaap:LeaseAgreementsMember 2018-07-01 2018-12-31 0001553643 us-gaap:LicensingAgreementsMember 2017-05-20 2017-06-08 0001553643 us-gaap:CapitalLeaseObligationsMember 2018-12-31 0001553643 us-gaap:NotesPayableOtherPayablesMember 2018-12-31 0001553643 us-gaap:PreferredClassAMember 2018-12-31 0001553643 us-gaap:FairValueInputsLevel3Member 2018-07-01 2018-12-31 0001553643 us-gaap:FairValueInputsLevel3Member 2017-07-01 2017-12-31 0001553643 rlmd:BetweenSeptember2017AndJanuary2018Member 2018-07-01 2018-12-31 0001553643 rlmd:BetweenSeptember2017AndJanuary2018Member 2018-12-31 0001553643 2018-10-02 2018-10-12 0001553643 2018-10-02 2018-10-18 0001553643 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2018-12-31 0001553643 2018-10-01 2018-12-31 0001553643 2017-10-01 2017-12-31 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember 2018-12-01 2018-12-20 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember srt:MinimumMember 2018-12-01 2018-12-31 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember srt:MaximumMember 2018-12-01 2018-12-31 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember 2018-12-20 0001553643 us-gaap:WarrantMember 2018-12-31 0001553643 us-gaap:WarrantMember 2018-12-20 0001553643 us-gaap:WarrantMember 2018-12-01 2018-12-20 0001553643 us-gaap:WarrantMember 2018-07-01 2018-12-31 0001553643 rlmd:StockOptionAndEquityIncentivePlanMember 2018-12-01 2018-12-31 0001553643 rlmd:SettlementAgreementMember rlmd:MarchTwoThousandNineteenMember us-gaap:SubsequentEventMember 2019-02-01 2019-02-06 0001553643 rlmd:SettlementAgreementMember rlmd:JuneTwoThousandNineteenMember us-gaap:SubsequentEventMember 2019-02-01 2019-02-06 0001553643 rlmd:SettlementAgreementMember rlmd:SeptemberTwoThousandNineteenMember us-gaap:SubsequentEventMember 2019-02-01 2019-02-06 0001553643 rlmd:SettlementAgreementMember rlmd:DecemberTwoThousandNineteenMember us-gaap:SubsequentEventMember 2019-02-01 2019-02-06 0001553643 rlmd:SettlementAgreementMember 2018-07-01 2018-12-31 0001553643 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001553643 us-gaap:CommonStockMember 2018-09-30 0001553643 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001553643 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001553643 us-gaap:RetainedEarningsMember 2018-09-30 0001553643 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001553643 2018-07-01 2018-09-30 0001553643 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001553643 us-gaap:CommonStockMember 2018-12-31 0001553643 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001553643 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001553643 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001553643 us-gaap:RetainedEarningsMember 2018-12-31 0001553643 2018-09-30 0001553643 2019-02-13 0001553643 2018-10-02 2018-10-31 0001553643 rlmd:SettlementAgreementMember us-gaap:SubsequentEventMember 2019-02-01 2019-02-06 0001553643 rlmd:AccreditedInvestorsMember us-gaap:SubsequentEventMember 2019-02-01 2019-02-12 0001553643 rlmd:AccreditedInvestorsMember us-gaap:SubsequentEventMember 2019-02-12 0001553643 rlmd:AccreditedInvestorsMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2019-02-01 2019-02-12 0001553643 rlmd:AccreditedInvestorsMember us-gaap:SubsequentEventMember us-gaap:WarrantMember 2019-02-01 2019-02-12 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 9200 20800 230700 345700 216000 10000 18300 41200 66700 426900 537700 16700 16700 4600 7300 173600 122800 55900 68300 659500 1390500 285200 285200 114700 2019-04-09 25625 P7Y P3Y 1611769 4111768 4111768 6611768 2700000 2700000 100000 2500000 2500000 371600 0.0235 3068865 5743240 1.45 1.28 511000 882000 415844 202908 2707 1130 1648372 50274 -406549 -321995 -7617 -232597 110744 -232043 -2591 2591 1710512 2238943 5939524 2426751 187808 4229012 5006653 6342265 6507700 1509 2131 10400 25400 48000 68300 12500 10000 P8Y9M18D P9Y1M6D 661167 207781 RELMADA THERAPEUTICS, INC. 0001553643 RLMD false --06-30 10-Q 2018-12-31 false Q2 2019 Non-accelerated Filer true 20718831 37625 2619240 5743240 9627426 14975591 12284291 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended December&#160;31,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14,100</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">386,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">188,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">415,800</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">202,900</td></tr></table> 9815025 14975591 3.96 2.22 415800 202900 386300 29500 188800 14100 P10Y P10Y P10Y 868528 215000 415000 -4818845 -2110662 -31570 -29040 170432 165435 127757 3843019 1266344 200658 17 P1Y false P4Y P4Y 949118 2.58 P7Y2M30D P3Y6M21D 192900 7.59 7500 1.00 1.15 1.50 P10Y 5168066 6482671 0.07 0.07 10731669 10731669 854334 4213732 5177085 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 - NOTES PAYABLE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2018, the Company entered into a note for approximately $285,200 in conjunction with a renewal of its director and officer insurance policy. The interest rate was 2.35% per annum. The note matures on April 9, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2018 and June 30, 2018, the note payable outstanding balances were approximately $114,700 and $285,200, respectively.&#160;</p> 7617 64486 67235 426921 537665 2737967 3031651 12080 9374 24788 18908 273244 238925 3048079 3298858 765439 358892 659455 1390547 285170 114738 5904698 1864177 2656457 8561155 1864177 12550 29764 88818681 106258627 -94344307 -104853710 3048079 3298858 0.001 0.001 0.001 0.001 200000000 3500000 200000000 3500000 2678900 316470 1257418 150720 3211314 2120971 2221566 1305865 5890214 2437441 3478984 1456585 -5890214 -2437441 -3478984 -1456585 -54636 335404 263907 341106 -790087 -309349 -139765 -311871 2350 -4619189 28405 -3650326 29235 -10509403 -2409036 -7129310 -1427350 -3380093 -3380093 -7129310 -0.55 -0.19 -0.28 -0.11 -0.55 -0.19 -0.28 -0.11 19066896 12540208 25583922 12547176 2574570 1.01 7.50 11.25 0.0233 P0Y11M12D 1.02 4194634 4194634 30526 4164108 4164108 4194634 175853 3683468 3843019 54634 -335404 -59397 -4189871 7205000 6534400 0.07 204900 90200 114700 204900 90200 114700 2019-01-31 2022-12-08 Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403. 9454 7529 55232 7500 6611768 10611768 4000000 1.15 0.99 1.15 2500000 93762 0.0269 0.0269 P6Y2M30D P6Y2M30D 1.023 1.023 0 0 3754000 4548543 0 0.001 0.001 100000000 100000000 12549870 29764210 12549870 29764210 10731699 -3774468 -3774468 -5880 394410 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 4 - FIXED ASSETS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets, net of accumulated depreciation, consisted of the following (rounded to nearest $00):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Useful lives</font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December&#160;31,</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June 30,</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%"><font style="font: 10pt Times New Roman, Times, Serif">Computer and software</font></td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3 years</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16,700</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16,700</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Less: accumulated depreciation</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(7,300</font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,600</font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 4pt"><font style="font: 10pt Times New Roman, Times, Serif">Fixed assets</font></td> <td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: Black 4pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,400</font></td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: Black 4pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,100</font></td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Useful lives</font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">December&#160;31,</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June 30,</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%"><font style="font: 10pt Times New Roman, Times, Serif">Computer and software</font></td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3 years</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16,700</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16,700</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Less: accumulated depreciation</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(7,300</font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,600</font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 4pt"><font style="font: 10pt Times New Roman, Times, Serif">Fixed assets</font></td> <td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: Black 4pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,400</font></td> <td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: Black 4pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,100</font></td> <td style="padding-bottom: 4pt">&#160;</td></tr> </table> 3774500 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Outstanding and vested at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,815,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.96</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(7,500</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Issued</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,168,066</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Outstanding and vested at December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,975,591</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.22</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number <br /> of <br /> Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price For Share</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Outstanding and expected to vest at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,068,865</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.8</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">511,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(25,625</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">7.59</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Issued</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,700,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1.15</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10.0</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Outstanding and expected to vest at December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,743,240</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.1</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">882,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Options exercisable at December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">949,118</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.25</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">192,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> 1500000 1105700 30266373 59397 8030367 -5513076 12550 88818681 -94344307 1434681 12550 -97724400 89030879 29764 106258627 -104853710 -8680971 12549870 12549870 29764210 263044 152801 152801 263044 11804833 10731 11794102 10731669 5177085 6483 5170602 6482671 6000 5177085 250000 250000 250000 250000 500000 303392 725000 805554 805554 523610 0.90 1.50 P5Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 &#8211; BUSINESS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relmada Therapeutics, Inc. (&#8220;Relmada&#8221; or the &#8220;Company&#8221;) (a Nevada corporation), is a clinical-stage, publicly traded biotechnology company focused on the development of d-methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. d-Methadone is a new chemical entity that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. REL-1017 is in Phase 2 for the treatment of major depressive disorder.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a portfolio of three 505b2 product candidates at various stages of development. These products are: LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab (oral buprenorphine, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and MepiGel (topical mepivacaine, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. These products are not currently in active development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the normal risks associated with a new business venture, there can be no assurance that the Company&#8217;s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the FDA and other governmental regulations and approval requirements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim unaudited consolidated financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. The unaudited consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended June 30, 2018 and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the issuance of these consolidated financial statements. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $4,818,845 for the six months ended December 31, 2018 and accumulated deficit of $104,853,710 from inception through December 31, 2018. These conditions raise doubt as to the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company will need to raise additional funds in order to continue our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. Management plans to raise additional funds through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements, to fund operations until the Company is able to generate enough revenues to cover operating costs. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders. In addition, the Company may never be able to generate sufficient revenue if any from its potential products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and recorded amounts related to income taxes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash and Cash Equivalents</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company&#8217;s cash deposits are held at two high-credit-quality financial institutions. The Company&#8217;s cash deposits at these institutions exceed federally insured limits. <b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Patents</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fixed Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software, leasehold improvements, and furniture and fixtures. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial instruments primarily include cash, accounts payable and notes payable. Due to the short-term nature of cash, accounts payable and notes payable the carrying amounts of these assets and liabilities approximate their fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.6pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value on a Recurring Basis</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required by Accounting Standard Codification (&#8220;ASC&#8221;) Topic No. 820 - 10 <i>Fair Value Measurement</i>, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments resulting from equity offerings in May 2014 and June 2014 have a down-round protection provision that, prior to the adoption of ASU 2017-11, was calculated with the Black Scholes option pricing model. Sensitivity analysis for the Black-Scholes has many inputs and is subject to judgement which includes volatility. Volatility is based upon the Company&#8217;s historical volatility and the expected term is based upon the expiration date of the warrants. The estimated fair value of the derivative instruments from the convertible promissory notes issued during the year ended June 30, 2018, which have a redemption feature was estimated using the Monte Carlo pricing model, prior to the debt conversion. On the date of debt conversion, when the conversion price of the notes was established and there was no uncertainty as to the conversion of the debt, the estimated fair value of the derivative instrument from the convertible promissory notes was valued using the Black-Scholes model which closely approximates the value under the Monte Carlo pricing model.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. As of December 31, 2018 and June 30, 2018, the Company had recognized a valuation allowance to the full extent of the Company&#8217;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company files a U.S. Federal income tax return and, various state returns. Uncertain tax positions taken on the Company&#8217;s tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at December 31, 2018 and June 30, 2018. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2015 through June 30, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loss per Common Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per common share attributable to common stockholders is calculated by dividing the loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended December 31, 2018 and 2017, the following potentially dilutive securities were excluded from the computation of diluted net loss per share, as the inclusion of such shares would be anti-dilutive:&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,743,240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,619,240</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted common stock</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">37,625</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,975,591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,627,426</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20,718,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,284,291</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,743,240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,619,240</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted common stock</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">37,625</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,975,591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,627,426</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20,718,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,284,291</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 - PREPAID EXPENSES </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepaid expenses consisted of the following (rounded to nearest $00):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Rent</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,200</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">230,700</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,800</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">216,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">345,700</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Taxes</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Legal</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">18,300</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">537,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">426,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Rent</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,200</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">230,700</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,800</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">216,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">345,700</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Taxes</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Legal</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">18,300</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">537,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">426,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5 - ACCRUED EXPENSES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accrued expenses consisted of the following (rounded to nearest $00):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,400</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">122,800</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">173,600</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest on promissory notes</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">371,600</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued vacation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,300</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">48,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Litigation settlement, net</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,105,700</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,390,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">659,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">June 30,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,400</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">122,800</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">173,600</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest on promissory notes</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">371,600</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued vacation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,300</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">48,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Litigation settlement, net</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,105,700</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,390,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">659,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 10 &#8211; RELATED PARTY TRANSACTIONS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Consulting Agreements</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On August 4, 2015, the Company entered into an Advisory and Consulting Agreement with Sandesh Seth, the Company&#8217;s Chairman of the Board. The effective date of the consulting agreement is June 30, 2015. Mr. Seth has substantial experience in, among other matters, business development, corporate planning, corporate finance, strategic planning, investor relations and public relations, and an expansive network of connections spanning the biopharmaceutical industry, accounting, legal and corporate communications professions. Mr. Seth will provide advisory and consulting services to assist the Company with strategic advisory services, assist in prioritizing product development programs per strategic objectives, assist in recruiting of key personnel and directors, corporate planning, business development activities, corporate finance advice, and assist in investor and public relations services. In consideration for the services to be provided, the Company agreed to pay Mr. Seth $12,500 per month on an ongoing basis. On June 6, 2017, Mr. Seth resigned from the Company to focus his attention on matters external to Relmada. The Company agreed to continue its advisory and consulting arrangement with Mr. Seth until December 31, 2017.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 12, 2017, the Company and Maged Shenouda, a director of the Company, entered into a Consulting Agreement. Pursuant to the terms of the agreement, Mr. Shenouda will assist the Company with matters that may be requested by the Company. Mr. Shenouda will be paid a consulting fee of $10,000 per month. The term of the agreement is for one year. On November 13, 2017, Mr. Shenouda and the Company agreed to terminate the Consulting Agreement effective December 31, 2017.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 11 &#8211; COMMITMENTS AND CONTINGENCIES</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Legal</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">From time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence. Except as disclosed below, the Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company&#8217;s business, financial condition, operating results, or cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In 2014, Relmada dismissed with prejudice its lawsuit against Najib Babul, which had sought to compel Najib Babul, Relmada&#8217;s former President, to account for questionable expenditures of Relmada funds made while Babul controlled the Company. Relmada&#8217;s decision to end its claims was informed by the fact that Babul came forward with plausible explanations for some of the expenditures, and the fact that, because Babul was a former officer and director of Relmada being sued for his conduct in office, the Company was required to advance his expenses of the litigation; hence, Relmada was paying all the lawyers and consultants on both sides of the dispute. Relmada also agreed to reinstate certain stock purchase warrants in Babul&#8217;s name, which had been cancelled during the pendency of the litigation, and offered Babul the right to exchange his shares in Relmada Therapeutics, Inc. (a Delaware corporation and subsidiary of the Company) for shares in the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Najib Babul has brought a second lawsuit against Relmada. Ruling on Relmada&#8217;s Motion to Dismiss, the United States District Court for the Eastern District of Pennsylvania dismissed Babul&#8217;s claims for breach of contract and intentional infliction of emotional distress, and left intact his claims for defamation, and wrongful use of civil process. The parties settled the lawsuit on February 6, 2019 see Note 12. Subsequent Events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Leases and Sublease</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leased its corporate headquarters at 750 Third Avenue, 9th Floor, New York, New York 10017. The monthly rental fee was $9,454 per month. The lease was terminated effective January 1, 2019. Effective January 1, 2019, the Company leased its headquarters at 880 Third Avenue, 12<sup>th</sup> floor, New York, NY 10022. The annualized monthly rent for 2019 is approximately $7,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 8, 2017, the Company entered into an Amended and Restated License Agreement with Actinium&#160;Pharmaceuticals, Inc. (&#8220;Actinium&#8221;). Pursuant to the terms of the agreement, Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office (&#8220;FFE&#8221;) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403. As of December 31, 2018, the balance of unearned interest income was approximately $55,232.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contractual Obligations</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following tables sets forth our contractual obligations for the next five years and thereafter:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Less than <br />1&#160;year</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">1 - 2 years</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">3 - 5 years</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">More than <br />5&#160;years</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Office lease</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">90,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">90,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">114,700</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">114,700</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total obligations</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">204,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">204,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td></tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Less than <br />1&#160;year</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">1 - 2 years</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">3 - 5 years</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">More than <br />5&#160;years</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Office lease</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">90,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">90,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">114,700</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">114,700</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total obligations</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">204,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">204,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> 59397 59397 12549870 12550 88878078 -94344307 -5453679 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">June 30,</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Common stock issuable upon exercise of warrants</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,574,570</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Market value of common stock on measurement date</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1.01</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise price</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">$<font style="font-size: 10pt">7.50&#160;and&#160;$11.25</font></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate (1)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.33</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life in years</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.95</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (2)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yields (3)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font-size: 10pt">None</font></td><td style="text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">Markets for <br /> Identical <br /> Assets</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">Other <br /> Observable <br /> Inputs</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">Significant <br /> Unobservable <br /> Inputs</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">Carrying <br /> Value as of <br /> June 30,</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Derivative liability &#8211; warrant instruments</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,526</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,526</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Derivative liabilities &#8211; embedded redemption feature&#160;of promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,164,108</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,164,108</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,194,634</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,194,634</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">December&#160;31,</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">December&#160;31,</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Beginning balance</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,194,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">175,853</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Adoption of ASU 2017-11 &#8211; warrants</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(59,397</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of derivative liabilities for redemption feature of promissory notes payable</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,843,019</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">54,634</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(335,404</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Extinguishment of derivative liabilities on conversion of promissory notes.</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,189,871</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,683,468</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 8 &#8211; PROMISSORY NOTES PAYABLE</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Between September 2017 and January 2018, the Company issued two-year Convertible Promissory Notes (the &#8220;Notes&#8221;) and warrants, for aggregate gross proceeds of $7,205,000, $6,534,400 net of direct debt issuance costs. The notes had an interest rate of 7% per annum.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of financings in October 2018, the principal and accumulated interest on the Convertible Promissory Notes was automatically converted into 10,731,669 shares of its common stock in accordance with the terms of the Notes. &#8220;This resulted in a loss on extinguishment of debt, a non cash item, of approximately $3,774,500 in the quarter ended December 31, 2018.&#8221;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 12 &#8211; SUBSEQUENT EVENTS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 6, 2019 the Company entered into a settlement agreement in which Najib Babul relinquished his 303,392 shares in Relmada, signed a consulting contract and Relmada committed to a $500,000 initial payment and four subsequent payments of $250,000 on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019. For accounting purposes no fair value was attributed to the consulting agreement. The Company recorded a liability at December 31, 2018 of $1,105,590 representing the total cash payments of $1,500,000 less the fair value of shares relinquished.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="background-color: white">On February 12, 2019 the Company closed </font>a private placement of securities <font style="background-color: white">to accredited investors. The Company received $725,000 and sold an aggregate of 805,554 units representing 805,554 shares of common stock and 523,610 warrants. The price per unit was $0.90 and the exercise price of each warrant is $1.50 with a 5-year term.</font></p> 1105590 59397 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 9 &#8211; STOCKHOLDERS&#8217; EQUITY</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended December 31, 2018, the Company closed on its private placements of securities on October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018 pursuant to Unit Purchase Agreements dated as of October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018, and Subscription Agreements, dated as of October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018. The Company issued an aggregate of 6,482,671 shares of common stock to investors in these closings, for net proceeds of $5,177,085.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The October 12, 2018 and October 18, 2018 financings represented an Equity Financing as defined in the Convertible Promissory Note agreement. <font style="background-color: white">As a result of the </font>October 12, 2018 and October 18, 2018 financings<font style="background-color: white">, the Company&#8217;s outstanding 7% Convertible Promissory Notes and accumulated interest converted into 10,731,669 shares of common stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2014, the Board of Directors adopted and the shareholders approved Relmada&#8217;s 2014 Stock Option and Equity Incentive Plan, as amended (the &#8220;Plan&#8221;), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company&#8217;s common stock to designated employees, non-employee directors, and consultants and advisors. The Plan allowed for the granting of 1,611,769 options or stock awards. In August 2015, the board approved an amendment to the Plan. Among other things, the Plan Amendment updates the definition of &#8220;change of control&#8221; and provides for accelerated vesting of all awards granted under the plan in the event of a change of control of the Company. In January 2017, the stockholders approved an increase of 2,500,000 shares authorized to be issued under the Plan, raising the total shares allowed under the Plan to 4,111,768. In December 2017 the board approved, and in February 2018 the shareholders approved, an amendment to the Plan that increased the number of shares of common stock authorized for issuance under the Plan by an additional 2,500,000 shares from 4,111,768 to 6,611,768.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of December 31, 2018, 868,528 shares were available for future grants under the Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2018 the board of directors approved an amendment to the Plan to increase the number of shares of common stock authorized for issuance under the Plan by an additional 4,000,000 shares from 6,611,768 to 10,611,768.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2018, no stock appreciation rights have been issued.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options and warrants. The price of common stock prior to the Company being public was determined from a third party valuation. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based on historical volatility. The Company routinely reviews its calculation of volatility changes in future volatility, the Company&#8217;s life cycle, its peer group, and other factors.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the simplified method for share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. Prior to the adoption of ASU 2018-07 on October 1, 2018, the Company used the contractual term for non-employee options to estimate the expected term, for share-based compensation in its option-pricing model.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 13, 2017, Mr. Michael Becker, the Company&#8217;s Chief Financial Officer, resigned and entered into a consulting agreement with the Company to provide financial, investor, digital media, and public relations services for the Company. As a result of Mr. Becker&#8217;s change from an employee to a consultant, his options and shares of restricted stock outstanding on such date continued to vest pursuant to the awards&#8217; original terms and were reclassified as non-employee awards. On December 15, 2017 Mr. Becker&#8217;s consulting agreement expired and all unvested options were cancelled.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On December 20, 2018, the Company awarded a total of 2,700,000 options to its chief executive officer, chief medical officer and board members with exercise price of $1.15 and a 10-year term vesting over 4-year period. The options have an aggregate fair value of $2.5 million calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At December 31, 2018, the Company has unrecognized stock-based compensation expense of approximately $3,754,000 related to unvested stock options over the weighted average remaining service period of 3.56 years.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Options</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A summary of the changes in options during the six months ended December 31, 2018 is as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number <br /> of <br /> Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price For Share</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Outstanding and expected to vest at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,068,865</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.8</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">511,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(25,625</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">7.59</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,700,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Outstanding and expected to vest at December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,743,240</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.1</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">882,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Options exercisable at December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">949,118</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.25</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">192,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Warrants</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">A summary of the changes in outstanding warrants during the six months ended December 31, 2018 is as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Outstanding and vested at June 30, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,815,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.96</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(7,500</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,168,066</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Outstanding and vested at December 31, 2018</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,975,591</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.22</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended December 31, 2018, in connection with the closings on October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018, the Company issued an aggregate of 4,213,732 warrants to the investors. The investor warrants have an exercise price of $1.50, are non-cancellable, vest upon issuance and expire on the fifth anniversary of the warrant date of issuance. The Company additionally issued an aggregate of 854,334 warrants to the placement agent in connection with the closings. The agent warrants have an exercise price of $0.99, are non-cancellable, vest upon issuance and expire on the fifth anniversary of the warrant date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2018, the Company granted 100,000 warrants to a contractor with exercise price of $1.15, a 10-year term and immediate vesting. The warrants have an aggregated fair value of $93,762 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At December 31, 2018 and June 30, 2018, the aggregate intrinsic value of warrants vested and outstanding was approximately $415,000 and $215,000, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes the components of stock-based compensation expense which includes stock options in the consolidated statements of operations for the six months ended December 31, 2018 and 2017 (rounded to nearest $00):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended December&#160;31,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14,100</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">386,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">188,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">415,800</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">202,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; DERIVATIVE LIABILITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC Topic No. 815 &#8211; <i>Derivatives and Hedging </i>provides guidance on determining what types of instruments or embedded features in an instrument issued by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. These requirements can affect the accounting for warrants and convertible preferred instruments issued by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2018 and June 30, 2018, the Company had warrants resulting from equity offerings in May 2014 and June 2014 that do not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future, the Company concluded that the instruments are not indexed to the Company&#8217;s stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until September 30, 2018, the Company followed ASC Topic No 815 and treated the warrants as derivative liabilities. In determining the fair value of the derivative liabilities, the Company used the Black-Scholes option pricing model at September 30 and June 30, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As noted in Note 2, the Company elected to early adopt ASU 2017-11 and reversed the derivative liability into equity effective July 1, 2018. The warrants balance of $59,397 was reversed to equity effective July 1, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the assumptions used in the valuation model at June 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">June 30,</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Common stock issuable upon exercise of warrants</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,574,570</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Market value of common stock on measurement date</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1.01</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise price</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">$<font style="font-size: 10pt">7.50&#160;and&#160;$11.25</font></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate (1)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.33</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life in years</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.95</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (2)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yields (3)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font-size: 10pt">None</font></td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"><font style="font-size: 10pt">(1)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">(2)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The historical trading volatility was determined by calculating the volatility of the Company&#8217;s stock.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">(3)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until October 18, 2018, the Company had promissory notes with a redemption feature that was not clearly and closely related to the host instrument and therefore is considered an embedded derivative which was bifurcated and recorded as a derivative liability. In determining the fair value of the derivative liabilities, the Company used the Monte-Carlo pricing model. The assumptions used in the valuation model considers the probability of redemption, the length of time to maturity and value of the redemption feature.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">On October 12 and 18, 2018,&#160;the Company conducted closings on its private placement of securities. As a result of these closings, the outstanding promissory notes converted into common stock. The redemption feature associated with the promissory notes was valued on October 18, 2018 using the Black Scholes model. The change in value of the derivative between October 1, 2018 and the October 18, 2018 was recorded as income. The notes were converted to common stock on October 18, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had no financial liabilities accounted for at fair value on a recurring basis as of December 31, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth, by level within the fair value hierarchy, the Company&#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">Markets for <br /> Identical <br /> Assets</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">Other <br /> Observable <br /> Inputs</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">Significant <br /> Unobservable <br /> Inputs</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">Carrying <br /> Value as of <br /> June 30,</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Description</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Derivative liability &#8211; warrant instruments</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,526</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,526</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Derivative liabilities &#8211; embedded redemption feature&#160;of promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,164,108</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,164,108</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,194,634</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,194,634</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy for the six months ended December 31, 2018 and 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">December&#160;31,</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">December&#160;31,</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Beginning balance</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,194,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">175,853</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Adoption of ASU 2017-11 &#8211; warrants</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(59,397</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of derivative liabilities for redemption feature of promissory notes payable</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,843,019</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">54,634</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(335,404</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Extinguishment of derivative liabilities on conversion of promissory notes.</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,189,871</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,683,468</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Accounting Pronouncements&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases&#8221; (Topic 842), whereby lessees will be required to recognize for all leases at the commencement date a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The new standard is effective for us on July 1, 2019. with early adoption permitted. We expect to adopt the new standard on its effective date. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. We expect to adopt the new standard on July 1, 2019 and use the effective date as our date of initial application.&#160;Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before July 1, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In July 2017, the FASB issued ASU No. 2017-11, <i>Earnings Per Share </i>(Topic 260); <i>Distinguishing Liabilities from Equity </i>(Topic 480); <i>Derivatives and Hedging </i>(Topic 815): (Part I) <i>Accounting for Certain Financial Instruments with Down Round Features. </i>These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2017-11 effective October 1, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,&#160;<i>Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting</i>, which simplifies the accounting for share-based payments made to non-employees so the accounting for such payments is substantially the same as those made to employees. Under this ASU, share based awards to non-employees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2018-07 effective October 1, 2018 and will apply the guidance to any future equity-classified share based awards to nonemployees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim unaudited consolidated financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. The unaudited consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended June 30, 2018 and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the issuance of these consolidated financial statements. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $4,818,845 for the six months ended December 31, 2018 and accumulated deficit of $104,853,710 from inception through December 31, 2018. These conditions raise doubt as to the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company will need to raise additional funds in order to continue our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. Management plans to raise additional funds through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements, to fund operations until the Company is able to generate enough revenues to cover operating costs. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders. In addition, the Company may never be able to generate sufficient revenue if any from its potential products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and recorded amounts related to income taxes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash and Cash Equivalents</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company&#8217;s cash deposits are held at two high-credit-quality financial institutions. The Company&#8217;s cash deposits at these institutions exceed federally insured limits. <b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Patents</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fixed Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software, leasehold improvements, and furniture and fixtures. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial instruments primarily include cash, accounts payable and notes payable. Due to the short-term nature of cash, accounts payable and notes payable the carrying amounts of these assets and liabilities approximate their fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.6pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value on a Recurring Basis</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required by Accounting Standard Codification (&#8220;ASC&#8221;) Topic No. 820 - 10 <i>Fair Value Measurement</i>, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments resulting from equity offerings in May 2014 and June 2014 have a down-round protection provision that, prior to the adoption of ASU 2017-11, was calculated with the Black Scholes option pricing model. Sensitivity analysis for the Black-Scholes has many inputs and is subject to judgement which includes volatility. Volatility is based upon the Company&#8217;s historical volatility and the expected term is based upon the expiration date of the warrants. The estimated fair value of the derivative instruments from the convertible promissory notes issued during the year ended June 30, 2018, which have a redemption feature was estimated using the Monte Carlo pricing model, prior to the debt conversion. On the date of debt conversion, when the conversion price of the notes was established and there was no uncertainty as to the conversion of the debt, the estimated fair value of the derivative instrument from the convertible promissory notes was valued using the Black-Scholes model which closely approximates the value under the Monte Carlo pricing model.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. As of December 31, 2018 and June 30, 2018, the Company had recognized a valuation allowance to the full extent of the Company&#8217;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company files a U.S. Federal income tax return and, various state returns. Uncertain tax positions taken on the Company&#8217;s tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at December 31, 2018 and June 30, 2018. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2015 through June 30, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loss per Common Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per common share attributable to common stockholders is calculated by dividing the loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended December 31, 2018 and 2017, the following potentially dilutive securities were excluded from the computation of diluted net loss per share, as the inclusion of such shares would be anti-dilutive:&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,<br /> 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br /> 2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,743,240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,619,240</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted common stock</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">37,625</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,975,591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,627,426</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20,718,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,284,291</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Accounting Pronouncements&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases&#8221; (Topic 842), whereby lessees will be required to recognize for all leases at the commencement date a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. The new standard is effective for us on July 1, 2019. with early adoption permitted. We expect to adopt the new standard on its effective date. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. We expect to adopt the new standard on July 1, 2019 and use the effective date as our date of initial application.&#160;Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before July 1, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="margin: 0pt 0; text-align: justify">I<font style="font: 10pt Times New Roman, Times, Serif; color: #000000">n July 2017, the FASB issued ASU No. 2017-11, <i>Earnings Per Share </i>(Topic 260); <i>Distinguishing Liabilities from Equity </i>(Topic 480); <i>Derivatives and Hedging </i>(Topic 815): (Part I) <i>Accounting for Certain Financial Instruments with Down Round Features. </i>These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2017-11 effective October 1, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,&#160;<i>Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting</i>, which simplifies the accounting for share-based payments made to non-employees so the accounting for such payments is substantially the same as those made to employees. Under this ASU, share based awards to non-employees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2018-07 effective October 1, 2018 and will apply the guidance to any future equity-classified share based awards to nonemployees.</p> The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date. The Company does not expect to pay a dividend in the foreseeable future. The historical trading volatility was determined by calculating the volatility of the Company's stock. EX-101.SCH 10 rlmd-20181231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Prepaid Expenses link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fixed Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Derivative Liabilities link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Promissory Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Fixed Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Derivative Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Fixed Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Derivative Liabilities (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Derivative Liabilities (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Derivative Liabilities (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Promissory Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Stockholders' Equity (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 rlmd-20181231_cal.xml XBRL CALCULATION FILE EX-101.DEF 12 rlmd-20181231_def.xml XBRL DEFINITION FILE EX-101.LAB 13 rlmd-20181231_lab.xml XBRL LABEL FILE Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 2 [Member] Equity Components [Axis] Stock-based compensation - warrants [Member] Fair Value, Inputs, Level 1 [Member] Derivative Instrument [Axis] Embedded Derivative Financial Instruments [Member] Class of Stock [Axis] Preferred Class A [Member] Common Stock [Member] Additional Paid-In Capital Retained Earnings / Accumulated Deficit Range [Axis] Minimum [Member] Maximum [Member] Award Type [Axis] Employee Stock Option [Member] Stock Option And Equity Incentive Plan [Member] Advisory Firm [Member] Stock-based compensation - restricted common stock [Member] Stock Option [Member] Common Stock Warrants [Member] Property, Plant and Equipment, Type [Axis] Furniture and Fixtures [Member] Computer Equipment [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Research and Development Expense [Member] Indefinite-lived Intangible Assets [Axis] Licensing Agreements [Member] Licensing Agreements [Member] Long-term Debt, Type [Axis] Office lease [Member] Note payable [Member] Short-term Debt, Type [Axis] Between September 2017 and January 2018 [Member] Sale of Stock [Axis] Private Placement [Member] SettlementAgreement [Axis] Settlement Agreement [Member] Scenario [Axis] MarchTwoThousandNineteen [Member] Subsequent Event Type [Axis] Subsequent Event [Member] June Two Thousand Nineteen [Member] SeptemberTwo Thousand Nineteen [Member] December Two Thousand Nineteen [Member] Title of Individual [Axis] Accredited investors [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Trading Symbol Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Statement [Table] Statement [Line Items] Class A Convertible Preferred Stock Assets Current assets: Cash and cash equivalents Other receivable Lease payments receivable - short-term Prepaid expenses Total current assets Fixed assets, net of accumulated depreciation Other assets Lease payments receivable - long-term Total assets Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable Accrued expenses Notes payable Derivative liabilities Total current liabilities Promissory notes payable, net of discount of $0 and $4,548,543 Total liabilities Commitments and contingencies Stockholders' equity: Preferred stock value Common stock, $0.001 par value,100,000,000 shares authorized, 29,764,210 and 12,549,870 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity (deficit) Total liabilities and stockholders' equity (deficit) Class A convertible preferred stock Promissory notes payable, net of discount Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Total Operating Expenses Loss from Operations Other income (expenses): Change in fair value of derivative liabilities Loss on extinguishment of debt Interest expense, net Other income Total other income (expenses) Net loss Loss per common share - basic Loss per common share - diluted Weighted average number of common shares outstanding - basic and diluted Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Stock-based compensation Amortization of deferred financing costs Change in fair value of derivative liabilities Fair value of shares relinquished in litigation Loss on promissory note extinguishment Changes in operating assets and liabilities: Other receivable Other assets Lease payment receivable Prepaid expenses Accounts payable Accrued expenses Net cash used in operating activities Cash flows from investing activities Purchase of fixed assets Net cash used in investing activities Cash flows from financing activities Proceeds from promissory notes and warrants, net of fees Principal payments of notes payable Net proceeds from sale of units Net cash provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Supplemental disclosure of cash flow information: Cash paid during the period for: Income taxes Interest Non-cash investing and financing transactions: Issuances of common stock resulting from cashless exercise of warrants Warrants issued to placement agent Warrants issued to promissory note holders Derivative associated with issuance of promissory notes Debt issuance cost from accrued financing fees Write-off of derivative liability due to adoption of ASU 2017-11 Conversion of promissory notes and accrued interest to common stock Common Stock Additional Paid-in Capital Accumulated Deficit Beginning Balance Beginning Balance, Shares Cumulative effect of write-off of derivative liability for adoption of ASU 2017-11 Adjusted Balances as at June 30, 2018 Adjusted Balances as at June 30, 2018, Shares Stock based compensation Conversion of Notes and accrued interest Conversion of Notes and accrued interest, Shares Equity units issued for cash Equity units issued for cash, Shares Ending Balance Ending Balance, Shares Organization, Consolidation and Presentation of Financial Statements [Abstract] BUSINESS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES Property, Plant and Equipment [Abstract] FIXED ASSETS Payables and Accruals [Abstract] ACCRUED EXPENSES Debt Disclosure [Abstract] NOTES PAYABLE Derivative Instruments and Hedging Activities Disclosure [Abstract] DERIVATIVE LIABILITIES PROMISSORY NOTES PAYABLE Stockholders' Equity Note [Abstract] STOCKHOLDERS' EQUITY Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Going Concern Principles of Consolidation Use of Estimates Cash and Cash Equivalents Patents Fixed Assets Fair Value of Financial Instruments Fair Value on a Recurring Basis Income Taxes Research and Development Stock-Based Compensation Loss per Common Share Recent Accounting Pronouncements Schedule of anti-dilutive securities Schedule of prepaid expenses Schedule of fixed assets, net of accumulated depreciation Schedule of accrued expenses Schedule of assumptions used in valuation model Schedule of fair value on a recurring basis Schedule of reconciliation of changes in the fair value of financial liabilities Schedule of changes in options outstanding Schedule of changes in outstanding warrants Schedule of stock-based compensation expense Schedule of contractual obligations Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Stock options [Member] Restricted common stock [Member] Common stock warrants [Member] Summary of anti-dilutive securities Total RegistrationRightsAgreementsDatesAxis [Axis] Summary of Significant Accounting Policies (Textual) Fixed assets, estimated useful life Negative operating cash flows Accumulated deficit Rent Research and development Insurance Taxes Legal Other Total Computer and software [Member] Computer and software Less: accumulated depreciation Fixed assets Useful lives Research and development Professional fees Interest on promissory notes Accrued vacation Litigation settlement, net Other Total Notes Payable (Textual) Note payable, conjunction of director and officer Note payable, interest rate per annum Note payable, outstanding balance Notes payable, maturity date Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of assumptions used in valuation model of derivatives liabilities Common stock issuable upon exercise of warrants Market value of common stock on measurement date Exercise price Risk free interest rate Expected life in years Expected volatility Expected dividend yields Fair Value Hierarchy and NAV [Axis] Markets for Identical Assets (Level 1) [Member] Other Observable Inputs (Level 2) [Member] Significant Unobservable Inputs (Level 3) [Member] warrant instruments [Member] embedded redemption feature of promissory notes [Member] Schedule of fair value, financial liabilities measured on recurring basis Derivative liability Promissory Notes Payable (Textual) [Table] Fair Value Input Liabilities Quantitative Information [LineItems] Beginning balance Adoption of ASU 2017-11 – warrants Fair value of derivative liabilities for redemption feature of promissory notes payable Change in fair value of derivative liabilities Extinguishment of derivative liabilities on conversion of promissory notes. Ending balance Derivative Liabilities (Textual) Derivative liability-Warrant Adjusted balance of reversed to equity Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Promissory Notes Payable (Textual) Aggregate gross proceeds of convertible notes payable Debt issuance costs, net Interest rate Notes converted into shares of common stock Loss on extinguishment of debt Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Options, Outstanding and expected to vest, Beginning balance Number of Options, Forfeited Number of Shares, Issued Number of Options, Outstanding and expected to vest, Ending balance Number of Shares, Options exercisable Weighted Average Exercise Price For Share, Outstanding and expected to vest - Beginning balance Weighted Average Exercise Price Per Share, Forfeited Weighted Average Exercise Price Per Share, Issued Weighted Average Exercise Price Per Share, Outstanding and expected to vest - Ending balance Weighted Average Exercise Price Per Share, Options exercisable Weighted Average Remaining Contractual Term (Years), Outstanding and expected to vest Weighted Average Remaining Contractual Term (Years), Issued Weighted Average Remaining Contractual Term (Years), Issued Weighted Average Remaining Contractual Term (Years), Options exercisable Aggregate Intrinsic Value, Outstanding and expected to vest - Beginning balance Aggregate Intrinsic Value, Outstanding and expected to vest - Ending balance Aggregate Intrinsic Value, Options exercisable Number of Shares, Outstanding and vested, Beginning balance Number of Shares, Forfeited Number of Shares, Issued Number of Shares, Outstanding and vested, Ending balance Weighted Average Exercise Price Per Share, Outstanding and vested, Beginning balance Weighted Average Exercise Price Per Share, Outstanding and vested, Ending balance Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Research and development [Member] General and administrative [Member] Stock-based compensation expense Warrants [Member] Placement agent [Member] Options [Member] Options [Member] Stockholders' Equity (Textual) Warrants to purchase of common stock Aggregate fair value of warrants issued Offering costs Number of consultants Issuance of common stock for consulting services, shares Issuance of common stock for consulting services Common stocks issued Shares issued for cashless exercise of warrants Number of options granted Stock options exercisable period Number of shares available for future grants under stock option plan Options to purchase of common stock Stock options term, description Options exercise price Options vest percentage Description of vesting rights Vesting period Unrecognized stock-based compensation expense Unvested stock options weighted average remaining service period Weighted average fair value of options granted Recognized weighted average remaining service period Aggregate intrinsic value of warrants outstanding Vested shares to be issued Shares authorized to be issued Warrants issued to note holders Warrants issued to placement agent, share Call option intrinsic percentage Warrant, granted Share awarded Aggregate fair value of options Discount rate Expected life term Expected volatility rate Expected dividends rate Stock-based compensation expense Weighted average remaining service period Options vested, description Expenses from issuances of warrants Common stock for issuances of restricted common stocks Funds received Units to be issued Private placement, description Aggregate common stock issued Net proceeds Percentage of convertible promissory notes Converted shares of common stock Conversion price Common stock authorized for issuance Award vesting period Description of fair value Warrants issued Warrants exercise price Related Party Transactions (Textual) Advisory services fee Consulting fee Consulting agreement term Other Commitments [Table] Other Commitments [Line Items] Contractual obligations due less than 1 year Contractual obligations due in 1-2 years Contractual obligations due in 3-5 years Contractual obligations due in more than 5 years Total obligations Schedule of Operating Leased Assets [Table] Operating Leased Assets [Line Items] Lease Agreements [Member] Commitments and Contingencies (Textual) Lease expiration date Lease term, description Rental fee Lease deposit in other assets Cost of license Unearned interest income Contingent liability Annualized monthly rent amount SettlementAgreementAxis [Axis] March 31, 2019 [Member] June 30, 2019 [Member] September 30, 2019 [Member] December 31, 2019 [Member] Subsequent Events (Textual) Initial payment Relinquished shares Subsequent payments Recorded liability Cash payments Proceeds from amount received Aggregate sale of units Price per unit Exercise price of each warrant Warrant term Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Call option intrinsic percentage. Cash paid during period. Class of warrant or right number granted. Common stock issuable upon exercise of warrants. Consulting fees. Amount of expenses from issuances of warrants. Fair value assumption exercise price. Fair value assumption expected dividend rate. Fair value assumption expected term. Expected volatility. Risk free interest rate. The fair value of Financing of note payable in noncash investing or financing activities. Disclosure of accounting policy for Fixed assets. Market value of common stock on measurement date. Number of consultants. Prepaid legal. Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. The entire disclosure for promissory notes payable. Schedule of share based compensation expense includes stock options warrants and restricted stock . Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share warrants (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share warrants or share units that were granted, exercised or converted, forfeited, and expired during the year. Unvested stock options over the weighted average remaining service period . Weighted Average Remaining Contractual Term Year Granted. Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term 1. Weighted average price at which grantees can acquire the shares reserved for issuance under the stock warrant plan Unvested stock over the weighted average remaining service period . Amount of shares authorized to be issued. Warrants issued to noteholders. Warrants issued to placement agent share. Unearned interest income. Contractual obligations due in 3-5 years. Increase decrease in lease payment receivable. Issuances of common stock resulting from cashless exercise of warrants. Warrants issued to placement agent. Warrants issued to promissory note holders. Derivative associated with issuance of promissory notes. Debt issuance cost from accrued financing fees. Consulting agreement term. Units to be Issued. Unit funds received. The entire disclosure of prepaid expenses. Purchase of units under a private placement. Disclosure of accounting policy regarding going concern. Description of fair value. Extinguishment of derivative liabilities on conversion of promissory notes. Present value of contingent liability. Amount of monthly lease payment. Disclosure of patents policy text block. Fair value of shares relinquished in litigation. The amount of initial payment. Total cash payments. Cumulative effect of write-off of derivative liability. The amount of write-off of derivative liability due to adoption of ASU 2017-11. The amount of conversion of promissory notes and accrued interest to common stock. Subsequent payments related to consulting agreement. Relinquished shares. The term of warrant. Adjusted balances. Number of shares issued which are neither adjusted balances. Adjusted balance of reversed to equity. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) FairValueOfSharesRelinquishedInLitigation Increase (Decrease) in Other Receivables Increase (Decrease) in Other Operating Assets IncreaseDecreaseInLeasePaymentReceivable Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Payments to Acquire Productive Assets Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Shares, Outstanding PrepaidExpensesTextBlock Basis of Presentation and Significant Accounting Policies [Text Block] Consolidation, Policy [Policy Text Block] Prepaid Research And Development Prepaid Expense Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment AccruedResearchAndDevelopmentExpenseCurrent Other Accrued Liabilities, Current Accrued Liabilities and Other Liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Other Extraordinary Gain (Loss) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years), Issued [Default Label] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Weighted Average Exercise Price Employee Benefits and Share-based Compensation UnitFundsReceived UnitsToBeIssuedCurrent Proceeds from Issuance of Common Stock ConsultingAgreementTerm EX-101.PRE 14 rlmd-20181231_pre.xml XBRL PRESENTATION FILE GRAPHIC 15 ex10-1_001.jpg GRAPHIC begin 644 ex10-1_001.jpg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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
6 Months Ended
Dec. 31, 2018
Feb. 13, 2019
Document and Entity Information [Abstract]    
Entity Registrant Name RELMADA THERAPEUTICS, INC.  
Entity Central Index Key 0001553643  
Trading Symbol RLMD  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Document Type 10-Q  
Document Period End Date Dec. 31, 2018  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2019  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Ex Transition Period false  
Entity Common Stock, Shares Outstanding   30,266,373
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Dec. 31, 2018
Jun. 30, 2018
Current assets:    
Cash and cash equivalents $ 2,426,751 $ 2,238,943
Other receivable 7,617
Lease payments receivable - short-term 67,235 64,486
Prepaid expenses 537,665 426,921
Total current assets 3,031,651 2,737,967
Fixed assets, net of accumulated depreciation 9,374 12,080
Other assets 18,908 24,788
Lease payments receivable - long-term 238,925 273,244
Total assets 3,298,858 3,048,079
Current liabilities:    
Accounts payable 358,892 765,439
Accrued expenses 1,390,547 659,455
Notes payable 114,738 285,170
Derivative liabilities 4,194,634
Total current liabilities 1,864,177 5,904,698
Promissory notes payable, net of discount of $0 and $4,548,543 2,656,457
Total liabilities 1,864,177 8,561,155
Commitments and contingencies
Stockholders' equity:    
Preferred stock value
Common stock, $0.001 par value,100,000,000 shares authorized, 29,764,210 and 12,549,870 shares issued and outstanding, respectively 29,764 12,550
Additional paid-in capital 106,258,627 88,818,681
Accumulated deficit (104,853,710) (94,344,307)
Total stockholders' equity (deficit) 1,434,681 (5,513,076)
Total liabilities and stockholders' equity (deficit) 3,298,858 3,048,079
Class A Convertible Preferred Stock    
Stockholders' equity:    
Preferred stock value
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Dec. 31, 2018
Jun. 30, 2018
Promissory notes payable, net of discount $ 0 $ 4,548,543
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 29,764,210 12,549,870
Common stock, shares outstanding 29,764,210 12,549,870
Class A convertible preferred stock    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 3,500,000 3,500,000
Preferred stock, shares issued
Preferred stock, shares outstanding
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Operating expenses:        
Research and development $ 1,257,418 $ 150,720 $ 2,678,900 $ 316,470
General and administrative 2,221,566 1,305,865 3,211,314 2,120,971
Total Operating Expenses 3,478,984 1,456,585 5,890,214 2,437,441
Loss from Operations (3,478,984) (1,456,585) (5,890,214) (2,437,441)
Other income (expenses):        
Change in fair value of derivative liabilities 263,907 341,106 (54,636) 335,404
Loss on extinguishment of debt (3,774,468)   (3,774,468)
Interest expense, net (139,765) (311,871) (790,087) (309,349)
Other income 2,350
Total other income (expenses) (3,650,326) 29,235 (4,619,189) 28,405
Net loss $ (7,129,310) $ (1,427,350) $ (10,509,403) $ (2,409,036)
Loss per common share - basic $ (0.28) $ (0.11) $ (0.55) $ (0.19)
Loss per common share - diluted $ (0.28) $ (0.11) $ (0.55) $ (0.19)
Weighted average number of common shares outstanding - basic and diluted 25,583,922 12,547,176 19,066,896 12,540,208
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities    
Net loss $ (10,509,403) $ (2,409,036)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 2,707 1,130
Stock-based compensation 415,844 202,908
Amortization of deferred financing costs 661,167 207,781
Change in fair value of derivative liabilities 54,636 (335,404)
Fair value of shares relinquished in litigation (394,410)
Loss on promissory note extinguishment 3,774,468
Changes in operating assets and liabilities:    
Other receivable 7,617 232,597
Other assets 5,880  
Lease payment receivable 31,570 29,040
Prepaid expenses (110,744) 232,043
Accounts payable (406,549) (321,995)
Accrued expenses 1,648,372 50,274
Net cash used in operating activities (4,818,845) (2,110,662)
Cash flows from investing activities    
Purchase of fixed assets (2,591)
Net cash used in investing activities (2,591)
Cash flows from financing activities    
Proceeds from promissory notes and warrants, net of fees 6,507,700
Principal payments of notes payable (170,432) (165,435)
Net proceeds from sale of units 5,177,085  
Net cash provided by financing activities 5,006,653 6,342,265
Net (decrease) increase in cash and cash equivalents 187,808 4,229,012
Cash and cash equivalents at beginning of the period 2,238,943 1,710,512
Cash and cash equivalents at end of the period 2,426,751 5,939,524
Cash paid during the period for:    
Income taxes
Interest 1,509 2,131
Non-cash investing and financing transactions:    
Issuances of common stock resulting from cashless exercise of warrants 17
Warrants issued to placement agent 200,658
Warrants issued to promissory note holders 1,266,344
Derivative associated with issuance of promissory notes 3,843,019
Debt issuance cost from accrued financing fees $ 127,757
Write-off of derivative liability due to adoption of ASU 2017-11 59,397  
Conversion of promissory notes and accrued interest to common stock $ 8,030,367  
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Statements of Stockholders' Equity - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Beginning Balance at Jun. 30, 2018 $ 12,550 $ 88,818,681 $ (94,344,307) $ (5,513,076)
Beginning Balance, Shares at Jun. 30, 2018 12,549,870      
Cumulative effect of write-off of derivative liability for adoption of ASU 2017-11   59,397   59,397
Adjusted Balances as at June 30, 2018 $ 12,550 88,878,078 (94,344,307) (5,453,679)
Adjusted Balances as at June 30, 2018, Shares 12,549,870      
Stock based compensation   152,801   152,801
Net loss     (3,380,093) (3,380,093)
Ending Balance at Sep. 30, 2018 $ 12,550 89,030,879 (97,724,400) (8,680,971)
Ending Balance, Shares at Sep. 30, 2018 12,549,870      
Beginning Balance at Jun. 30, 2018 $ 12,550 88,818,681 (94,344,307) (5,513,076)
Beginning Balance, Shares at Jun. 30, 2018 12,549,870      
Net loss       (10,509,403)
Ending Balance at Dec. 31, 2018 $ 29,764 106,258,627 (104,853,710) 1,434,681
Ending Balance, Shares at Dec. 31, 2018 29,764,210      
Beginning Balance at Sep. 30, 2018 $ 12,550 89,030,879 (97,724,400) (8,680,971)
Beginning Balance, Shares at Sep. 30, 2018 12,549,870      
Stock based compensation   263,044 263,044
Conversion of Notes and accrued interest $ 10,731 11,794,102 11,804,833
Conversion of Notes and accrued interest, Shares 10,731,669      
Equity units issued for cash $ 6,483 5,170,602 5,177,085
Equity units issued for cash, Shares 6,482,671      
Net loss     (7,129,310) (7,129,310)
Ending Balance at Dec. 31, 2018 $ 29,764 $ 106,258,627 $ (104,853,710) $ 1,434,681
Ending Balance, Shares at Dec. 31, 2018 29,764,210      
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business
6 Months Ended
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS

NOTE 1 – BUSINESS

 

Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (a Nevada corporation), is a clinical-stage, publicly traded biotechnology company focused on the development of d-methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. d-Methadone is a new chemical entity that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. REL-1017 is in Phase 2 for the treatment of major depressive disorder.

 

The Company has a portfolio of three 505b2 product candidates at various stages of development. These products are: LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab (oral buprenorphine, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and MepiGel (topical mepivacaine, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. These products are not currently in active development.

 

In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the FDA and other governmental regulations and approval requirements.

XML 23 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
6 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim unaudited consolidated financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. The unaudited consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended June 30, 2018 and notes thereto contained in the Company’s Annual Report on Form 10-K.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the issuance of these consolidated financial statements. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $4,818,845 for the six months ended December 31, 2018 and accumulated deficit of $104,853,710 from inception through December 31, 2018. These conditions raise doubt as to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company will need to raise additional funds in order to continue our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. Management plans to raise additional funds through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements, to fund operations until the Company is able to generate enough revenues to cover operating costs. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders. In addition, the Company may never be able to generate sufficient revenue if any from its potential products.

 

Principles of Consolidation

 

The unaudited consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and recorded amounts related to income taxes.

  

Cash and Cash Equivalents

 

The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash deposits at these institutions exceed federally insured limits.  

 

Patents

 

Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.

 

Fixed Assets

 

Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software, leasehold improvements, and furniture and fixtures. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments primarily include cash, accounts payable and notes payable. Due to the short-term nature of cash, accounts payable and notes payable the carrying amounts of these assets and liabilities approximate their fair value.

 

Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:

 

Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

 

Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.

 

Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

  

Fair Value on a Recurring Basis

 

As required by Accounting Standard Codification (“ASC”) Topic No. 820 - 10 Fair Value Measurement, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments resulting from equity offerings in May 2014 and June 2014 have a down-round protection provision that, prior to the adoption of ASU 2017-11, was calculated with the Black Scholes option pricing model. Sensitivity analysis for the Black-Scholes has many inputs and is subject to judgement which includes volatility. Volatility is based upon the Company’s historical volatility and the expected term is based upon the expiration date of the warrants. The estimated fair value of the derivative instruments from the convertible promissory notes issued during the year ended June 30, 2018, which have a redemption feature was estimated using the Monte Carlo pricing model, prior to the debt conversion. On the date of debt conversion, when the conversion price of the notes was established and there was no uncertainty as to the conversion of the debt, the estimated fair value of the derivative instrument from the convertible promissory notes was valued using the Black-Scholes model which closely approximates the value under the Monte Carlo pricing model.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. As of December 31, 2018 and June 30, 2018, the Company had recognized a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.

 

The Company files a U.S. Federal income tax return and, various state returns. Uncertain tax positions taken on the Company’s tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at December 31, 2018 and June 30, 2018. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2015 through June 30, 2018.

 

Research and Development

 

Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. 

 

Stock-Based Compensation

 

The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased. 

 

Loss per Common Share

 

Basic loss per common share attributable to common stockholders is calculated by dividing the loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

 

For the six months ended December 31, 2018 and 2017, the following potentially dilutive securities were excluded from the computation of diluted net loss per share, as the inclusion of such shares would be anti-dilutive: 

 

   Six months ended 
   December 31,
2018
   December 31,
2017
 
Stock options   5,743,240    2,619,240 
Restricted common stock   -    37,625 
Common stock warrants   14,975,591    9,627,426 
Total   20,718,831    12,284,291 

 

Recent Accounting Pronouncements 

 

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), whereby lessees will be required to recognize for all leases at the commencement date a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new standard is effective for us on July 1, 2019. with early adoption permitted. We expect to adopt the new standard on its effective date. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. We expect to adopt the new standard on July 1, 2019 and use the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before July 1, 2019.

 

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2017-11 effective October 1, 2018.

 

In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, which simplifies the accounting for share-based payments made to non-employees so the accounting for such payments is substantially the same as those made to employees. Under this ASU, share based awards to non-employees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2018-07 effective October 1, 2018 and will apply the guidance to any future equity-classified share based awards to nonemployees.

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Prepaid Expenses
6 Months Ended
Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
PREPAID EXPENSES

NOTE 3 - PREPAID EXPENSES

 

Prepaid expenses consisted of the following (rounded to nearest $00):

 

   December 31,
2018
   June 30,
2018
 
Rent  $-   $9,200 
Research and development   230,700    20,800 
Insurance   216,000    345,700 
Taxes   6,000      
Legal   18,300    10,000 
Other   66,700    41,200 
Total  $537,700   $426,900 
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fixed Assets
6 Months Ended
Dec. 31, 2018
Property, Plant and Equipment [Abstract]  
FIXED ASSETS

NOTE 4 - FIXED ASSETS

 

Fixed assets, net of accumulated depreciation, consisted of the following (rounded to nearest $00):

 

    Useful lives   December 31,
2018
    June 30,
2018
 
Computer and software   3 years   $ 16,700     $ 16,700  
Less: accumulated depreciation         (7,300 )     (4,600 )
Fixed assets       $ 9,400     $ 12,100
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Expenses
6 Months Ended
Dec. 31, 2018
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

NOTE 5 - ACCRUED EXPENSES

 

Accrued expenses consisted of the following (rounded to nearest $00):

 

   December 31,
2018
   June 30,
2018
 
Research and development  $25,400   $10,400 
Professional fees   122,800    173,600 
Interest on promissory notes   -    371,600 
Accrued vacation   68,300    48,000 
Litigation settlement, net   1,105,700    - 
Other   68,300    55,900 
Total  $1,390,500   $659,500 
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Payable
6 Months Ended
Dec. 31, 2018
Debt Disclosure [Abstract]  
NOTES PAYABLE

NOTE 6 - NOTES PAYABLE

 

In June 2018, the Company entered into a note for approximately $285,200 in conjunction with a renewal of its director and officer insurance policy. The interest rate was 2.35% per annum. The note matures on April 9, 2019.

 

At December 31, 2018 and June 30, 2018, the note payable outstanding balances were approximately $114,700 and $285,200, respectively. 

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liabilities
6 Months Ended
Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE LIABILITIES

NOTE 7 – DERIVATIVE LIABILITIES

 

ASC Topic No. 815 – Derivatives and Hedging provides guidance on determining what types of instruments or embedded features in an instrument issued by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. These requirements can affect the accounting for warrants and convertible preferred instruments issued by the Company.

 

At December 31, 2018 and June 30, 2018, the Company had warrants resulting from equity offerings in May 2014 and June 2014 that do not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future, the Company concluded that the instruments are not indexed to the Company’s stock.

 

Until September 30, 2018, the Company followed ASC Topic No 815 and treated the warrants as derivative liabilities. In determining the fair value of the derivative liabilities, the Company used the Black-Scholes option pricing model at September 30 and June 30, 2018.

 

As noted in Note 2, the Company elected to early adopt ASU 2017-11 and reversed the derivative liability into equity effective July 1, 2018. The warrants balance of $59,397 was reversed to equity effective July 1, 2018.

 

The following is a summary of the assumptions used in the valuation model at June 30, 2018:

 

   June 30, 
   2018 
Common stock issuable upon exercise of warrants   2,574,570 
Market value of common stock on measurement date  $1.01 
Exercise price   $7.50 and $11.25 
Risk free interest rate (1)   2.33%
Expected life in years  $0.95 
Expected volatility (2)   102%
Expected dividend yields (3)   None 

 

(1) The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date.
(2) The historical trading volatility was determined by calculating the volatility of the Company’s stock.
(3) The Company does not expect to pay a dividend in the foreseeable future.

 

Until October 18, 2018, the Company had promissory notes with a redemption feature that was not clearly and closely related to the host instrument and therefore is considered an embedded derivative which was bifurcated and recorded as a derivative liability. In determining the fair value of the derivative liabilities, the Company used the Monte-Carlo pricing model. The assumptions used in the valuation model considers the probability of redemption, the length of time to maturity and value of the redemption feature.

 

On October 12 and 18, 2018, the Company conducted closings on its private placement of securities. As a result of these closings, the outstanding promissory notes converted into common stock. The redemption feature associated with the promissory notes was valued on October 18, 2018 using the Black Scholes model. The change in value of the derivative between October 1, 2018 and the October 18, 2018 was recorded as income. The notes were converted to common stock on October 18, 2018.

 

The Company had no financial liabilities accounted for at fair value on a recurring basis as of December 31, 2018.

 

The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018:

 

   Markets for
Identical
Assets
   Other
Observable
Inputs
   Significant
Unobservable
Inputs
   Carrying
Value as of
June 30,
 
Description  (Level 1)   (Level 2)   (Level 3)   2018 
Derivative liability – warrant instruments  $       -   $          -   $30,526   $30,526 
Derivative liabilities – embedded redemption feature of promissory notes   -    -    4,164,108    4,164,108 
   $-   $-   $4,194,634   $4,194,634 

 

The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy for the six months ended December 31, 2018 and 2017:

 

   Six Months Ended 
   December 31,   December 31, 
   2018   2017 
Beginning balance  $4,194,634   $175,853 
Adoption of ASU 2017-11 – warrants   (59,397)   - 
Fair value of derivative liabilities for redemption feature of promissory notes payable   -    3,843,019 
Change in fair value of derivative liabilities   54,634    (335,404)
Extinguishment of derivative liabilities on conversion of promissory notes.   (4,189,871)   - 
Ending balance  $-   $3,683,468
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Promissory Notes Payable
6 Months Ended
Dec. 31, 2018
Debt Disclosure [Abstract]  
PROMISSORY NOTES PAYABLE

NOTE 8 – PROMISSORY NOTES PAYABLE

 

Between September 2017 and January 2018, the Company issued two-year Convertible Promissory Notes (the “Notes”) and warrants, for aggregate gross proceeds of $7,205,000, $6,534,400 net of direct debt issuance costs. The notes had an interest rate of 7% per annum.

 

As a result of financings in October 2018, the principal and accumulated interest on the Convertible Promissory Notes was automatically converted into 10,731,669 shares of its common stock in accordance with the terms of the Notes. “This resulted in a loss on extinguishment of debt, a non cash item, of approximately $3,774,500 in the quarter ended December 31, 2018.”

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity
6 Months Ended
Dec. 31, 2018
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY

NOTE 9 – STOCKHOLDERS’ EQUITY

 

Common Stock

 

During the six months ended December 31, 2018, the Company closed on its private placements of securities on October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018 pursuant to Unit Purchase Agreements dated as of October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018, and Subscription Agreements, dated as of October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018. The Company issued an aggregate of 6,482,671 shares of common stock to investors in these closings, for net proceeds of $5,177,085.

 

The October 12, 2018 and October 18, 2018 financings represented an Equity Financing as defined in the Convertible Promissory Note agreement. As a result of the October 12, 2018 and October 18, 2018 financings, the Company’s outstanding 7% Convertible Promissory Notes and accumulated interest converted into 10,731,669 shares of common stock.

 

Options

 

In December 2014, the Board of Directors adopted and the shareholders approved Relmada’s 2014 Stock Option and Equity Incentive Plan, as amended (the “Plan”), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors. The Plan allowed for the granting of 1,611,769 options or stock awards. In August 2015, the board approved an amendment to the Plan. Among other things, the Plan Amendment updates the definition of “change of control” and provides for accelerated vesting of all awards granted under the plan in the event of a change of control of the Company. In January 2017, the stockholders approved an increase of 2,500,000 shares authorized to be issued under the Plan, raising the total shares allowed under the Plan to 4,111,768. In December 2017 the board approved, and in February 2018 the shareholders approved, an amendment to the Plan that increased the number of shares of common stock authorized for issuance under the Plan by an additional 2,500,000 shares from 4,111,768 to 6,611,768.

 

Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of December 31, 2018, 868,528 shares were available for future grants under the Plan.

 

In December 2018 the board of directors approved an amendment to the Plan to increase the number of shares of common stock authorized for issuance under the Plan by an additional 4,000,000 shares from 6,611,768 to 10,611,768.

 

As of December 31, 2018, no stock appreciation rights have been issued.

 

The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options and warrants. The price of common stock prior to the Company being public was determined from a third party valuation. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based on historical volatility. The Company routinely reviews its calculation of volatility changes in future volatility, the Company’s life cycle, its peer group, and other factors.

 

The Company uses the simplified method for share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. Prior to the adoption of ASU 2018-07 on October 1, 2018, the Company used the contractual term for non-employee options to estimate the expected term, for share-based compensation in its option-pricing model.

 

On February 13, 2017, Mr. Michael Becker, the Company’s Chief Financial Officer, resigned and entered into a consulting agreement with the Company to provide financial, investor, digital media, and public relations services for the Company. As a result of Mr. Becker’s change from an employee to a consultant, his options and shares of restricted stock outstanding on such date continued to vest pursuant to the awards’ original terms and were reclassified as non-employee awards. On December 15, 2017 Mr. Becker’s consulting agreement expired and all unvested options were cancelled.

 

On December 20, 2018, the Company awarded a total of 2,700,000 options to its chief executive officer, chief medical officer and board members with exercise price of $1.15 and a 10-year term vesting over 4-year period. The options have an aggregate fair value of $2.5 million calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends.

 

At December 31, 2018, the Company has unrecognized stock-based compensation expense of approximately $3,754,000 related to unvested stock options over the weighted average remaining service period of 3.56 years.

 

Options

 

A summary of the changes in options during the six months ended December 31, 2018 is as follows:

 

   Number
of
Options
   Weighted Average Exercise Price For Share   Weighted Average Remaining Contractual Term (Years)   Aggregate Intrinsic
Value
 
Outstanding and expected to vest at June 30, 2018   3,068,865   $1.45    8.8   $511,000 
Forfeited   (25,625)  $7.59    -   $- 
Issued   2,700,000    1.15    10.0    - 
Outstanding and expected to vest at December 31, 2018   5,743,240   $1.28    9.1   $882,000 
Options exercisable at December 31, 2018   949,118   $2.58    7.25   $192,900 

 

Warrants

 

A summary of the changes in outstanding warrants during the six months ended December 31, 2018 is as follows:

 

   Number of Shares   Weighted Average Exercise Price Per Share 
Outstanding and vested at June 30, 2018   9,815,025   $3.96 
Forfeited   (7,500)   - 
Issued   5,168,066    1.00 
Outstanding and vested at December 31, 2018   14,975,591   $2.22 

 

During the six months ended December 31, 2018, in connection with the closings on October 12, 2018, October 18, 2018, November 2, 2018 and December 5, 2018, the Company issued an aggregate of 4,213,732 warrants to the investors. The investor warrants have an exercise price of $1.50, are non-cancellable, vest upon issuance and expire on the fifth anniversary of the warrant date of issuance. The Company additionally issued an aggregate of 854,334 warrants to the placement agent in connection with the closings. The agent warrants have an exercise price of $0.99, are non-cancellable, vest upon issuance and expire on the fifth anniversary of the warrant date of issuance.

 

On December 20, 2018, the Company granted 100,000 warrants to a contractor with exercise price of $1.15, a 10-year term and immediate vesting. The warrants have an aggregated fair value of $93,762 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends.

 

At December 31, 2018 and June 30, 2018, the aggregate intrinsic value of warrants vested and outstanding was approximately $415,000 and $215,000, respectively.

 

The following summarizes the components of stock-based compensation expense which includes stock options in the consolidated statements of operations for the six months ended December 31, 2018 and 2017 (rounded to nearest $00):

 

   Six Months Ended December 31,
2018
   Six Months Ended December 31,
2017
 
Research and development  $29,500   $14,100 
General and administrative   386,300    188,800 
Total  $415,800   $202,900 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions
6 Months Ended
Dec. 31, 2018
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 10 – RELATED PARTY TRANSACTIONS

 

Consulting Agreements

 

On August 4, 2015, the Company entered into an Advisory and Consulting Agreement with Sandesh Seth, the Company’s Chairman of the Board. The effective date of the consulting agreement is June 30, 2015. Mr. Seth has substantial experience in, among other matters, business development, corporate planning, corporate finance, strategic planning, investor relations and public relations, and an expansive network of connections spanning the biopharmaceutical industry, accounting, legal and corporate communications professions. Mr. Seth will provide advisory and consulting services to assist the Company with strategic advisory services, assist in prioritizing product development programs per strategic objectives, assist in recruiting of key personnel and directors, corporate planning, business development activities, corporate finance advice, and assist in investor and public relations services. In consideration for the services to be provided, the Company agreed to pay Mr. Seth $12,500 per month on an ongoing basis. On June 6, 2017, Mr. Seth resigned from the Company to focus his attention on matters external to Relmada. The Company agreed to continue its advisory and consulting arrangement with Mr. Seth until December 31, 2017. 

 

On June 12, 2017, the Company and Maged Shenouda, a director of the Company, entered into a Consulting Agreement. Pursuant to the terms of the agreement, Mr. Shenouda will assist the Company with matters that may be requested by the Company. Mr. Shenouda will be paid a consulting fee of $10,000 per month. The term of the agreement is for one year. On November 13, 2017, Mr. Shenouda and the Company agreed to terminate the Consulting Agreement effective December 31, 2017.

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
6 Months Ended
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 11 – COMMITMENTS AND CONTINGENCIES

 

Legal

 

From time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence. Except as disclosed below, the Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company’s business, financial condition, operating results, or cash flows.

 

In 2014, Relmada dismissed with prejudice its lawsuit against Najib Babul, which had sought to compel Najib Babul, Relmada’s former President, to account for questionable expenditures of Relmada funds made while Babul controlled the Company. Relmada’s decision to end its claims was informed by the fact that Babul came forward with plausible explanations for some of the expenditures, and the fact that, because Babul was a former officer and director of Relmada being sued for his conduct in office, the Company was required to advance his expenses of the litigation; hence, Relmada was paying all the lawyers and consultants on both sides of the dispute. Relmada also agreed to reinstate certain stock purchase warrants in Babul’s name, which had been cancelled during the pendency of the litigation, and offered Babul the right to exchange his shares in Relmada Therapeutics, Inc. (a Delaware corporation and subsidiary of the Company) for shares in the Company.

 

Najib Babul has brought a second lawsuit against Relmada. Ruling on Relmada’s Motion to Dismiss, the United States District Court for the Eastern District of Pennsylvania dismissed Babul’s claims for breach of contract and intentional infliction of emotional distress, and left intact his claims for defamation, and wrongful use of civil process. The parties settled the lawsuit on February 6, 2019 see Note 12. Subsequent Events.

 

Leases and Sublease

 

The Company leased its corporate headquarters at 750 Third Avenue, 9th Floor, New York, New York 10017. The monthly rental fee was $9,454 per month. The lease was terminated effective January 1, 2019. Effective January 1, 2019, the Company leased its headquarters at 880 Third Avenue, 12th floor, New York, NY 10022. The annualized monthly rent for 2019 is approximately $7,500.

  

On June 8, 2017, the Company entered into an Amended and Restated License Agreement with Actinium Pharmaceuticals, Inc. (“Actinium”). Pursuant to the terms of the agreement, Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office (“FFE”) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403. As of December 31, 2018, the balance of unearned interest income was approximately $55,232.

 

Contractual Obligations

 

The following tables sets forth our contractual obligations for the next five years and thereafter:

 

   Total   Less than
1 year
   1 - 2 years   3 - 5 years   More than
5 years
 
Office lease  $90,200    90,200   $-   $-   $- 
Note payable   114,700    114,700    -    -    - 
Total obligations  $204,900   $204,900   $-   $-   $-
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
6 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 12 – SUBSEQUENT EVENTS

 

On February 6, 2019 the Company entered into a settlement agreement in which Najib Babul relinquished his 303,392 shares in Relmada, signed a consulting contract and Relmada committed to a $500,000 initial payment and four subsequent payments of $250,000 on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019. For accounting purposes no fair value was attributed to the consulting agreement. The Company recorded a liability at December 31, 2018 of $1,105,590 representing the total cash payments of $1,500,000 less the fair value of shares relinquished.

 

On February 12, 2019 the Company closed a private placement of securities to accredited investors. The Company received $725,000 and sold an aggregate of 805,554 units representing 805,554 shares of common stock and 523,610 warrants. The price per unit was $0.90 and the exercise price of each warrant is $1.50 with a 5-year term.

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim unaudited consolidated financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. The unaudited consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended June 30, 2018 and notes thereto contained in the Company’s Annual Report on Form 10-K.

Going Concern

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the issuance of these consolidated financial statements. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $4,818,845 for the six months ended December 31, 2018 and accumulated deficit of $104,853,710 from inception through December 31, 2018. These conditions raise doubt as to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company will need to raise additional funds in order to continue our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. Management plans to raise additional funds through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements, to fund operations until the Company is able to generate enough revenues to cover operating costs. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders. In addition, the Company may never be able to generate sufficient revenue if any from its potential products.

Principles of Consolidation

Principles of Consolidation

 

The unaudited consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and recorded amounts related to income taxes.

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash deposits at these institutions exceed federally insured limits.  

Patents

Patents

 

Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.

Fixed Assets

Fixed Assets

 

Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software, leasehold improvements, and furniture and fixtures. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company’s financial instruments primarily include cash, accounts payable and notes payable. Due to the short-term nature of cash, accounts payable and notes payable the carrying amounts of these assets and liabilities approximate their fair value.

 

Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:

 

Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

 

Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.

 

Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Fair Value on a Recurring Basis

Fair Value on a Recurring Basis

 

As required by Accounting Standard Codification (“ASC”) Topic No. 820 - 10 Fair Value Measurement, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments resulting from equity offerings in May 2014 and June 2014 have a down-round protection provision that, prior to the adoption of ASU 2017-11, was calculated with the Black Scholes option pricing model. Sensitivity analysis for the Black-Scholes has many inputs and is subject to judgement which includes volatility. Volatility is based upon the Company’s historical volatility and the expected term is based upon the expiration date of the warrants. The estimated fair value of the derivative instruments from the convertible promissory notes issued during the year ended June 30, 2018, which have a redemption feature was estimated using the Monte Carlo pricing model, prior to the debt conversion. On the date of debt conversion, when the conversion price of the notes was established and there was no uncertainty as to the conversion of the debt, the estimated fair value of the derivative instrument from the convertible promissory notes was valued using the Black-Scholes model which closely approximates the value under the Monte Carlo pricing model.

Income Taxes

Income Taxes

 

The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. As of December 31, 2018 and June 30, 2018, the Company had recognized a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.

 

The Company files a U.S. Federal income tax return and, various state returns. Uncertain tax positions taken on the Company’s tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at December 31, 2018 and June 30, 2018. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2015 through June 30, 2018.

Research and Development

Research and Development

 

Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. 

Stock-Based Compensation

Stock-Based Compensation

 

The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased. 

Loss per Common Share

Loss per Common Share

 

Basic loss per common share attributable to common stockholders is calculated by dividing the loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

 

For the six months ended December 31, 2018 and 2017, the following potentially dilutive securities were excluded from the computation of diluted net loss per share, as the inclusion of such shares would be anti-dilutive: 

 

   Six months ended 
   December 31,
2018
   December 31,
2017
 
Stock options   5,743,240    2,619,240 
Restricted common stock   -    37,625 
Common stock warrants   14,975,591    9,627,426 
Total   20,718,831    12,284,291 
Recent Accounting Pronouncements

Recent Accounting Pronouncements 

 

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), whereby lessees will be required to recognize for all leases at the commencement date a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new standard is effective for us on July 1, 2019. with early adoption permitted. We expect to adopt the new standard on its effective date. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. We expect to adopt the new standard on July 1, 2019 and use the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before July 1, 2019.

 

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2017-11 effective October 1, 2018.

 

In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, which simplifies the accounting for share-based payments made to non-employees so the accounting for such payments is substantially the same as those made to employees. Under this ASU, share based awards to non-employees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees. This ASU is effective for the Company beginning July 1, 2019 and early adoption is permitted. The Company elected to early adopt ASU 2018-07 effective October 1, 2018 and will apply the guidance to any future equity-classified share based awards to nonemployees.

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Schedule of anti-dilutive securities

   Six months ended 
   December 31,
2018
   December 31,
2017
 
Stock options   5,743,240    2,619,240 
Restricted common stock   -    37,625 
Common stock warrants   14,975,591    9,627,426 
Total   20,718,831    12,284,291 

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Prepaid Expenses (Tables)
6 Months Ended
Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of prepaid expenses
   December 31,
2018
   June 30,
2018
 
Rent  $-   $9,200 
Research and development   230,700    20,800 
Insurance   216,000    345,700 
Taxes   6,000      
Legal   18,300    10,000 
Other   66,700    41,200 
Total  $537,700   $426,900 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fixed Assets (Tables)
6 Months Ended
Dec. 31, 2018
Property, Plant and Equipment [Abstract]  
Schedule of fixed assets, net of accumulated depreciation
    Useful lives   December 31,
2018
    June 30,
2018
 
Computer and software   3 years   $ 16,700     $ 16,700  
Less: accumulated depreciation         (7,300 )     (4,600 )
Fixed assets       $ 9,400     $ 12,100  
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Expenses (Tables)
6 Months Ended
Dec. 31, 2018
Payables and Accruals [Abstract]  
Schedule of accrued expenses
   December 31,
2018
   June 30,
2018
 
Research and development  $25,400   $10,400 
Professional fees   122,800    173,600 
Interest on promissory notes   -    371,600 
Accrued vacation   68,300    48,000 
Litigation settlement, net   1,105,700    - 
Other   68,300    55,900 
Total  $1,390,500   $659,500 
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liabilities (Tables)
6 Months Ended
Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of assumptions used in valuation model
   June 30, 
   2018 
Common stock issuable upon exercise of warrants   2,574,570 
Market value of common stock on measurement date  $1.01 
Exercise price   $7.50 and $11.25 
Risk free interest rate (1)   2.33%
Expected life in years  $0.95 
Expected volatility (2)   102%
Expected dividend yields (3)   None 
Schedule of fair value on a recurring basis
   Markets for
Identical
Assets
   Other
Observable
Inputs
   Significant
Unobservable
Inputs
   Carrying
Value as of
June 30,
 
Description  (Level 1)   (Level 2)   (Level 3)   2018 
Derivative liability – warrant instruments  $       -   $          -   $30,526   $30,526 
Derivative liabilities – embedded redemption feature of promissory notes   -    -    4,164,108    4,164,108 
   $-   $-   $4,194,634   $4,194,634 
Schedule of reconciliation of changes in the fair value of financial liabilities
   Six Months Ended 
   December 31,   December 31, 
   2018   2017 
Beginning balance  $4,194,634   $175,853 
Adoption of ASU 2017-11 – warrants   (59,397)   - 
Fair value of derivative liabilities for redemption feature of promissory notes payable   -    3,843,019 
Change in fair value of derivative liabilities   54,634    (335,404)
Extinguishment of derivative liabilities on conversion of promissory notes.   (4,189,871)   - 
Ending balance  $-   $3,683,468 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Tables)
6 Months Ended
Dec. 31, 2018
Stockholders' Equity Note [Abstract]  
Schedule of changes in options outstanding
   Number
of
Options
   Weighted Average Exercise Price For Share   Weighted Average Remaining Contractual Term (Years)   Aggregate Intrinsic
Value
 
Outstanding and expected to vest at June 30, 2018   3,068,865   $1.45    8.8   $511,000 
Forfeited   (25,625)  $7.59    -   $- 
Issued   2,700,000    1.15    10.0    - 
Outstanding and expected to vest at December 31, 2018   5,743,240   $1.28    9.1   $882,000 
Options exercisable at December 31, 2018   949,118   $2.58    7.25   $192,900 
Schedule of changes in outstanding warrants
   Number of Shares   Weighted Average Exercise Price Per Share 
Outstanding and vested at June 30, 2018   9,815,025   $3.96 
Forfeited   (7,500)   - 
Issued   5,168,066    1.00 
Outstanding and vested at December 31, 2018   14,975,591   $2.22 
Schedule of stock-based compensation expense
   Six Months Ended December 31,
2018
   Six Months Ended December 31,
2017
 
Research and development  $29,500   $14,100 
General and administrative   386,300    188,800 
Total  $415,800   $202,900
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Tables)
6 Months Ended
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Schedule of contractual obligations
   Total   Less than
1 year
   1 - 2 years   3 - 5 years   More than
5 years
 
Office lease  $90,200    90,200   $-   $-   $- 
Note payable   114,700    114,700    -    -    - 
Total obligations  $204,900   $204,900   $-   $-   $- 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Details) - shares
6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Summary of anti-dilutive securities    
Total 20,718,831 12,284,291
Stock options [Member]    
Summary of anti-dilutive securities    
Total 5,743,240 2,619,240
Restricted common stock [Member]    
Summary of anti-dilutive securities    
Total 37,625
Common stock warrants [Member]    
Summary of anti-dilutive securities    
Total 14,975,591 9,627,426
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Details Textual) - USD ($)
6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Jun. 30, 2018
Summary of Significant Accounting Policies (Textual)      
Negative operating cash flows $ (4,818,845) $ (2,110,662)  
Accumulated deficit $ (104,853,710)   $ (94,344,307)
Furniture and Fixtures [Member]      
Summary of Significant Accounting Policies (Textual)      
Fixed assets, estimated useful life 7 years    
Computer Equipment [Member]      
Summary of Significant Accounting Policies (Textual)      
Fixed assets, estimated useful life 3 years    
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Prepaid Expenses (Details) - USD ($)
Dec. 31, 2018
Jun. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Rent $ 9,200
Research and development 230,700 20,800
Insurance 216,000 345,700
Taxes 6,000  
Legal 18,300 10,000
Other 66,700 41,200
Total $ 537,700 $ 426,900
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fixed Assets (Details) - USD ($)
6 Months Ended
Dec. 31, 2018
Jun. 30, 2018
Computer and software $ 16,700 $ 16,700
Less: accumulated depreciation (7,300) (4,600)
Fixed assets $ 9,374 $ 12,080
Computer and software [Member]    
Useful lives 3 years  
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Expenses (Details) - USD ($)
Dec. 31, 2018
Jun. 30, 2018
Payables and Accruals [Abstract]    
Research and development $ 25,400 $ 10,400
Professional fees 122,800 173,600
Interest on promissory notes 371,600
Accrued vacation 68,300 48,000
Litigation settlement, net 1,105,700
Other 68,300 55,900
Total $ 1,390,500 $ 659,500
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Payable (Details) - USD ($)
12 Months Ended
Jun. 30, 2018
Dec. 31, 2018
Notes Payable (Textual)    
Note payable, conjunction of director and officer $ 285,200  
Note payable, interest rate per annum 2.35%  
Note payable, outstanding balance $ 285,200 $ 114,700
Notes payable, maturity date Apr. 09, 2019  
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liabilities (Details)
12 Months Ended
Jun. 30, 2018
$ / shares
shares
Summary of assumptions used in valuation model of derivatives liabilities  
Common stock issuable upon exercise of warrants | shares 2,574,570
Market value of common stock on measurement date $ 1.01
Risk free interest rate 2.33% [1]
Expected life in years 11 months 12 days
Expected volatility 102.00% [2]
Expected dividend yields [3]
Maximum [Member]  
Summary of assumptions used in valuation model of derivatives liabilities  
Exercise price $ 11.25
Minimum [Member]  
Summary of assumptions used in valuation model of derivatives liabilities  
Exercise price $ 7.50
[1] The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date.
[2] The historical trading volatility was determined by calculating the volatility of the Company's stock.
[3] The Company does not expect to pay a dividend in the foreseeable future.
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liabilities (Details 1) - USD ($)
Dec. 31, 2018
Jun. 30, 2018
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability $ 4,194,634
embedded redemption feature of promissory notes [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability   4,164,108
Markets for Identical Assets (Level 1) [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability  
Markets for Identical Assets (Level 1) [Member] | embedded redemption feature of promissory notes [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability  
Markets for Identical Assets (Level 1) [Member] | warrant instruments [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability  
Other Observable Inputs (Level 2) [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability  
Other Observable Inputs (Level 2) [Member] | embedded redemption feature of promissory notes [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability  
Other Observable Inputs (Level 2) [Member] | warrant instruments [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability  
Significant Unobservable Inputs (Level 3) [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability   4,194,634
Significant Unobservable Inputs (Level 3) [Member] | embedded redemption feature of promissory notes [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability   4,164,108
Significant Unobservable Inputs (Level 3) [Member] | warrant instruments [Member]    
Schedule of fair value, financial liabilities measured on recurring basis    
Derivative liability   $ 30,526
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liabilities (Details 2) - Significant Unobservable Inputs (Level 3) [Member] - USD ($)
6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Fair Value Input Liabilities Quantitative Information [LineItems]    
Beginning balance $ 4,194,634 $ 175,853
Adoption of ASU 2017-11 – warrants (59,397)
Fair value of derivative liabilities for redemption feature of promissory notes payable 3,843,019
Change in fair value of derivative liabilities 54,634 (335,404)
Extinguishment of derivative liabilities on conversion of promissory notes. (4,189,871)
Ending balance $ 3,683,468
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liabilities (Details Textual) - USD ($)
6 Months Ended
Dec. 31, 2018
Jun. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Derivative liability-Warrant $ 4,194,634
Adjusted balance of reversed to equity $ 59,397  
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Promissory Notes Payable (Details) - USD ($)
1 Months Ended 6 Months Ended
Oct. 31, 2018
Dec. 31, 2018
Promissory Notes Payable (Textual)    
Notes converted into shares of common stock 10,731,699  
Loss on extinguishment of debt   $ 3,774,500
Between September 2017 and January 2018 [Member]    
Promissory Notes Payable (Textual)    
Aggregate gross proceeds of convertible notes payable   7,205,000
Debt issuance costs, net   $ 6,534,400
Interest rate   7.00%
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Details) - Employee Stock Option [Member] - USD ($)
6 Months Ended 12 Months Ended
Dec. 31, 2018
Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of Options, Outstanding and expected to vest, Beginning balance 3,068,865  
Number of Options, Forfeited (25,625)  
Number of Shares, Issued 2,700,000  
Number of Options, Outstanding and expected to vest, Ending balance 5,743,240 3,068,865
Number of Shares, Options exercisable 949,118  
Weighted Average Exercise Price For Share, Outstanding and expected to vest - Beginning balance $ 1.45  
Weighted Average Exercise Price Per Share, Forfeited 7.59  
Weighted Average Exercise Price Per Share, Issued 1.15  
Weighted Average Exercise Price Per Share, Outstanding and expected to vest - Ending balance 1.28 $ 1.45
Weighted Average Exercise Price Per Share, Options exercisable $ 2.58  
Weighted Average Remaining Contractual Term (Years), Outstanding and expected to vest 9 years 1 month 6 days 8 years 9 months 18 days
Weighted Average Remaining Contractual Term (Years), Issued 10 years  
Weighted Average Remaining Contractual Term (Years), Options exercisable 7 years 2 months 30 days  
Aggregate Intrinsic Value, Outstanding and expected to vest - Beginning balance $ 511,000  
Aggregate Intrinsic Value, Outstanding and expected to vest - Ending balance 882,000 $ 511,000
Aggregate Intrinsic Value, Options exercisable $ 192,900  
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Details 1) - Stock-based compensation - warrants [Member]
6 Months Ended
Dec. 31, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Shares, Outstanding and vested, Beginning balance | shares 9,815,025
Number of Shares, Forfeited | shares (7,500)
Number of Shares, Issued | shares 5,168,066
Number of Shares, Outstanding and vested, Ending balance | shares 14,975,591
Weighted Average Exercise Price Per Share, Outstanding and vested, Beginning balance | $ / shares $ 3.96
Weighted Average Exercise Price Per Share, Forfeited | $ / shares
Weighted Average Exercise Price Per Share, Issued | $ / shares 1.00
Weighted Average Exercise Price Per Share, Outstanding and vested, Ending balance | $ / shares $ 2.22
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Details 2) - USD ($)
6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation expense $ 415,800 $ 202,900
Research and development [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation expense 29,500 14,100
General and administrative [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation expense $ 386,300 $ 188,800
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Details Textual) - USD ($)
1 Months Ended 6 Months Ended
Oct. 12, 2018
Dec. 31, 2018
Dec. 20, 2018
Oct. 18, 2018
Feb. 28, 2018
Jan. 31, 2017
Dec. 31, 2014
Dec. 31, 2018
Jun. 30, 2018
Stockholders' Equity (Textual)                  
Aggregate common stock issued               $ 6,482,671  
Net proceeds               $ 5,177,085  
Percentage of convertible promissory notes 7.00%     7.00%          
Converted shares of common stock 10,731,669     10,731,669          
Options [Member]                  
Stockholders' Equity (Textual)                  
Number of options granted     2,700,000     4,111,768 1,611,769    
Stock options exercisable period     10 years         10 years  
Number of shares available for future grants under stock option plan               868,528  
Options exercise price     $ 1.15            
Vesting period     4 years         4 years  
Shares authorized to be issued         2,500,000 2,500,000      
Aggregate fair value of options     $ 2,500,000            
Discount rate     2.69%            
Expected life term     6 years 2 months 30 days            
Expected volatility rate     102.30%            
Expected dividends rate     0.00%            
Stock-based compensation expense               $ 3,754,000  
Weighted average remaining service period               3 years 6 months 21 days  
Common stock authorized for issuance   4,000,000              
Options [Member] | Minimum [Member]                  
Stockholders' Equity (Textual)                  
Number of options granted         4,111,768        
Common stock authorized for issuance   6,611,768              
Options [Member] | Maximum [Member]                  
Stockholders' Equity (Textual)                  
Number of options granted         6,611,768        
Common stock authorized for issuance   10,611,768              
Options [Member]                  
Stockholders' Equity (Textual)                  
Number of options granted               2,700,000  
Weighted average fair value of options granted               $ 1.15  
Aggregate intrinsic value of warrants outstanding   $ 415,000           $ 415,000 $ 215,000
Weighted average remaining service period               7 years 2 months 30 days  
Warrants [Member]                  
Stockholders' Equity (Textual)                  
Number of options granted     100,000            
Stock options exercisable period     10 years            
Options exercise price   $ 0.99 $ 1.15         $ 0.99  
Weighted average fair value of options granted               $ 1.50  
Aggregate fair value of options     $ 93,762            
Discount rate     2.69%            
Expected life term     6 years 2 months 30 days            
Expected volatility rate     102.30%            
Expected dividends rate     0.00%            
Warrants issued   $ 4,213,732           $ 4,213,732  
Warrants [Member] | Placement agent [Member]                  
Stockholders' Equity (Textual)                  
Warrants issued   $ 854,334           $ 854,334  
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details) - USD ($)
12 Months Ended
Jun. 12, 2017
Jun. 30, 2015
Related Party Transactions (Textual)    
Consulting fee $ 10,000  
Consulting agreement term 1 year  
Advisory Firm [Member]    
Related Party Transactions (Textual)    
Advisory services fee   $ 12,500
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Details)
Dec. 31, 2018
USD ($)
Other Commitments [Line Items]  
Contractual obligations due less than 1 year $ 204,900
Contractual obligations due in 1-2 years
Contractual obligations due in 3-5 years
Contractual obligations due in more than 5 years
Total obligations 204,900
Office lease [Member]  
Other Commitments [Line Items]  
Contractual obligations due less than 1 year 90,200
Contractual obligations due in 1-2 years
Contractual obligations due in 3-5 years
Contractual obligations due in more than 5 years
Total obligations 90,200
Note payable [Member]  
Other Commitments [Line Items]  
Contractual obligations due less than 1 year 114,700
Contractual obligations due in 1-2 years
Contractual obligations due in 3-5 years
Contractual obligations due in more than 5 years
Total obligations $ 114,700
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 6 Months Ended
Jun. 08, 2017
Dec. 31, 2018
Lease Agreements [Member]    
Commitments and Contingencies (Textual)    
Lease expiration date   Jan. 31, 2019
Rental fee   $ 9,454
Annualized monthly rent amount   7,500
Licensing Agreements [Member]    
Commitments and Contingencies (Textual)    
Lease expiration date Dec. 08, 2022  
Lease term, description Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403.  
Cost of license $ 7,529  
Unearned interest income   $ 55,232
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Details) - USD ($)
6 Months Ended
Feb. 12, 2019
Feb. 06, 2019
Dec. 31, 2018
Subsequent Event [Member] | Accredited investors [Member]      
Subsequent Events (Textual)      
Proceeds from amount received $ 725,000    
Aggregate sale of units 805,554    
Price per unit $ 0.90    
Exercise price of each warrant $ 1.50    
Warrant term 5 years    
Subsequent Event [Member] | Accredited investors [Member] | Common Stock [Member]      
Subsequent Events (Textual)      
Aggregate sale of units 805,554    
Subsequent Event [Member] | Accredited investors [Member] | Warrants [Member]      
Subsequent Events (Textual)      
Aggregate sale of units 523,610    
Settlement Agreement [Member]      
Subsequent Events (Textual)      
Recorded liability     $ 1,105,590
Cash payments     $ 1,500,000
Settlement Agreement [Member] | Subsequent Event [Member]      
Subsequent Events (Textual)      
Initial payment   $ 500,000  
Relinquished shares   303,392  
Settlement Agreement [Member] | Subsequent Event [Member] | March 31, 2019 [Member]      
Subsequent Events (Textual)      
Subsequent payments   $ 250,000  
Settlement Agreement [Member] | Subsequent Event [Member] | June 30, 2019 [Member]      
Subsequent Events (Textual)      
Subsequent payments   250,000  
Settlement Agreement [Member] | Subsequent Event [Member] | September 30, 2019 [Member]      
Subsequent Events (Textual)      
Subsequent payments   250,000  
Settlement Agreement [Member] | Subsequent Event [Member] | December 31, 2019 [Member]      
Subsequent Events (Textual)      
Subsequent payments   $ 250,000  
EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 103 232 1 true 36 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://relmada.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://relmada.com/role/Consolidatedbalancesheetsunaudited Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://relmada.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://relmada.com/role/Consolidatedstatementsofoperationsunaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://relmada.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Statements of Stockholders' Equity Sheet http://relmada.com/role/StatementsOfStockholdersEquity Statements of Stockholders' Equity Statements 6 false false R7.htm 00000007 - Disclosure - Business Sheet http://relmada.com/role/Business Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://relmada.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Prepaid Expenses Sheet http://relmada.com/role/PrepaidExpenses Prepaid Expenses Notes 9 false false R10.htm 00000010 - Disclosure - Fixed Assets Sheet http://relmada.com/role/FixedAssets Fixed Assets Notes 10 false false R11.htm 00000011 - Disclosure - Accrued Expenses Sheet http://relmada.com/role/AccruedExpenses Accrued Expenses Notes 11 false false R12.htm 00000012 - Disclosure - Notes Payable Notes http://relmada.com/role/NotesPayable Notes Payable Notes 12 false false R13.htm 00000013 - Disclosure - Derivative Liabilities Sheet http://relmada.com/role/DerivativeLiabilities Derivative Liabilities Notes 13 false false R14.htm 00000014 - Disclosure - Promissory Notes Payable Notes http://relmada.com/role/PromissoryNotesPayable Promissory Notes Payable Notes 14 false false R15.htm 00000015 - Disclosure - Stockholders' Equity Sheet http://relmada.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 00000016 - Disclosure - Related Party Transactions Sheet http://relmada.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://relmada.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://relmada.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://relmada.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://relmada.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://relmada.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://relmada.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Prepaid Expenses (Tables) Sheet http://relmada.com/role/PrepaidExpensesTables Prepaid Expenses (Tables) Tables http://relmada.com/role/PrepaidExpenses 21 false false R22.htm 00000022 - Disclosure - Fixed Assets (Tables) Sheet http://relmada.com/role/FixedAssetsTables Fixed Assets (Tables) Tables http://relmada.com/role/FixedAssets 22 false false R23.htm 00000023 - Disclosure - Accrued Expenses (Tables) Sheet http://relmada.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://relmada.com/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - Derivative Liabilities (Tables) Sheet http://relmada.com/role/DerivativeLiabilitiesTables Derivative Liabilities (Tables) Tables http://relmada.com/role/DerivativeLiabilities 24 false false R25.htm 00000025 - Disclosure - Stockholders' Equity (Tables) Sheet http://relmada.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://relmada.com/role/StockholdersEquity 25 false false R26.htm 00000026 - Disclosure - Commitments and Contingencies (Tables) Sheet http://relmada.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://relmada.com/role/CommitmentsAndContingencies 26 false false R27.htm 00000027 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails2 Summary of Significant Accounting Policies (Details) Details http://relmada.com/role/SummaryofSignificantAccountingPoliciesTables 27 false false R28.htm 00000028 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://relmada.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://relmada.com/role/SummaryofSignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - Prepaid Expenses (Details) Sheet http://relmada.com/role/PrepaidExpensesDetails Prepaid Expenses (Details) Details http://relmada.com/role/PrepaidExpensesTables 29 false false R30.htm 00000030 - Disclosure - Fixed Assets (Details) Sheet http://relmada.com/role/FixedAssetsDetails Fixed Assets (Details) Details http://relmada.com/role/FixedAssetsTables 30 false false R31.htm 00000031 - Disclosure - Accrued Expenses (Details) Sheet http://relmada.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://relmada.com/role/AccruedExpensesTables 31 false false R32.htm 00000032 - Disclosure - Notes Payable (Details) Notes http://relmada.com/role/NotesPayableDetails Notes Payable (Details) Details http://relmada.com/role/NotesPayable 32 false false R33.htm 00000033 - Disclosure - Derivative Liabilities (Details) Sheet http://relmada.com/role/DerivativeLiabilitiesDetails Derivative Liabilities (Details) Details http://relmada.com/role/DerivativeLiabilitiesTables 33 false false R34.htm 00000034 - Disclosure - Derivative Liabilities (Details 1) Sheet http://relmada.com/role/DerivativeLiabilitiesDetails1 Derivative Liabilities (Details 1) Details http://relmada.com/role/DerivativeLiabilitiesTables 34 false false R35.htm 00000035 - Disclosure - Derivative Liabilities (Details 2) Sheet http://relmada.com/role/DerivativeLiabilitiesDetails2 Derivative Liabilities (Details 2) Details http://relmada.com/role/DerivativeLiabilitiesTables 35 false false R36.htm 00000036 - Disclosure - Derivative Liabilities (Details Textual) Sheet http://relmada.com/role/DerivativeLiabilitiesDetailsTextual Derivative Liabilities (Details Textual) Details http://relmada.com/role/DerivativeLiabilitiesTables 36 false false R37.htm 00000037 - Disclosure - Promissory Notes Payable (Details) Notes http://relmada.com/role/PromissoryNotesPayableDetails Promissory Notes Payable (Details) Details http://relmada.com/role/PromissoryNotesPayable 37 false false R38.htm 00000038 - Disclosure - Stockholders' Equity (Details) Sheet http://relmada.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://relmada.com/role/StockholdersEquityTables 38 false false R39.htm 00000039 - Disclosure - Stockholders' Equity (Details 1) Sheet http://relmada.com/role/StockholdersEquityDetails3 Stockholders' Equity (Details 1) Details http://relmada.com/role/StockholdersEquityTables 39 false false R40.htm 00000040 - Disclosure - Stockholders' Equity (Details 2) Sheet http://relmada.com/role/StockholdersEquityDetails4 Stockholders' Equity (Details 2) Details http://relmada.com/role/StockholdersEquityTables 40 false false R41.htm 00000041 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://relmada.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://relmada.com/role/StockholdersEquityTables 41 false false R42.htm 00000042 - Disclosure - Related Party Transactions (Details) Sheet http://relmada.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://relmada.com/role/RelatedPartyTransactions 42 false false R43.htm 00000043 - Disclosure - Commitments and Contingencies (Details) Sheet http://relmada.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://relmada.com/role/CommitmentsAndContingenciesTables 43 false false R44.htm 00000044 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://relmada.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://relmada.com/role/CommitmentsAndContingenciesTables 44 false false R45.htm 00000045 - Disclosure - Subsequent Events (Details) Sheet http://relmada.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://relmada.com/role/SubsequentEvents 45 false false All Reports Book All Reports rlmd-20181231.xml rlmd-20181231.xsd rlmd-20181231_cal.xml rlmd-20181231_def.xml rlmd-20181231_lab.xml rlmd-20181231_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 67 0001213900-19-002391-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-19-002391-xbrl.zip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end